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Abstract  
 
Cell membrane plays a crucial role in several biological processes, such as the regulation of molecule 
and ion exchange, protein functioning and lipid signalling. Inappropiate lifestyles or stress situations 
can enhance the production of free radicals that, in their turn, are able to trigger chain reactions 
leading to the damage of the main cell constituents. Normally, the cell possesses physiological 
mechanisms to counteract the increase of radical stress, but when it is no longer able to do so, 
deterioration of biomolecules can occur, from which inflammation may start and be perpetuated, thus 
leading to pathological conditions. 
Changes in the lipid compositions at the membrane level can be monitored by fatty acid-based 
lipidomics, which represents a powerful diagnostic tool for the detection of membrane impairments 
and their association with different physiological and pathological conditions. It is known that, under 
radical stress, polyunsaturated fatty acids (PUFA) moieties are the most susceptible to oxidative 
damages, and lipid peroxidation can be monitored by the loss of PUFAs from membranes. Membrane 
peroxidation can compete with a reaction induced by sulfur-centered radicals, that is called cis-trans 
isomerization, in which the conversion of the cis double bonds of the unsaturated fatty acids to the 
unnatural trans geometry occurs. Trans fatty acids (TFAs) can affect the membrane functionality by 
reducing the membrane permeability and fluidity, however more information is needed to evaluate 
the extent at which such unnatural molecules affect health. TFAs can also be generated by chemical 
and physical processes, used also in food industry, such as partial hydrogenation and deodorization. 
As matter of facts, radical chemistry and nutritional research both evidenced the formation of TFAs. 
In particular, studies about deodorized fish oils used for nutraceutical supplementation, regarded the 
ω-3 mono-trans PUFA isomers. The impact of fatty acids on health is nowadays well understood, 
especially as for the inadequate intake of PUFAs is concerned, which is known to strongly affect the 
pathophysiology of neurological pathologies, such as Autism, and neurodegenerative diseases, such 
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as Alzheimer. Therefore, the molecular profiles obtained from lipidomic studies can contribute to the 
development of a multidisciplinary approach for the diagnosis of these diseases. 
The experimental work described in this thesis started with our focusing on the lipidomic profile of 
children affected by Autism Spectrum Disorder (ASD), a group of neurodevelopmental disorders 
characterized by social and behaviour impairments. A dual approach centered on the erythrocyte 
membranes was for the first time applied to a group of healthy and ASD children. It consisted of the 
erythrocyte membrane fatty acid analysis combined with the detection of spectral properties related 
to the membrane organization by using an innovative biophotonic methodology called hyperspectral 
enhanced dark field microscopy (HDFM). The multidisciplinary collaboration with a medical unit for 
the clinical evaluation and biophysic researchers brought to an important result of membrane-based 
diagnostics with high predictive value for ASD, published in Scientific Reports in August 2017. 
The PhD thesis was also carried out within the frame of a Marie Curie network called ClickGene, 
which was focused on studying possible membrane cooperative aspects to be used for innovative 
oxidative damage-based antitumoral strategies. As an Early Stage Researcher of this network, I had 
the chance to take part in the “Free Radicals in Bio- and Nano-Technology” Group, at the National 
Institute of Scientific Research “Demokritos” in Athens, where I had the opportunity to deepen three 
subjects related to cell membranes: 
1) the membrane involvement in several physiological and pathological processes, using in vitro 
experiments on a neuroblastoma cell line. In particular, the membrane remodeling induced by 
two different isoforms of apolipoproteins, ApoE4 and ApoE3, was examined, being 
apolipoproteins involved in the cholesterol and lipid transport in the brain and the ε4 allele, 
that codifies for ApoE4, the major genetic risk factor for Alzheimer’s disease. The results, 
that were published in BBA Biomembranes in July 2017, showed consistent differences in the 
membrane fatty acid profiles in the presence of both isoforms, opening a debate about the role 
of nutritional and metabolic adaptations as epigenetic determinants over the genetic 
predisposition; 
2) the biophysical and biotechnological meaning of trans fatty acids in cell membranes using 
liposome formulations, as models of cell membrane or as nanocarriers for the delivery of 
substances. Depending on whether liposomes contained natural cis or unnatural trans fatty 
acid residues, consistent differences in the lipid bilayer properties (rigidity, diameter, ζ-
potential) and in their encapsulation/release abilities were established. These results, 
published in the journal Molecules in November 2017, foresee the insertion of toxic trans 
fatty acids in tumor cell membranes, which would lead to a synergic antitumoral approach;  
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3) the chemical and analytical characteristics of the mono-trans isomers of DHA as the first 
unnatural isomers produced by the application of chemical and physical reagents to the natural 
cis DHA. For the first time the complete characterization using a dual synthetic approach, that 
allowed the identification of the six DHA mono-trans isomers by gas chromatography and 
nuclear magnetic resonance, has been performed. This characterization has been useful for 
analyses of nutraceutical formulations available in the market, and identification of trans 
isomer contaminants, harmful for the health. The work was published in Chemical Research 
in Toxicology in February 2018. 
Taken together, these results could better clarify the role of fatty acids in the composition of cellular 
membranes, which is affected by environmental, nutritional and metabolic conditions, providing also 
a palette of methodologies for the examination of membrane behaviors, impairments and changes 
linked with the fatty acid geometry and types. The contribution of this PhD thesis will be 
multidisciplinary in the fields of free radicals in medicine, membrane behavior in different culture 
conditions, biotechnology of liposomes and lipid analysis of nutraceuticals.  
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Chapter 1 
Introduction 
 
1.1. Cell membrane 
Cell membrane is a mixture of fluid state lipids, in which proteins and other molecules are embedded. 
It intervenes in many cellular processes [1].  
Its role is to delimit the cell externally, defining a physical barrier that separates the intracellular 
cytoplasmatic components from the extracellular environment, thus allowing nutritional exchange 
and communication with the surrounding environment, essential to ensure the cellular life. Indeed, 
the cell membrane can be freely crossed by small liposoluble molecules, but it is almost impenetrable 
by the water-soluble ones.  
Several transport mechanisms (either passive or active) allow it to selectively regulate what enters 
and exits the cell. Cell membrane also takes part in signal transduction, being a source of lipid 
mediators, which can be mobilized in response to specific stimuli [2]. 
The most abundant lipid components of the cell membrane are the phospholipids (Figure 1.1), 
consisting of a L-glycerol molecule in which the hydroxyl groups in positions 1 and 2 are esterified 
with two fatty acids and the hydroxyl group in position 3 is esterified with a phosphate group, which 
in turn is bound to small polar molecules such as choline, serine, ethanolamine or inositol.  
The presence of two hydrophobic hydrocarbon chains and a polar head confers amphipathic 
characteristics to these molecules, but also a cylindrical shape, that prevents them from forming 
spherical micelles.  
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Due to their nature, in fact, phospholipids spontaneously aggregate to bury their hydrophobic tails in 
the membrane inner layer and expose their hydrophilic heads to water, thus forming a continuous 
bilayer, where the hydrophobic tails are sandwiched between the hydrophilic head groups [3]. 
 
 
 
Figure 1.1. Structure of a membrane phospholipid bilayer. The enlargement shows the molecular structure of a 
representative phospholipid (1-palmitoyl, 2-oleoyl phosphatidylcoline). 
 
The tails are made of fatty acids, that may differ for the length of the carboxylic chain (normally 
between 14 and 24 carbon atoms) or for the presence (or absence) - and number - of double bonds. 
Using the classification based on the structure of the hydrocarbon chain (Figure 1.2), fatty acids can 
be distinguished in: 
 Saturated fatty acids (SFAs), which do not contain double bonds within the acyl chain; 
 Unsaturated fatty acids (UFAs), which are the ones that possess at least one double bond. 
They can be distinguished in: 
o Monounsaturated fatty acids (MUFAs), which present a single double bond in their 
structure; 
o Polyunsaturated fatty acids (PUFAs), which are characterized by the presence of two 
or more double bonds along the acyl chain. Depending on the position of the double 
bonds, PUFAs can be further distinguished between ω-3 and ω-6 PUFAs.  
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Figure 1.2. Molecular structures of representative components of the main fatty acid families. The spatial hindrance 
varies according to the number and the configuration of the double bonds in the acyl chain. 
 
In literature, fatty acids are usually reported (Table 1.1) with their non-systematic historical common 
names, which are concise and generally univocal.  
However, the most technically clear and descriptive nomenclature is the one based on the IUPAC 
directives, which has been established in 1979 to give uniformity and avoid ambiguities. Counting 
begins from the carboxylic acid end and double bond geometry, when necessary, is indicated with Z- 
or E-, whether the substituents are on the same side (Z, from German zusammen = together) or on 
opposite sides (E, from German entgegen = opposite) of the double bond [4].  
Some abbreviated descriptions, which usually indicate the number of carbons constituting the acyl 
chain, and the number of double bonds if present, are also in use. These are usually reported as C:D, 
where C represents the number of carbon atoms in the fatty acid chain and D is the number of double 
bonds. For example, a fatty acid that consists of 18 carbon atoms and has no double bonds is indicated 
as 18:0, whereas 18:1 describes an 18-carbon chain with one double bond in it. This notation can be 
ambiguous because different fatty acids can have the same length and the same numbers of double 
bonds, but each double bond can be either in a cis- or in a trans- configuration and take a specific 
position, therefore, not all the 18:1 fatty acids (for example) are identical. Consequently, the C:D 
notation is usually paired with other abbreviations that take into account the position of the double 
bonds along the acyl chain.  
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The double bond location is usually numbered starting from the carboxylic group, in which case the 
notation is Δ-n, where n represents the number of carbons that separate the double bond form the 
carboxylic group. There is a second notation in use, called ω-n, in which the numbering of carbon 
atoms starts from the terminal methyl group (CH3) rather than from the carboxyl group and n indicates 
the number of methyl groups that outdistance the unsaturation from the end of the acyl chain.  
Based on this last classification, PUFAs can be further classified in two families, omega-3 (ω-3 or n-
3) and omega-6 (ω-6 or n-6), according to the location of the last double bond relative to the terminal 
methyl end of the molecule. Such classification also reflects the fact that ω-6 and ω-3 fatty acids 
belong to different families, as they are synthesized starting from two different precursors that cannot 
be produced through physiological enzymatic pathways and need to be taken up with diet. These two 
fatty acid precursors are linoleic acid (LA, 9c,12c, 18:2), the precursor of the ω-6 series, and α-
linolenic acid (ALA, 9c,12c,15c, 18:3), the precursor for the ω-3 series; both linoleic and α-linolenic 
acids are considered essential fatty acids (EFAs).  
 
Table 1.1. Examples of the different nomenclatures of some common fatty acids. 
Common name IUPAC name C:D ∆-n ω-n 
Palmitic acid Hexadecanoic acid 16:0 / / 
Stearic acid Octadecanoic acid 18:0 / / 
Oleic acid 9Z-Octadecenoic acid 18:1 cis-Δ9 ω-9 
Elaidic acid 9E-Octadecenoic acid 18:1 trans-Δ9 ω-9 
Linoleic acid 9Z,12Z-Octadecadienoic acid 18:2 All-cis-Δ9,Δ12 ω-6 
α-Linolenic acid 9Z,12Z,15Z-Octadecatrienoic acid 18:3 All-cis-Δ9,Δ12,Δ15 ω-3 
Dihomo-γ-linolenic acid 8Z,11Z,14Z-Eicosatrienoic acid 20:3 All-cis-Δ8,Δ11,Δ14 ω-6 
Arachidonic acid 5Z,8Z,11Z,14Z-Eicosatetraenoic acid 20:4 All-cis-Δ5,Δ8,Δ11,Δ14 ω-6 
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1.2. Lipid geometry  
Double bonds in unsaturated fatty acids may have either the cis or the trans configuration, cis meaning 
that the two alkyl groups, R1 and R2, are on the same side of the C=C (Figure 1.3 A), trans meaning 
that the two alkyl groups are on opposite sides of the C=C (Figure 1.3 B). In eukaryotes, naturally 
occurring double bonds are in the cis configuration. This specific geometry induces a chain kink of 
30°, responsible for the characteristic angled structure that distinguishes unsaturated from saturated 
fatty acids. This kink has important effects on membrane organization. Indeed, saturated fatty acids 
are characterized by a linear shape that makes saturated acyl chains to form an ordered and tightly 
packed state in the phospholipid bilayer. On the other hand, unsaturated fatty acids, having cis-double 
bonds that produce the characteristic kinks in the phospholipid acyl chains, can disrupt the regularly 
packed assembly of saturated phospholipids, creating free spaces within the membrane bilayer. This 
disordered arrangement increases membrane permeability and fluidity, which in turn affect molecular 
exchanges within the membrane.  
Double bonds with cis geometry are generated during the biosynthesis of MUFAs and PUFAs by the 
regioselective and stereospecific activity of desaturase enzymes, which act only in specific positions 
of the carboxy chain and always mediate the formation of cis bonds [5]. 
 
 
Figure 1.3. Cis (A) and trans (B) configurations of double bonds. 
 
The trans geometric arrangement is not naturally present in mammalian cells because eukaryotic 
enzymes, at variance with prokariotic ones, do not have the ability to form trans double bounds or to 
carry out a trans isomerization.  
On the other hand, bacteria, such as Pseudomonas aeruginosa, Vibrio cholera and others, are 
endowed with an enzyme called isomerase, which, under environmental stress conditions, can convert 
the double bonds of the membrane phospholipids from the cis to the trans configuration. This is 
considered a short-term reversible defense mechanism, where the cis restitution passage is 500 times 
slower than the cis to trans isomerization. In fact, the trans configuration, by reducing the 
permeability and increasing the rigidity of the membrane, allows bacteria to survive to temperature 
increases or in the presence of disinfectants [6,7].  
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Since phospholipids are the main components of the membrane, their structure regulates the 
sopramolecular organization and the properties of the double layer. If one considers only the degree 
of unsaturation, a general rule on lipid assembly is that the lowest the number of double bonds, the 
higher the packing order of lipids. Thus, lipids are assembled with increasing rigidity according to 
this order: saturated> trans-unsaturated> cis-unsaturated acyl chain. The linear configuration of trans 
fatty acids (TFAs) generates strong intermolecular chain–chain interactions, resulting in a higher gel-
liquid phase transition temperature (Tm) for TFA chain melting. Tm is the temperature required to 
induce a change in lipid physical state, from the ordered gel phase, where the lipid chains are 
stretched, to the liquid crystalline phase, where the lipid chains are randomly oriented. For example, 
in the case of phosphatidylcholines (PCs) (Figure 1.4), keeping fixed the fatty acid in position 1 as 
palmitic acid (16:0), the variation from stearic (18:0) to elaidic (9t, 18:1) and oleic (9c, 18:1) acids in 
position 2, produces changes in the Tm value from 41.5, to 35 and -3 ° C, respectively [8,9]. 
 
 
Figure 1.4. Effects of lipid composition on membrane fluidity. 1-palmitoyl, 2-stearoyl, phosphatidylcholine (PSPC), 1-
palmitoyl, 2-elaidoyl, phosphatidylcholine (PEPC) and 1-palmitoyl, 2-oleoyl, phosphatidylcholine (POPC) differ for fatty 
acids in position R2: stearic (18:0), elaidic (9t, 18:1) and oleic (9c, 18:1) acids, respectively.  
 
The presence of TFAs has been reported for the first time in nutrition-related researches. TFAs can 
be found in foods that underwent industrial procedures such as partial hydrogenation and 
deodorization but also in dairy and meat products due to the microbial biohydrogenation process that 
16 
 
takes place in ruminants. It is now known that trans lipids can also derive from endogenous processes 
such as radical reactions involving sulfur-reactive species, which catalyze in vivo the cis-trans 
isomerization of double bonds. Here nutrition science meets free radical science, since both deal with 
understanding the role of the lipid geometry in membrane functionality, as well as in metabolic and 
signalling processes involving fatty acids. Indeed, since physiological mechanisms and membrane 
equilibria are based on the natural cis geometry of membrane fatty acids, the presence of the trans 
configuration in biological structures, either induced by radical stress or due to industrial 
manipulation, can lead to significant metabolic and pathological consequences. 
 
1.3. Effect of radical stress on lipids 
Cell membrane functionality is guaranteed by the correct quantitative balance among the fatty acid 
families mentioned above. Imbalances in favor of one family can lead to physio-pathological 
problems. It has been reported that eccessive radical stress induced by free radical molecules can alter 
the lipid composition of cell membrane and compromise its functionality. Free radicals are highly 
unstable and reactive molecules, characterized by the presence of an unpaired electron in their outer 
orbital. The peculiar electronic distribution makes free radicals very unstable and prone to reach a 
more stable state by interacting with other radicals or by subtracting hydrogen atoms from other 
molecules. 
Reactive Oxygen Species (ROS) and other reactive radical species are endogenously produced by the 
cells during normal physiological processes. Indeed, free radicals can derive from enzymatic 
processes like electron transport in the respiratory chain, phagocytosis, peroxysomal activity and 
detoxification mechanisms involving cytochrome P450. For example, the superoxide radical O2•(-) 
can be formed by interaction of molecular oxygen with electrons that occasionally escape the 
respiratory chain, especially in the oxo-reductive passage between coenzyme Q and cytochromes at 
the level of NADH-ubichinone reductase and ubichinone-cytochrome C reductase enzymes [10]. 
 
Another well-known biological mechanism is the Fenton reaction, which involves metal ions (such 
as Fe2+ and Cu2+) and gives rise to the hydroxyl radical (•OH) [11].  
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During inflammatory processes, cyclooxygenase (COX) and lipoxygenase (LOX) enzymes convert 
fatty acids into prostaglandins and thromboxanes through a specific free radical-catalyzed mechanism 
[12,13]. 
However, radical species can also have exogenous origins. Ionizing radiations (e.g. radioactive 
sources such as 60Co) or light (e.g. UV radiation) can induce omolitic processes with enough energy 
to omolytically break a covalent bond and produce free radical species [14]. 
In physiological conditions, living systems possess endogenous antioxidant defense mechanisms that 
counterbalance the effects of oxidants and protect structural and functional biomolecules from free 
radical attack. Superoxide dismutase, catalase, and glutathione peroxidase are the primary enzymes 
involved in direct elimination of ROS, whereas glutathione reductase and glucose-6-phosphate 
dehydrogenase intervene later to mantain a steady concentration of glutathione and NADPH, 
necessary for optimal functioning of the primary antioxidant enzymes [15-18].  
In these processes, micronutrients such as selenium, iron, copper, zinc, and manganese are required 
as cofactors for optimal catalytic activity and effective antioxidative defense. [19]. Additionally, 
glutathione, iron-binding transferrin, copper-binding ceruloplasmin, α-tocopherol (Vitamin E), 
carotenoids, and ascorbic acid (Vitamin C) are also involved in the anti-ROS defense system [20-22]. 
The production of radical substances may increase in some physiological conditions and in many 
pathological processes, such as inflammation, infections, cancerogenesis and aging. On the other 
hand, the endogenous production of antioxidant molecules and enzymes may be deficient for genetic, 
environmental or age-related reasons. Stressful lifestyle and bad habits, like excessive ozone 
exposure, sigarette smoking or unhealthy diet, can further compromise the equilibrium between the 
production and the elimination of radical species by antioxidant defenders.  
When the ROS levels exceed the antioxidant capacity of the cell, a condition known as oxidative 
stress, free radicals can quickly react with biological macromolecules, such as DNA, lipids and 
proteins, and lead to cell death via apoptosis or necrosis [23]. For this reason, oxidative stress is 
associated with numerous chronic conditions such as cardiovascular disorders (i.e. atherosclerosis, 
ischemia, stroke), diabetes, cancer, neurodegenerative diseases (i.e. Parkinson's and Alzheimer's 
diseases) and developmental disorders such as autism [24-29]. 
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1.3.1.  Lipid peroxidation 
At a membrane level, ROS can attack lipid chains of fatty acids (FAs) and start a process known as 
lipid peroxidation [30]. The main targets of this reaction are PUFAs, which are present in high 
concentrations in the cellular membrane phospholipids. 
Lipid peroxidation (Figure 1.5) proceeds through three sequential phases: 
 Initiation 
 Propagation 
 Termination 
The initiation of lipid peroxidation in membranes results from free radical attack that abstracts a 
hydrogen from a bisalyl methylene group of PUFA by an oxygen radical, generally the hydroxyl 
radical •OH, generating a carbon-centered lipid radical (L•).  
In the propagation phase, L• rearranges to produce a conjugated diene, which then readily reacts with 
molecular oxygen to yield a lipid hydroperoxyl radical (LOO•).  
LOO• can propagate the oxidizing chain reaction by abstracting electrons form other susceptible 
PUFAs, forming another carbon-centered radical and a lipid hydroperoxide (LOOH).  
The reaction is interrupted when two radical species combine in various ways to give non-radical 
products or by termination in the presence of a hydrogen or an electron donor.  
At the cell membrane level, peroxidated or degraded lipids are removed by phospholipase (PLA) 
action and this results in loss of PUFAs and increased permeability of the membrane to substances 
such as calcium ions.  
In this way, lipid peroxidation can seriously alter the membrane functionality and integrity, since it 
can lead to loss of enzyme and receptor activity and can have deleterious effects on secretory 
functions [31]. 
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Figure 1.5. Reaction mechanism of lipid peroxidation induced by reactive oxygen species. 
 
Depending on the membrane fatty acid composition, the membrane vulnerability to peroxidation can 
substantially differ, with PUFAs being generally the most vulnerable. Therefore, membrane 
susceptibility to peroxidation can be expressed by the peroxidation index (PI), which considers the 
relative percentages and susceptibility to peroxidation damage of the different fatty acids (Figure 
1.6).  
High values of PI correlate with high percentages of PUFAs in the membrane and reflects high 
susceptibility to peroxidation. On the other hand, low PI values are correlated with a reduced content 
of PUFAs in favour of SFAs and MUFAs, and for this reason to a high resistance to ROS attack [32-
34].  
 
 
Figure 1.6. Peroxidation index equation. 
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1.3.2.  Cis-trans isomerization 
It is well documented that sulfur-centered radicals can compete with ROS to give lipid damage [35]. 
Sulfur-centered radicals can attack MUFAs and PUFAs and catalyze the conversion from cis to trans 
geometry of lipid double bonds, in a reaction known as cis-trans isomerization.  
Several radicals (e.g. RS•, RSe•, RSO2•, NO2•) and atoms (such as Br• or I•) can induce the cis-trans 
isomerization reaction but among them the most relevant from a biological point of view are the thiyl 
radicals (RS•) [36].  
RS• can be formed from sulfur-containing molecules such as free molecules (e.g. H2S and CH3SH), 
amino acids (e.g. cysteine and methionine), peptides or proteins (e.g. glutathione, Met-enkephalin, 
albumin, β-amyloid and metallothionein) [37-39]. 
The reaction mechanism consists of an addition-elimination reaction (Figure 1.7). Initially, the RS• 
sulfur radical attacks the double bond, forming a radical intermediate that evolves into a very rapid 
monomolecular process with fragmentation of the radical species and restoration of the double bond. 
However, when the double bond is restored, it has a different geometry, the trans one, that is 
thermodynamically and kinetically more stable than the cis configuration. In this process only 
geometric trans isomers can be obtained because there is no possibility of double bond rearrangement 
that would lead to positional isomers. 
 
 
Figure 1.7. Mechanism of cis-trans isomerization catalyzed by thiyl radicals (RS•). 
The rate constants obtained at 22°C are reported. 
 
In the cis-trans isomerization reaction, the radical acts as a catalyst as it is regenerated at each 
isomerization step. It can carry out a catalytic cycle that reaches the value of about 300 molecules per 
cycle, depending on the conditions and molecules involved. 
Various methods for reproducing the endogenous cis-trans isomerization reaction in the laboratory 
are provided in the literature. They involve the use of various thiol compounds, which differ not only 
for the molecular structure but also for their partition coefficient. Among the various compounds 
tested, the one that has proved to be the most widely applicable for the study of this reaction is 2-
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mercaptoethanol (HOCH2CH2SH). Indeed, having amphiphilic properties, 2-mercaptoethanol makes 
it possible to study the cis-trans isomerization reaction in both organic and aqueous solvents, with no 
restrictions related to the distribution coefficient. 
For the generation of sulfur-centered radical species, various techniques can be employed. Among 
them, photolysis, that requires a UV lamp (254 nm) with low pressure mercury vapor (5.5 W), can 
be used to induce the homolytic breakdown of a thiol S-H bond (RSH) and generate a thiyl radical 
(RS•) (Figure 1.8). 
 
Figure 1.8. Mechanism of formation of thiyl radicals (RS•) induced by photolysis. 
 
Another technique that can be used to form thiyl radicals is gamma (γ)-radiolysis, which causes the 
radiolysis of water (Figure 1.9) to give rise to a hydroxyl radical (•OH) and a hydrogen atom (H•). 
The generated radicals are in their turn able to extract a hydrogen atom from a thiol, thus producing 
a thiyl radical (RS•).  
 
Figure 1.9. Radiolysis of water induced by γ-radiolysis and formation of thiyl radicals (RS•). 
In brackets the values representing the radiation yields (G) expressed in μmol J-1. 
 
The isomerization reaction is a step-by-step reaction (Figure 1.10). This means that if the reaction 
occurs in the presence of PUFAs, the double bonds are isomerized one by one, so that the first product 
consists of mono-trans isomers, from which di-trans, tri-trans and so on, can also be formed.  
When the cis-trans isomerization reaction takes place in a homogeneous solution, every cis double 
bond is isomerized with the same efficacy independently from the position of the double bond along 
the chain. Therefore, mono-trans isomers, as well as being the first products to be formed, are also 
obtained in the same amounts for all the double bonds involved. 
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Figure 1.10. Step-by-step mechanism of cis-trans isomerization in PUFAs. The reaction of the thiyl radical (RS•) with 
the all-cis isomer (1) leads to the formation of two mono-trans isomers (2 and 3), that are precursors of the di-trans isomer 
(4). 
 
However, in the biological environment, fatty acids (FAs) are constituents of the cell membrane and 
for this reason the cis-trans isomerization is influenced by the supramolecular organization of the 
phospholipids. Indeed, thiyl radicals must penetrate in the depth of the cellular membrane prior to 
give rise to the isomerization reaction. This means that the double bonds are not as equivalently 
reactive as they were in solution because the double bonds that are close to the polar head are more 
exposed and easily attacked by free radicals than the ones hidden in the hydrophobic bilayer depth.  
 
1.4. Exogenous sources of trans fatty acids 
In addition to cis-trans isomerization catalyzed by sulfur-centered radicals, trans fatty acids (TFAs) 
can be formed during specific industrial processes and enter the biological structures and metabolism 
after ingestion of trans containing foods.  
 
1.4.1.  Partial Hydrogenation  
Hydrogenation [40] is a chemical process that leads to saturation (or partial saturation) of PUFAs 
present in vegetable oils by addition of hydrogen atoms to the double bonds (Figure 1.11).  
A big limitation for companies on the use of PUFA-rich oils is that PUFA double bonds are highly 
unstable and susceptible to oxidation, causing fat rancidity and flavor alterations of foods. 
Hydrogenated fats find large application in the industrial preparation of baked goods and in the 
composition of margarines because, having a reduced number of unsaturated bonds, they display 
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higher chemical stability to oxidation compared to unsaturated lipids. For this reason, hydrogenated 
fats have replaced unsaturated oils in the preparation of biscuits, snacks, ice creams and junk food, 
since they represent the cheaper alternative to other saturated animal derivatives, like butter and lard, 
and they increase the durability, consistency and palatability of commercial products [41]. 
 
   
Figure 1.11. Mechanism of formation of trans fatty acids (TFAs) during the hydrogenation process. 
 
Often, during the hydrogenation process, saturation fails leading to significant alterations in the 
structure of FAs, that is the conversion from cis to trans double bond geometry and the formation of 
TFAs [42].  
TFA levels depend on several parameters, such as the initial lipid composition, the type of catalyst 
employed and other hydrogenation conditions such as temperature, pressure and stirring conditions. 
For example, low hydrogen pressure, moderate stirring speed and high temperatures lead to scarcity 
of hydrogen on the catalyst surface, which in turn favors the formation of TFAs [43].  
TFAs produced during these processes can be either in the form of geometric isomers, when the trans 
double bond remains in the same position, and positional isomers, when the trans double bond 
migrates sideways in either direction along the acyl chain. (Figure 1.12).  
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Figure 1.12. Representative positional and geometrical trans isomers of oleic acid (9c, 18:1). 
 
1.4.2.  Deodorization 
Another process that food industries commonly employ to satisfy the needs of the market is 
deodorization. Deodorization is an oil refining treatment that is used to eliminate or minimize the 
unpleasant smell of some oily products, for example fish oils used in ω-3 supplements.  
During deodorization, through the use of high vacuum vapor (1-10 mbar) and high temperature (180-
220 °C) distillation, volatile components that are responsible for the smell, are removed so that the 
distilled final product has the ideal organoleptic characteristics for industrial use.  
Unfortunately, deodorization, as well as other refining processes, can worsen the antioxidant activity 
of natural compounds and produce TFAs as degradation products [44]. When isomerization is 
produced by heat, almost exclusively geometric isomers are formed, wherein the double bond position 
remains the same as in the starting fatty acids. The amount of trans isomers, however, is strongly 
dependent on the degree of molecular unsaturation, which increases the lipid vulnerability to heat 
treatment.  
Recently, rats fed with low- and high-fat diet including deodorized fish oil were studied in order to 
detect the presence of trans isomers of eicosapentaenoic acid (EPA). It was noticed that mono-trans 
isomers of EPA, in particular 17-trans, were incorporated at the level of the liver mitochondrial 
membranes [45]. 
 
1.4.3.  Frying 
Excessive thermal exposure, as is the case of frying oils at a temperature close to or higher than the 
smoke point, favors the cis to trans conversion [46-48]. During the frying process, heat transfer from 
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oil to food occurs. Among the several physical and chemical modifications like oxidation, pyrolysis, 
polymerization, hydrolysis that occur, cis-trans isomerization reaction also takes place [49].  
The formation of TFAs during food frying is closely related to the temperature reached and to the 
times oil is used [50]. When partially hydrogenated fats are used, the final concentration of TFAs is 
even higher, due to the high initial content of these fatty acids in the starting materials [51].  
 
1.4.4.  Microbial biohydrogenation  
Some foods naturally contain TFAs, such as, for example, meat, milk and other diary products from 
ruminants, such as cattle, sheeps and goats [52]. This phenomenon is related to the gastrointestinal 
physiology of ruminants which undergo bacterial fermentation of the digestive content. During the 
digestive process, the microorganism activity results in the conversion of cis fatty acids into TFAs, 
that can be absorbed into the intestine and consequently secreted in milk and/or accumulated in the 
meat. Trans-vaccenic acid (11t, 18:1), whose metabolism and fuctions have been widely studied, is a 
typical trans isomer derived from bacterial fermentation [53].  
Microbial hydrogenation can also lead to the formation of conjugated linoleic acids (CLAs), a group 
of positional and geometric isomers of linoleic acid (LA, 9c, 12c, 18:2) which are characterized by 
the presence of two conjugated double bonds, i.e. bonds that are not separated, as in LA, by methylene 
groups (-CH2-). Despite the presence of trans unsaturations, CLAs are reported to have 
antiinflammatory, anticarcinogenic, antiadipogenic, antidiabetic and antihypertensive effects in 
animal models [54-58].  
 
1.5. Effects of trans fatty acids 
TFAs have been reported to induce several adverse effects in humans [59]. Among them, TFAs have 
been associated with higher levels of systemic inflammation markers, in particular tumor necrosis 
factor-α, interleukin-6 and C-reactive protein, thus suggesting a possible pro-inflammatory activity 
of TFAs. High intake of TFAs has been related with high levels of intercellular and vascular cell 
adhesion molecules (sICAM-1 and sVCAM-1), which are circulating markers of endothelial 
dysfunction.  
TFA consumption has been positively correlated with plasma E-selectin concentrations, another 
endothelial marker, reinforcing the idea that TFAs may compromise endothelial integrity. Although 
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the action mechanism is not clear, hypotheses about the incorporation of TFAs into cell membrane 
phospholipids and the alteration of specific membrane receptors have been formulated. Activation of 
inflammatory responses and endothelial dysfunction may show a connection between TFA 
consumption and risk of coronary heart disease and diabetes. In animal studies, TFA intake alters 
adipocyte gene expression of peroxisome proliferator-activated receptor, resistin, and lipoprotein 
lipase [60]. TFAs also influence adipocyte fatty acid metabolism in humans [61].  
TFAs have been implicated in the incidence of obesity and many adverse effects of TFAs have been 
related to cardiovascular and coronary complications [40,62]. TFAs, similarly to SFAs, tend to 
increase total cholesterolemia and low-density lipoproteins (LDLs), whose accumulation within the 
vascular walls can result in the formation of atherosclerotic plaques with increased risk of mortality. 
Lipid profile changes are aggravated by the fact that TFAs reduce the plasma levels of the high-
density lipoproteins (HDLs), which represent the antiatherogenic fraction [63].  
A study demonstrated that elaidic acid (9t,18:1) increases plasma cholesteryl ester transfer protein 
activity in comparison with oleic acid (9c, 18:1), resulting in increased transfer of TFA-enriched 
cholesteryl esters from HDL to LDL [64,65]. Higher plasmatic levels of trans-18:2 and lower levels 
of trans-18:1 fatty acids have been associated with fatal ischemic heart disease and sudden cardiac 
death have been reported. This association might also be due to proarrhythmic effects of trans-18:2 
[66]. A high consumption of TFAs during pregnancy has been reported to affect intrauterine 
development [67].  
Additionally, studies on the incorporation and metabolism of cis- and trans-MUFAs in developing 
and mature brain, have shown that elaidic acid can be incorporated into phospholipids in similar rates 
as the cis isomer but is preferentially esterified to the l-position of phosphoglycerides, probably due 
to its similarity with stearic acid, the corresponding SFA. This suggests that the brain does not ensure 
metabolic exclusion of these potentially deleterious components from the brain membrane lipids, 
although there may be a mechanism for a more rapid removal of TFAs [68]. 
TFA analysis has gained more importance since the establishment of maximum TFA daily intake to 
1% of total ingested calories by the World Health Organization (WHO), which corresponds to no 
more than 2-2.5 grams per day of TFAs. In order to comply with such restrictions, the Food and Drug 
Administration (FDA) has required to list the TFA content among the nutritional values on product 
labels [69]. 
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1.6. Lipid signalling  
Lipids have long since been recognized as crucial bioactive molecules involved in several 
physiological responses to regulate metabolic homeostasis, signal transduction and molecular 
recognition pathways. Indeed, lipids can respond to physiological, pathological and environmental 
variations through the dynamic remodeling of membrane lipids, which consist in the redistribution of 
FAs in membrane phospholipids. The FA remodeling usually involves two enzymes, phospholipase 
A1 (PLA1) and phospholipase A2 (PLA2), which hydrolyze the acyl bond in positions 1 and 2, 
respectively, to release a free FA (FFA) and a lysophospholipid (LPL).  
This mechanism is important not only for the physiological lipid turnover but also for the host 
defence, since it removes damaged phospholipids and initiates signalling pathways. Indeed, PUFAs, 
that usually occupy position 2 of membrane phospholipids, can be easily peroxidated by ROS, 
resulting in a structural and functional alteration of the membrane.  
PLA2 can remove these fatty acids at the level of the double lipid layer, replacing them with fatty 
acids present in the cytoplasmic pool. The bioactive lipids generated from LPLs include 
lysophosphatidylcholine, platelet activating factor, lysophosphatydic acid, sphingosine-1-phosphate 
and endocannabinoids.  
Depending on the nature of phospholipids involved, over two dozens of bioactive lipid mediators can 
be formed from FFAs, some of which have pro-inflammatory effects, while others have anti-
inflammatory and pro-resolution properties. For example, ARA, an ω-6 fatty acid, can give rise to 
eicosanoid metabolites. They consist of prostaglandins (PGs) and thromboxanes (TXs) generated via 
the action of cyclooxygenases 1 and 2 (COX-1 and COX-2), or leukotrienes (LTs), generated via the 
action of 5-lipoxygenase (5-LOX). All these madiators are involved in the inflammatory cascade. 
However, recent studies indicate that, as inflammation proceeds, neutrophils within confined 
exudates, influenced by cells and substrates in the local environment, can change their phenotype and 
start converting ARA into lipoxins (LXs), that intervene to actively terminate inflammation and 
promote resolution [70-72]. Inflammation resolution consists in the reduction or removal of 
leukocytes and debris from inflamed sites, thus enabling the return to homeostasis. 
Literature reports three other new families of bioactive mediators, named (neuro)protectins (NPs), 
resolvins (RVs) and maresins (MARs) which have anti-inflammatory and pro-resolution properties. 
These mediators are biosyntesized from essential FA precursors of the ω-3 series, EPA and DHA 
(Figure 1.13) [73,74].  
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Figure 1.13. Omega-3 and omega-6 fatty acid metabolic pathways with main eicosanoid derivatives of DGLA, ARA, 
EPA and DHA. PGE: prostaglandin E, PGI: prostacyclin, TXA: thromboxane A, LTB: leukotriene B, LTC: leukotriene 
C, LTE: leukotriene E, LXA: lipoxin A, RVE: resolvin E, RVD: resolvin D, NPD: neuroprotection D, MAR: maresines. 
Adapted from [77,78].  
 
Uncontrolled inflammation has been associated with many diseases that had not previously been 
considered to be classic inflammatory diseases, including atherosclerosis, cancer, asthma and several 
neurological disorders, such as Alzheimer's disease and Parkinson's disease. In this view, a close 
connection between nutrition, dietary supplementation and biosynthesis of lipid mediators, must be 
considered. 
As previously mentioned (Chapter 1, Paragraph 1.1), the precursors of the ω-6 and ω -3 series, that 
are linoleic acid (LA, 18:2 ω-6) and α-linolenic acid (ALA, 18:3 ω-3), respectively, are both essential 
fatty acids (EFAs) that have to be introduced throught the diet because the human body cannot 
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sinthesize them due to the lack of specific desaturase enzymes. Often, dietary assumption of these 
precursors is not sufficient to supply the correct amount of their important long chain derivatives. 
Indeed, ARA can be synthesized from LA by alternative chain desaturation and elongation steps. 
However, convertion of ALA to DHA is limited, resulting in lower blood levels of DHA than those 
obtained through direct uptake.  
Western diets over the last decades tends to be largely unbalanced towards the ω-6 fatty acids, 
showing deficiencies of ω-3 fatty acids and consequently increasing the ω-6 to ω-3 ratio (ω-6/ω-3) 
[75]. Because of lifestyle, nutrition, metabolism and stress, imbalances in lipid signalling pathways 
can contribute to disease progression in chronic inflammation, autoimmunity, allergy, cancer, 
atherosclerosis, hypertension, heart hypertrophy, metabolic and degenerative diseases [76]. 
 
1.7. Lipidomics for lipid biomarker discovery 
Variations in the composition of human body lipids can be monitored through lipidomics, which 
represents a powerful diagnostic tool to assess the quantity and quality of FA constituents and to 
monitor the remodeling of membrane FA composition associated with various physiological and 
pathological conditions [79].  
Lipidomics aims at understanding membrane lipid role in the functioning and regulation of cellular 
behaviour. Indeed, it is possible to detect lipid variations occurring in health and disease situations, 
in order to gain knowledge on their connections with complex mechanisms of cellular homeostasis 
and signalling. The "dynamic" perspective offered by lipidomics allows the possibility of deepening 
the knowledge about the individual heritage and lipid transformation and of relating lipid type and 
quantity with health conditions. It is now possible to identify, for each tissue, the normality ranges 
for membrane FA composition in standard health conditions.  
To date, lipidomic analytical strategies are applied to a wide variety of biological samples, such as 
blood, plasma, serum, cerebrospinal fluid, urine and biological tissue derived from animal models or 
clinical patients. In particular, red blood cells (RBCs) can be ideal reporters for evaluating individual 
values and possible deviations connected with intrinsic or extrinsic metabolic reasons (e.g. 
inflammation, stress and dysfunctional diet). Indeed, unlike traditional analyses, which are carried 
out on plasma and give information about FA dietary intakes of a few weeks before withdrawal, RBC 
lipidomic analyses account for more stable information obtained from metabolic transformations 
together with stabilized dietary contributions.  
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In this view, the lipidomics approach could contribute to underline alterations in the lipid metabolism 
or in both physiological and pathological conditions, information that can be used as guidance for 
personalized medicine, dietary intervention, as well as in biomarker discovery. Indeed, lipidomics 
has been successfully applied to discover biomarkers for a variety of diseases, such as metabolic and 
cardiovascular disease.  
Moreover, lipidomics can play a key role in mechanistic studies, risk prediction, and therapeutic 
monitoring for such pathologies in which aberrant lipid metabolism occur, such as diabetes and 
obesity. Since lipids play important roles in cell growth and metabolism, which are essential for 
rapidly proliferating cancer cells, lipidomics has been used to report changes in lipid metabolism and 
homeostasis undergone by cancer cells.  
Lipidomic analysis also clarified the role of some lipid-derived bioactive molecules that are involved 
in ophthalmological processes releated with eye disease [80].  
Lipidomics has been used as well to understand diet-induced changes in the structure, composition, 
and function of cellular lipids. Addtionally, lipidomics might be useful for evaluating chronic effects 
associated with the dietary intake of specific components and for providing nutritional advice and 
lifestyle corrections.  
The ultimate goal is to integrate the lipidomic knowledge with therapeutical, nutritional and 
nutraceutical aspects, and include lipids as important elements for prevention strategies and integrated 
medicine. 
 
 
31 
 
1.8. Thesis Goals and Objectives  
In view of the above-mentioned importance of cell membrane lipid composition in health and disease, 
during my PhD I focused my interest on four different topics.  
The first task has been the study of the cell membrane involvement in Autism Spectrum Disorder 
(ASD), a heterogeneous group of neurodevelopmental disorders caused by a combination of complex 
genetic traits and environmental factors. We designed an innovative diagnostic approach focused on 
the erythrocyte membranes, which included the lipidomic analysis of mature erythrocytes and their 
hyperspectral characterization by means of hyperspectral enhanced dark field microscopy (HDFM), 
with the aim of detecting differences between ASD and healthy subjects in the membrane fatty acid 
composition and in the scattering spectra and of finding correlations with clinical features of ASD. 
Within the “ClickGene” Marie Curie network, having as objective the study of membrane cooperative 
effects for innovative antitumoral strategies based on oxidative damages, I carried out some 
experiments at the National Center of Scientific Research “Demokritos”, in Athens, focused on three 
different aspects, the first being a study related to the major neurodegenerative and disabling disorder 
in the elders, Alzheimer’s disease (AD), that has long been correlated with enhanced oxidative stress 
and altered lipid metabolism. The study was aimed at investigating whether expressing the ε4 allele 
of the apoE gene (considered to be predisponent to the disease) or the ε3 allele (considered to be 
protective) induced changes in the membrane lipidomics. 
Another study carried out at the Demokritos Center concerned the biophysical and biotechnological 
implications of the presence of trans fatty acids in cell membranes, where the development of specific 
liposomal formulations was used to study whether different concentrations of trans fatty acid-
containing phospholipid affected liposome diameter, fluidity and permeability.   
Finally, the chemical and analytical characterization of the six mono-trans isomers of DHA, an 
essential ω-3 fatty acid, was performed using two different synthetic approaches combined with gas 
chromatography and nuclear magnetic resonance. Such characterization was finalized to the building 
of a molecular reference library to be used for the identification of DHA trans isomers in nutraceutical 
formulations.  
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Chapter 2 
Analytical Methodologies 
 
2.1. Lipid analyses 
Lipidomic approach is used to study complex mixtures containing different lipid classes. The 
analytical techniques for the detection and quantification of lipids are characterized by high 
selectivity, that is the ability to determine the analyte in the presence of interferents in the matrix. 
The lipid analysis of a sample usually involves some common key steps [1]: 
 extraction of the lipid fraction from the starting matrix; 
 isolation of the lipid fractions of interest; 
 derivatization of the lipid components; 
 identification and quantification of FAs. 
The accuracy of the analysis is influenced by the effectiveness of each single step. For this reason, 
the analytical method of extraction should be developed taking into account the following 
requirements: 
 ability to inhibit the action of enzymes such as lipases and phospholipases, in order to avoid 
lipid degradation during the analysis; 
 ability to limit oxidative and isomerization phenomena of the double bonds during extraction 
(generally induced by high temperatures and unsuitable solvents); 
 ability to extract all the constituents of the lipid fraction; 
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 ability to separate lipids from other low polarity components (apolar interferents) that could 
compromise the quality of the analysis. 
 
2.2. Lipid extraction 
Lipid extraction permits to isolate lipids from biological matrices and remove any sources of 
interference, such as proteins and sugars. Lipids are usually characterized by hydrophobic properties 
that make them immiscible with water and soluble in non polar (organic) solvents. However, due to 
the broad variety of lipids, some classes of lipids, such as phospholipids, have amphiphilic properties, 
that confer them greater polarity. 
For this reason, the most efficient lipid extraction method is the liquid-liquid extraction proposed by 
Folch in 1957, which suggested the use of a chloroform/methanol mixture (2:1 v/v) for quantitative 
lipid isolation. [2]. Even if other effective mixtures were identified, aimed at reducing the solvent 
toxicity and increasing selectivity, Folch method remains the most commonly used procedure for the 
extraction of lipids from biological matrices.  
 
2.3. Thin Layer Chromatography (TLC) 
After the extraction step, thin layer chromatography (TLC) can be used to verify in a fast and 
relatively unexpensive way the efficiency of the extraction method [3]. Usually, it is particularly 
suitable for carrying out qualitative or semi-quantitative evaluations as well as to follow the progress 
of a chemical reaction. 
Like all chromatographic techniques, TLC is based on the different distribution of similar substances 
between a stationary phase and a mobile phase, depending on the affinity of each substance with the 
substrates. Molecules with high affinity for the mobile phase will migrate faster along the plate, while 
molecules with high affinity for the stationary phase will stuck close to the baseline, without 
significally migrating. The TLC plate is usually coated with a suitable adsorbing material, such as 
silice gel or alumina, that constitutes the stationary phase. The mobile phase is a solvent (or a mixture 
of solvents) that is characterized by a low affinity with the stationary phase and a good ability to 
separate the components of interest. Depending on the polarity of the lipid families present in the 
sample, different mobile phases can be employed. 
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The procedure consists on the deposition of a small amount of the lipid sample on the TLC plate, that 
is then immersed in a chamber saturated with the appropiate mobile phase. Over time, the solvent 
moves up the TLC plate due to capillary forces and separates different lipid fractions based on their 
affinity for the absorbing material. Standard reference substances are usually spotted beside the lipid 
mixture to allow recognition and assignment of the lipid components.  
Since most lipids are colorless and TLC spots cannot be seen, stains can be applied at the end of the 
separation by spraying - or by dipping the plate into - a staining solution, to form colored compounds 
that can be identified by direct observation or UV analysis.  
For these set of experiment, cerium ammonium molibdate (CAM) was chosen as staining technique, 
due to its sensitivity and wide applicability. CAM can be prepared by dissolving 1.5 g of 
phosphomolybdic acid and 1.0 g of cerium (IV) sulfate in a mixture of 6 ml of sulfuric acid (H2SO4) 
and 94 ml of distilled water. After exposure to heating conditions, Mo5+ and Mo4+ compounds are 
formed and green to blue colored spots on a yellow background appear on the plate. 
Each substance has a specific retention factor (Rf), corresponding to the distance of the spot from the 
origin compared with the distance covered by the solvent (solvent front). By comparing the distance 
reached by the experimental spots with that of standards of known composition, it is possible to 
identify the lipids present in the original mixture (Figure 2.1).  
 
 
Figure 2.1. Schematic representation of a TLC plate and Rf definition. 
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2.3.1. Silver-ion thin layer chromatography (Ag-TLC) 
 
Silver-ion thin layer chromatography (Ag-TLC) is a well-known analytical method for monitoring 
the isomerization reaction since it allows the separation of cis and trans lipid isomers [4].  
The separation by Ag-TLC is based on the ability of unsaturated organic compounds to form 
complexes with transition metals, specifically with silver ion Ag (I). Indeed, the pi electrons of double 
bonds in the lipid fatty acyl residues reversibly react with silver ions to form polar complexes; the 
greater the number of double bonds, the stronger the complexation effect. 
The formation of the lipid-Ag+ complex involves a charge transfer, in which the unsaturated 
compound acts as an electron donor and the Ag+ ion acts as an electron-acceptor (Figure 2.2).  
On this regard, the current model assumes the formation of a sigma-type bond between the occupied 
2p orbitals of an olefinic double bond and the free 5s and 5p orbitals of the transition metal ion, and 
a (probably weaker) pi acceptor backbond between the occupied 4d orbitals of the metal ion and the 
free antibonding 2p pi* orbitals of the olefinic bond [5,6]. 
 
 
Figure 2.2. Interaction between Ag+ and an olefinic double bond. Image from http://lipidlibrary.aocs.org. 
 
The complex formation efficiency is influenced by the ease with which the overlapping of the orbitals 
can occur, which is determined by steric factors. Generally, fully saturated lipids do not form 
complexes and migrate to the top of the plate, while those containing one or more unsaturated bonds 
come next. This technique is exploited for the separation of geometrical isomers, since the isomers in 
the cis configuration form a more stable complex with the stationary phase and are retained more 
compared to their trans analogues. By optimizing the mobile phase to yield the suitable separation, 
trans-isomers have higher Rf, while cis-isomers run slower on the Ag-TLC plate.  
A 5% w/v silver nitrate solution (AgNO3) in acetonitrile was prepared dissolving 2.5 g of AgNO3 in 
50 mL of acetonitrile. The silica-based plates with glass support were immersed for 15 minutes in 
this solution of 5% AgNO3 in acetonitrile protected from light, and subsequently dried in an oven for 
one hour. The surface-functionalized TLC plates can be stored in a dry and dark place for a maximum 
of one week. The spots can be detected by spraying with CAM stain and by heating until blue brown 
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spots on a yellow background could be observed. When employed for preparative use, Ag-TLC plates 
are treated with CAM only on a small portion, to allow the recovery of the unaltered compounds from 
the remaining portion.  
 
2.4. Gas Chromatography (GC) 
The step that follows lipid extraction is the fatty acid derivatization to more volatile compounds, using 
the transesterification reaction that leads to fatty acid methyl ester (FAME) derivatives.  
FAMEs can be analyzed by gas chromatography (GC), that is the election technique for lipid 
separation and quantification. The derivatization step is necessary since most lipids have low 
volatility and some tendency to degrade at high temperatures.  
The transesterification procedure to FAMEs can take place with both acidic or basic reagents as 
catalysts. The most efficient derivatization method to obtain FAMEs is the transesterification reaction 
carried out in a basic environment [7]. The conditions usually require anhydrous methanol (CH3OH) 
in the presence of a basic catalyst, usually potassium hydroxide (KOH), which facilitates the 
exchange between methanol and glycerol of the O-acyl lipids, such as triglycerides and phospholipids 
(Figure 2.3). 
 
 
Figure 2.3. Base-catalysed transesterification mechanism of an acyl chain to its methyl ester derivative. 
 
In this step, not only the base but also the molarity and type of solvent used become determinative 
for the quantitative success of the reaction. In basic conditions, the reaction takes place in a very short 
time without inducing isomerization and migration phenomena, processes that easily take place in 
acidic environment. Attention must be paid to exclude the presence of water in the reaction 
environment and to prevent the occurrence of hydrolysis and FFA formation. Water is used to quench 
the reaction, since it neutralizes the anions present, and FAMEs can be extracted with hexane and, 
once anhydrified, can be injected in the GC.  
GC equipment (Figure 2.4) consists of a sample injection system, connected to a capillary column 
that is flushed with the carrier gas in a thermostated chamber (oven). The column leads to a detector 
that is connected to an external unit equipped with software for data processing. In gas 
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chromatography, the mobile phase is a carrier gas, usually an inert gas such as helium or an unreactive 
gas such as nitrogen. The sample is heated in the injection chamber to volatilize the FAMEs and then 
carried into the separating column by a heated carrier gas.  
To inject a liquid phase sample into a capillary column, spit or splitless modes can be used. In the 
split mode, 1 μL of the sample is introduced into the injector, but only a small percentage of steam 
generated within the liner enters in the column, while the remaining part is removed though the 
operation of a valve. This mode guarantees high resolution separations thanks to the high flow rate at 
the split point. In the case of trace compound analyses, however, the splitless mode is more indicated, 
which involves the processing of the full injected sample in the column. 
 
 
Figure 2.4. Schematic representation of a gas chromatogram equipped with a spit/splitless sample injector. 
 
FAMEs in the mixture can be separated because of their differing affinities for the matrix in the 
column. The stronger the affinity between a specific molecule and the matrix the slower it passes 
through the column. After being separated by the column, each molecule passes by a suitable detector 
that allows its quantification.  
For the GC analyses reported in this thesis, a gas chromatograph (GC) equipped with a 60 meters 
capillary column in fused silica having a stationary phase consisting of (50%-cyanopropyl)-
methylpolysiloxane (DB-23, Agilent, USA), was used. The GC is connected to a flame ionization 
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detector (FID). The operating mechanism of FID provides the detection of ions formed by organic 
compound combustion on a hydrogen flame, that is proportional to the concentration of organic 
species in the sample gas stream. The molar response of hydrocarbons is usually equal to the number 
of carbon atoms in their molecule, while oxygenated lipids and other species that 
contain heteroatoms tend to have a lower response factor.  
For more details regarding gas carrier, volume of injection, oven temperature program and operating 
pressures, please refer to the experimental sections of each chapter. 
The specificities of DB-23 column, including the length and the medium polarity of the stationary 
phase, combined with the oven temperature set up, guarantee the selectivity and efficiency required 
for the resolution of complex FAME mixture and achieve the separation of a high number of 
geometrical isomers. 
With the conditions set up in our laboratory, elution order depends on the number of carbon atoms 
and the number of double bonds in the acyl chain. For example, the retention time of FAMEs 
increases as the number of carbons increases, being short chain fatty acids the first ones to elute and 
long chain fatty acids the last ones (14:0 < 16:0 < 18:0 < 20:0 < 22:0). When chains differ in the 
number or in the position of unsaturated bonds rather than in the chain length, SFAs are usually the 
first ones to elute, while MUFAs and PUFAs strongly interact with the stationary phase and are 
retained with increasing strenght inside the column (18:0 < 18:1 < 18:2 < 18:3).  
Considering the position of the double bonds, usually FAMEs with the unsaturation closer to the 
carboxylic group are eluted first (9c,18:1 < 11c,18:1), and the same happens when the double bond 
has trans geometry (9t,18:1 < 11t,18:1). In analogy with saturated FAMEs, when the only difference 
is the configuration of the double bond, trans isomers are less retained compared to the cis analogues 
(9t,18:1 < 9c,18:1). 
However, these should only be considered general indications, because for FAMEs with more than 
18 carbon atoms, the separation of trans isomers does not comply with these elution criteria. The 
unpredictable elution of PUFA methyl esters with more than 18 carbons reinforces the need of 
molecular reference libraries of standards for the precise interpretation of GC chromatograms. The 
most common FAMEs with the cis geometry are commercially available. However, for the mono-
trans isomers of our interest, such as ARA [8] and EPA [9], it was necessary to build up synthetic 
methods for the full characterization and the correct allocation of the peaks. 
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GC presents many advantages, since it requires small samples (typically 1-2 μL) and is characterized 
by high resolution and high sensitivity for effect of the capillary columns. Depending on the length 
of the column and the set up of the oven ramp, the analyses can require longer analysis times.  
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Chapter 3 
Autism Spectrum Disorder 
 
3.1. Introduction 
Autism Spectrum Disorder (ASD) is a major neurodevelopmental disorder, which affects the ability 
of interaction and social communication, induces repetitive behaviors and drastically limits the 
interest for external events. Currently, ASD is an incurable condition whose causes are both genetic 
and environmental. 
Increasing evidences support the involvement of altered FA metabolic pathways in the nervous 
system malfunctioning and their contribution to autism spectrum disorder.  
Compared with other organs, the brain presents a high intrinsic concentration of polyunsaturated 
lipids, which increase its vulnerability to ROS damage, as further induced by high metabolism and 
high levels of iron compared to relatively low levels of enzymes encharged of free fradical depletion.  
Since the diagnosis is actually based only on clinical symptoms, the development of comprehensive 
diagnostic tools will be useful, in order to help the pediatrician to make as early a diagnosis as 
possible; it is hoped that an early intervention, comprehensive of nutritional advice, may be useful 
for a milder prognosis.  
In this thesis we show preliminary data of an integrated approach based on biophotonics, lipidomics 
and clinical evaluation as powerful strategy for an early ASD diagnosis. Specifically, we focused on 
RBCs of autistic children, mapping the cell surface by hyperspectral dark-field microscopy (HDFM) 
and in parallel monitoring membrane phospholipid FA composition by lipidomic analysis.  
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These results foresee the use of biophotonic methodologies combined with other clinical evaluations 
to better define an ASD diagnostic panel and design a personalized and targeted plan of intervention.  
 
3.2. Autism Spectrum Disorder (ASD) 
ASD is a neurodevelopmental disorder characterized by impairment of social interaction and 
deficiencies of verbal and nonverbal communication, which causes interest deficits and repetitive 
behaviors [1].  
This condition is characterized by behavioural alterations that can be classified in three main areas 
and be employed as diagnostic parameters [2,3]:  
 Social Impairment: it refers to the inability of establishing social and/or emotional 
relationships with other people. Usually ASD children show little interest in other children or 
adults, do not react when called by name and become aggressive in noisy and unusual 
environments. 
 Communication: it refers to the inability of expressing ideas and feelings. Usually, delay or 
total lack of languange are seen. If language is present, it is often abnormal and consisting of 
repeated sounds or single words which cannot be organized in sentences. They also display 
problems in understanding conversations and concepts.  
 Rigidity and perseveration: it refers to a constant dedication to one or more types of interest 
with exaggerated reactions to specific topics or events (i.e. ability to memorize with no efforts 
name lists, hystorical events, sportive charts or to solve mathematic problems). The activities 
of children affected by ASD are usually characterized by repetitive and stereotyped behaviors. 
They repeatedly perform purposeless motor movements and they show persistent attachment 
to objects or toys that reflets anxiety and resistance to changes. 
Finally, other typical autistic behaviors are abrupt mood swings, hyperactivity or apathy, self-
aggressive behaviors such as hand biting or hair grabbing, phobias, sleep disturbances and eating 
disorders.  
Since the variety of symptoms makes it difficult to provide a consistent clinical description, within 
the ASD definition are included several pathologies or syndromes characterized by the same 
behaviors, although at different degrees of intensity. The severity of the pathological disorder and the 
appearance of the symptoms are very variable, and this fact makes autism diagnosis and personalized 
interventions very difficult.  
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The incidence of the disorder in 2007 was reported to be of 6.6 cases per thousand children [4], but 
the US Centers for Disease Control and Prevention have recently reported the prevalence of ASD in 
14.7 per thousand of 8-years-old children. This suggests that the incidence of ASD has dramatically 
increased. There is a marked difference in prevalence among males and females: for every ASD 
female with autism there are three to four males with the same disorder [5].  
Parents usually notice the first signs within the baby's first two years of life and reliable diagnosis can 
often be made within the thirty months of life. For the diagnosis the Childhood Autism Rating Scale 
(CARS), a widely recognized investigation tool for ASD, can be employed [6].  
CARS consists on the evaluation of children referring to a list of 15 items related to the main 
behavioral areas. For each point, a seven-degree scale can be used to indicate how much the subject 
behavior deviates from the norm relating to his age, assessing 1 as the normal behavior and 7 as the 
most abnormal one. The final CARS score allows to distinguish mild to medium ASD from the more 
severe cases. 
 
3.3. Lipidomics for ASD biomarkers 
ASD is a multifactorial disorder [7,8] which is thought to have correlations with genetic, epigenetic, 
environmental and immunological factors, with oxidative stress as linking mechanism [9-13].  
The brain is highly vulnerable to oxidative stress; the reason can be found in the limited antioxidant 
ability of this organ and in its high requirement of energy, especially in the form of lipids and iron. 
Therefore, neuron functionality is the first one to be compromised in the presence of ROS and 
shortage of antioxidant.  
Children have a natural deficit in detoxification capacity and associated lower levels of glutathione 
compared to adults [14]. Additionally, environmental factors that induce oxidative stress were found 
to accumulate in the placenta and to be found in higher concentration in infants [15]. 
Taken together, these studies suggest that children are highly vulnerable to oxidative stress and that 
certain conditions could compromise normal neurodevelopment and increase the risk of 
neurodevelopmental disorders such as autism. 
Plasmatic levels of lipid peroxidation indicators were found to be increased in ASD children 
compared to developmentally normal, aged-matched children [16]. Several studies have suggested 
alterations in the antioxidatant enzymes. Children with ASD showed reduced activity of glutathione 
peroxidase in plasma and erythrocytes, lower levels of total glutathione, and decreased catalase and 
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SOD activity in erythrocytes [17,18]. Additionally, other antioxidant proteins, transferrin and 
ceruloplasmin, were found to be reduced in autistic children. Being trasferrin an iron-binding protein 
and ceruloplasmin a copper-binding protein, abnormalities in the iron and copper metabolism have 
been suggested to have, together with oxidative stress, a pathological role in autism [19,20].  
In a recent study from our group, we described erythrocyte membrane alterations in autistic children. 
In particular, an increase in MUFAs, a decrease EPA and DHA, and a consequently increased ω-6/ω-
3 ratio that was associated with a reduction of the erythrocyte membrane fluidity, were observed. 
Increased levels of thiobarbituric acid reactive substances, urinary isoprostane, and hexanoyl-lysine, 
together with a significant reduction of Na+/K+-ATPase activity were also reported [16]. 
There are increasing evidences of abnormalities in membrane lipid metabolism and in immune and 
inflammatory responses in autism [21,22]. Other studies focused on the role of fatty acid deficiencies 
or imbalances in the appearance of neurodevelopmental disorders such as attention-
deficit/hyperactivity disorder, dyslexia, dyspraxia, and autistic spectrum disorders [23,24]. Scientific 
evidences have been collected on the deficiency of EFAs, possibly correlated with overactive/over-
expressed PLA2 enzymes [25,26]. 
Plasma methionine and S-adenosylmethionine to S-adenosylhomocysteine ratio, an indicator of 
methylation capacity, were significantly decreased in ASD. In addition, plasma levels of cysteine, 
glutathione, and the ratio of reduced to oxidized glutathione, an indication of antioxidant capacity 
and redox homeostasis, were significantly decreased, suggesting that impairment in the methylation 
ability might occur in autism [27]. 
In addition to high levels of oxidative stress, a state of neuroinflammation with activation of the 
microglia and high levels of proinflammatory cytokines have been found to play a key role in the 
development of histopathological alterations [28]. Recently, the possible role of trans lipids in this 
disease has been discussed [29]. 
The efficacy of ω-3 fatty acid supplementation to children with autism has been investigated in a 
number of studies [30]. ω-3 supplements were found to reduce hyperactivity and stereotypies in 
children with ADS after six-week treatment [31]; caregivers reported improvements in cognitive and 
motor skills, concentration, sleep quality and sociability as well as reductions in irritability, 
hyperactivity and aggression in children supplemented with ω-3-rich oils [25].  
Taken together, these evidences support the idea of lipid membrane homeostasis as a therapeutic 
target in ASD. We focused on RBC membranes, since erythrocytes are a sort of observational window 
to understand the health conditions of the whole organism [32]. We combined the lipidomic analysis 
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of RBCs from ASD patients and matched control subjects with the hyperspectral characterization and 
cell surface mapping of RBCs, using hyperspectral dark-field microscopy. 
 
3.4. Hyperspectral dark-field microscopy (HDFM) 
Given the importance of RBCs to monitor the health status of patients and the ease of obtaining blood 
samples, a large number of blood-based analytical techniques have been developed for many 
pathologies. Microscopic examination of blood samples is generally used to detect defects in the 
morphology of blood cells or the presence of bacteria and parasites.  While bacterial and eukaryotic 
parasites can be studied by optical microscopy, albeit with limits in resolution capacity, electron 
microscopy, requiring more complex preparation techniques, can be used for virus identification.   
Hyperspectral dark-field microscopy (HDFM) is an emerging biophotonic imaging methodology, 
patented by CytoViva, Inc., that finds many applications in life and material sciences [33-35]. Indeed, 
HDFM technique is a highly versatile method that provides simultaneous spatial and spectroscopic 
characterization of nonfluorescent samples in a single measurement and does not require contact 
between the object and the sensor. 
In typical dark-field microscopy, the sample is illuminated by indirect light to enhance the image 
contrast of unstained samples. To do so, a disk is placed underneath the condenser lens so that only 
the light that is scattered from the analyzed objects can be collected to produce an image. The 
CytoViva technology (Figure 3.1) provides numerous advantages compared to traditional dark field 
microscopes. The main difference between an optical image and a hyperspectral image, although 
apparently similar, is that the latter provides, for each pixel, the complete reflectance spectral response 
of that pixel’s spatial area within the visible and near-infrared spectral range (VNIR 400 nm–1000 
nm). This enables nondestructive spectral measurements at a nanoscale level in the full spatial context 
of the sample image. More specifically, CytoViva’s patented enhanced dark-field illumination 
system, unlike standard microscope condensers, works by coupling the source illumination directly 
to the condenser optics and creates a very narrow illumination angle that can be precisely focused 
into the sample but bypasses the objective. The result is a very intense scatter from nanoscale samples 
against a very dark background. Additionally, non-fluorescent live cells and pathogens can be easily 
observed with such precision that cannot be reached with traditional optical imaging techniques. 
Finally, signal-to-noise ratio in CytoViva’s enhanced darkfield microscope optics is ten times higher 
than that obtained in standard darkfield optics, enabling particles down to 10-20 nm size to be 
properly imaged.  
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CytoViva’s technology simultaneously captures the optical spectrum of each point in the image by 
combining motion of the microscope stage with digital imaging spectroscopy. In this way, samples 
can be imaged by acquiring hundreds of contiguous wavelengths or bands, which associate scattering 
spectral information to every pixel [36]. 
 
 
Figure 3.1. Diagram of the CytoViva microscope used for dark-field enhanced hyperspectral image acquisition. 
 
Abundant literature is available on surface mapping and material identification; in the biological field, 
HDFM was applied in the field of drug delivery using metallic nanoparticles; at present, it shows 
potentials for spectral characterization of bacteria and pathogens in the blood [37,38], in the 
cytological diagnosis of cancerous tissues [39,40], as well as in the spectral characterization of gold 
nanoparticle distribution and pathogens in the blood [37,41]. An initial approach to HDFM analysis 
of blood cells evidenced the possibility to detect light scattering changes of blood cells induced by 
morphological alterations [42]. 
There is growing interest for studies aimed at clarifying morphological characteristics that can be 
obtained from the scattering spectrum of blood cells. In fact, alterations in the erythrocyte shape could 
reflect chemical variances or physical abnormalities of RBC membrane itself or of its content [43]. 
The shape is critical for RBC functioning, and emerging evidence indicates oxidative stress as a key 
factor for erythrocyte shape alteration [44-46]. Additionally, a high percentage of altered RBC shapes, 
predominantly elliptocytes, combined with erythrocyte membrane oxidative damage, and β-actin 
52 
 
alterations was observed in ASD patients [47]. Scattering spectra obtained by HDFM analyses depend 
on the thickness, shape, refractive index, anisotropy and geometry of the membrane compartment 
and, at molecular level, are affected by the structures and properties of the light-intercepting 
components.  
A study from our group demonstrated that it is possible to correlate the presence of bands in the RBC 
spectral library with information about phospholipids, hemoglobin, spectrin, cholesterol and 
protoporphyrin moieties [48]. 
Since alterations in lipid composition, possibly important in regulating membrane fluidity, have been 
reported in ASD, we investigated whether RBCs from patients and aged-mached controls could be 
distinguished by HDFM analysis. The combination of HDFM and lipidomic analyses could represent 
an innovative and promising diagnostic tool for ASD pathology, potentially helpful for early 
diagnosis and design of specific nutritional interventions and supplementations. 
 
3.5. Experimental part 
Chloroform, methanol and n-hexane (HPLC grade) were purchased from Merck (Darmstadt, 
Germany). Sodium sulphate anhydrous (Na2SO4) was purchased from Carlo Erba (Milan, Italy). 
Potassium hydroxide (KOH) and protoporphyrin IX were purchased from Sigma Aldrich (St. Louis, 
MO, USA). Phospholipid egg lecithin was available from Avanti Polar Lipids (Alabaster, AL, USA). 
All FAMEs used as standard references for GC analysis were purchased from Sigma Aldrich or Fluka 
(Switzerland) and used without further purification. 
 
3.5.1. Erythrocyte membrane fatty acid analysis 
Blood sample were provided by the Child Neuropsychiatric Unit of the Bellaria Hospital (IRCCS, 
Bologna) which took care of recruitment, clinical diagnostic assessment and comprehensive 
neurological work up of the patients. A total of 41 children, 21 with ASD (15 Males and 6 Females, 
mean age 7.2 ± 0.8 years) and 20 with a typical development (13 Males and 7 Females, mean age 9.0 
± 0.9 years), were recruited.  
The present study was carried out according to the guidelines laid down in the Declaration of Helsinki 
and the Ethical Committee of Bologna Health Authority approved all procedures involving human 
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patients (authorization n. 13062). Blood testing and clinical data collection were authorized by 
children parents, which gave written informed consent.  
Autism diagnosis was made according to the currently accepted clinical evaluation panels, however 
this was not a topic of the present PhD Thesis; for more information please refer to [49]. 
In all 21 patients any medical, genetic and neurological comorbidity was excluded. Control group 
children were healthy typically developing children, recruited in the local community, with no sign 
of cognitive, learning and psychiatric involvement, as clinically and anamnestically determined by 
experienced clinicians. All control group children were attending mainstream school and had not been 
subjected to stressful events. Dietary habits were assessed by a food questionnaire. All patients and 
controls were on a typical Mediterranean diet. Both ASD and control groups were drug and 
supplementation free. 
An aliquote (250 μL) of blood sample was processed for lipidomic analysis. The erythrocyte 
membrane pellet for fatty acid membrane profile analysis was obtained as decribed in literature [50]. 
For this study, a specific erythrocyte fraction corresponding to the aged erythrocytes (RBC age > 3 
months) was selected due to their higher density and smaller diameter compared to the average 
erythrocyte population [51-53]. Whole blood was firstly centrifuged at 2000 g × 5 minutes to remove 
plasma, and subsequently centrifuged at 4000g × 4 °C × 5 minutes to yield a stratification by cell 
density. The phospholipid fraction was extracted using the well known Folch Method (Chapter 2, 
Paragraph 2.2). Breefly, the mature RBC pellet was treated with chloroform/methanol (2:1 v/v) and 
washed with brine to remove proteins and other water-soluble substances. Organic extracts were dried 
with anhydrous Na2SO4. A TLC using n-hexane/ethyl ether/acetic acid (7:3:0.1 v/v) as mobile phase 
[54] was performed to ascertain the presence of phospholipids and cholesterol, the main lipid 
membrane constituents. The residue was subjected to transesterification reaction using 0.5 M 
KOH/methanol solution and kept under stirring for 10 minutes at 22 °C and then quenched with brine 
solution [55]. This procedure led to the formation of FAME derivatives of membrane phospholipids, 
that were extracted using n-hexane. The hexane phase was collected and dried with anhydrous 
Na2SO4. After filtration, the solvent was eliminated by evaporation using a rotary evaporator, and the 
thin white film corresponding to FAMEs dissolved in a small volume of n-hexane. Approximately 1 
μL of this solution was injected into the GC.  
An Agilent 6850 gas chromatograph, equipped with a (50%-cyanopropyl)-methylpolysiloxane (DB-
23, Agilent, USA) capillary column (60 m × 0.25 mm i.d. × 0.25 μm film thickness) was used for the 
analysis. The instrument had a flame ionization detector (FID) that required air (450 mL/min) and 
hydrogen (40 mL/min) and was kept at 250 °C. The method used for the analysis started from an 
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initial temperature of 165 °C held for 3 min, followed by an increase of 1 °C/min up to 195 °C, held 
for 40 minutes. A final ramp, with a temperature increase of 10 °C/min up to a maximum temperature 
of 240 °C, was mantained for 10 minutes for column purge.  
After the acquisition of the chromatograms, FAMEs were identified by comparison with the retention 
times of commercially available standards or trans fatty acid references, synthesized by known 
protocols described elsewhere [56]. 
 
3.5.2. HDFM analysis 
Dark-field images were recorded using an enhanced dark-fild illumination system (CytoViva, 
Auburn, AL) attached to an Olympus microscope (EDFM). The system consisted of a CytoViva 150 
dark field condenser in place of the microscope original condenser attached via a fiber optic light 
guide to a 150 W quartz halogen light source (Dolan Jenner DC-950, Massachusetts, USA), which 
covers the full spectrum from 400 nm to 2500 nm. A 100x oil immersion colour corrected objective 
with numerical aperture of 1.35–0.55 (Olympus UPlanAPO fluorite) was integral to the system. The 
optical images consisted of 700.000 pixels with 2 nm resolution.  
 
3.5.2.1. HDFM analysis of RBCs  
5 µl of whole blood (EDTA-treated) obtained from control and ASD children, were loaded in the 
centre of a glass slide and sandwiched with coverslip; samples were left 120 minutes to stabilize prior 
to proceed with optical acquisition to avoid image blurring. For reproducibility, the protocol required 
to include approximately thirty regularly shaped RBCs and no other blood cells. Two acquisitions 
were carried out for each sample.  
The optical images obtained from control samples, after background subtraction, were used to create 
a spectral library. Pixel regions with similar features were identified and selected as region of interest 
(ROI). Spectra were then characterized for number of peaks, maximum wavelengths and overall 
spectral shape. Setting the maximum angle on single value and keeping it at 0.1 radian with the 
spectral angle mapper (SAM) function, eight spectra were individuated which satisfied the 
requirements of optimal coverage of the optical image. Results are reported as relative spectral 
distribution ± SD.  
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3.5.2.2. HDFM analysis of phospholipids  
4.8 mM egg lecithin phospholipid suspension was prepared in tri-distilled water according to known 
procedures [57]. Liposome vesicles were formed, and the average vesicle diameter size of 200 nm 
was detected by dynamic light scattering (DLS) measurements (Zetasizer Nano Z, Malvern 
Instruments). From an optical image made of 700.000 pixels, after background subtraction, the ROI 
was selected and the hyperspectral image of the sample was acquired. The obtained spectrum is 
shown in Figure 3.6. Bands at 525, 563, 595, 620 nm are observed [48]. 
 
3.5.2.3. HDFM analysis of Protoporphyrin IX  
6.5 mM protoporphyrin IX was dissolved in tri-distilled water and vortexed at 300 rpm for 1 hour at 
37 °C, as previously described [48], to respect the biological concentration [58]. The same procedure 
described above for the selection of ROI was followed. The resulting spectrum is shown in Figure 
3.6. Typical bands at 505, 555, 564, 605, 618 nm were observed. 
 
3.5.3. Statistical analysis 
Statistical analyses were carried out by a group of expert statisticians, which considered the 
heterogeneity of the groups and the confounding factors. Statistical analysis was performed using 
SAS v. 9.2 and STATA 12. To compare groups, normality tests to determine wheter data sets 
followed a Gaussian distribution were applied to all numeric variables. Appropriate parametric tests 
(ANOVA, Student’s t test for independent data) or the nonparametric equivalent (Wilcoxon-Mann-
Whitney) were used. In detail, analysis of variance (ANOVA) was used to compare the difference 
between the internal variability of two or more groups and the variability between the groups. 
Student’s t test for independent data was used to establish if there was a statistically significant 
difference between the means in two unrelated groups. Wilcoxon-Mann-Whitney test was applied 
when it was necessary to compare the means of two groups of independent samples, in which a 
Gaussian distribution could not be assumed. Non-parametric correlation (Spearman’s rho), a measure 
of the linear relationship between two variables, was used to correlate clinical features and 
biochemical data in the ASD group (non-parametric ANOVA for cognitive/developmental level). 
Differences were considered significant at p value < 0.05. Spectrum 4 and DHA value were found to 
differ in a statistically significant way by ANOVA test with p values of 0.0021 and 0.0344, 
respectively. Receiver operating characteristic (ROC) curves were also used to estimate the 
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performance of a given parameter as a binary classifier, i.e. the ability of a test to assign a specific 
subject to either one of two groups - in this case healthy controls (negative group) or ASD patients 
(positive group). Plotting the true positive rate, or sensitivity, against the false positive rate, or 
specificity, at various threshold settings, creates the curve. The sensitivity is the ability to correctly 
classify positive cases (patients), whereas the specificity is the ability to correctly classify negative 
cases (controls). The ROC curves were used in conjunction with the Youden Index (J), as a way of 
summarizing the performance of the diagnostic test. Its value ranges from 0 to 1, a value of 1 
indicating the absence of false positives or false negatives. ROC curve analyses were based on non-
parametric methods. The confidence intervals of ROC curves were set at 95%.   
J = sensitivity + specificity − 1 
When two parameters were combined, such as in the case of HDFM data and DHA values, a 
mathematical treatment to eliminate the measurement unit has been applied. Principal components 
analysis (PCA) is a statistical method that uses an orthogonal transformation to sort out affinities 
among different variables; the higher the value of “factorial weights”, the higher the affinity of a 
variable to that specific factor. It was carried out for the different variables reported in this study 
finding four factors that gather > 90% of the variability of the data. Factor 2 contains DHA values 
and Spectrum 4 together with “cc”, which is the variable that discriminate cases and controls, and the 
CARS total score. Therefore, PCA indicates that these four parameters belong to the same factor, 
putting clinical, biophotonic and molecular data together with the variable that discriminates cases 
and controls. 
 
3.6. Results  
3.6.1. Erythrocyte membrane fatty acid analysis 
A sample of fresh whole blood treated with ethylenediaminetetraacetic acid (EDTA) as anticoagulant, 
was collected from all subjects and used for membrane lipidome analysis and HDFM measurements. 
An aliquot of blood sample (250 μL) from healthy and ASD children was processed for FA analysis 
of membrane phospholipids. The corpusculated portion of blood, consisting of RBCs, was treated 
with a robotic protocol performed at Lipinutragen srl. This procedure allowed the isolation of 
membrane phospholipids of mature RBCs, as they are effective reporters for metabolism and 
nutritional conditions, reflecting the balance established between fatty acids that come from 
biosynthesis or diet. A cluster of 12 FAs (10 cis and 2 trans) was choosen since it represents more 
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than the 98% of the total peaks in the GC chromatogram (Figure 3.2). The RBC membrane FAs of 
healthy and ASD subjects are reported in Table 3.1. 
 
Figure 3.2. Representative GC chromatogram obtained from the analysis of erythrocytes.  
 
Table 3.1. Fatty acid obtained from RBC cell membrane phospholipid analysis of healthy (CTR) and ASD children.  
FAME 
CTR children 
(n=20) 
ASD children 
(n=21) 
p values 
16:0 24.8 ± 1.32 25.23 ± 0.86 0.7557 
9c, 16:1 0.31 ± 0.04 0.29 ± 0.04 0.3549 
18:0 18.20 ± 0.57 18.17 ± 0.69 0.8711 
9t, 18:1 0.12 ± 0.03 0.12 ± 0.04 0.9443 
9c, 18:1 16.42 ± 0.33 17.07 ± 0.84 0.0960 
11c, 18:1 1.24 ± 0.11 1.22 ± 0.08 0.9350 
LA 12.82 ± 0.50 12.40 ± 0.60 0.2851 
DGLA 2.05 ± 0.20 2.14 ± 0.19 0.2973 
ARA 18.56 ± 1.29 18.60 ± 0.86 0.7660 
∑ARA mt 0.09 ± 0.03 0.07 ± 0.03 0.5415 
EPA 0.55 ± 0.09 0.51 ± 0.07 0.4066 
DHA 4.81 ± 0.56 4.14 ± 0.41 0.0424* 
The values obtained from GC analysis of FAMEs are reported as relative percentage (%rel) of the total fatty acid peak 
areas detected in the GC chromatograms, corresponding to >98% of the total peaks. Results are expressed as mean ± SD. 
mt= mono-trans 
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The interest in RBC membrane fatty acid composition derives from the fact that mature RBCs have 
a stable and representative composition that reflects the general state of the organism, connected to 
an in vivo exchange with tissues and lipoproteins that occurs during normal cellular metabolism. 
Erythrocytes have a cell turnover of about 120 days: we decided to extract and to analyze the fraction 
corresponding to mature erythrocytes, because they are considered efficient reporters of the general 
metabolic and nutritional status, which reflects the balance established between FAs coming from the 
biosynthesis and FAs taken from the diet [59]. 
GC analysis showed that the most abundant SFA is palmitic acid (16:0), followed by stearic acid 
(18:0). Among the MUFAs, the most abundant fatty acid is oleic acid (9c, 18:1) while the most 
abundant PUFAs correspond to linoleic (LA, 9c,12c, 18:2) and arachidonic (ARA, 20:4 ω-6) acids. 
The analytical conditions employed and the sensitivity of the instrument allowed to identify the 
presence of mono-trans derivatives of oleic acid, LA and ARA, but no significant differences were 
found between the two groups. 
Lipidomic analyses evidenced a significant DHA decrease in ASD subjects (p value = 0.0424), as 
already reported for a previously studied cohort [16,60]. Using ANOVA test to compare the two 
groups, the DHA decrease in ASD was found to be significant (p value = 0.0344). This decrease was 
not attributable to dietary differences between the two groups, since food questionnaire reported fish 
consuption for both groups (data not shown). 
 
3.6.2. HDFM analysis  
For HDFM analyses, 5 μl of whole blood (EDTA-treated) from healthy and ASD children were 
loaded in the centre of glass slide and sandwiched with coverslip and left 120 minutes to stabilize 
prior to proceed with optical acquisitions. For reproducibility reasons, we established that each optical 
image of RBCs acquired by HDFM technology should be characterized by the presence of 
approximatelly thirty RBCs of round shape. Therefore, erythrocytes with altered morphology, such 
as echinocytes and stomatocytes, were not included in the optical field, in order to avoid an increase 
in the intrinsic variability of the procedure, notwithstanding the fact that RBCs with irregular shape 
are increased in subjects with ASD [60, 47]. Indeed, RBC shape deformation can also depend from 
pH and other blood parameters [61]. 
Accurate collection of the spectral reflectance from RBCs gave rise to eight spectra in the 430–800 
nm wavelength region (Figure 3.3), that using a small spectral angle (0.1 in radians) gave a 
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fingerprint of the region of interest (ROI), with optimal coverage of the optical image (>98%) as 
shown in Figure 3.4.  
 
Figure 3.3. The HDFM spectral library identified for RBC imaging. 
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Figure 3.4. RBC optical images and the corresponding hyperspectral image for healthy (left panels) and ASD (right 
panels) children. In yellow box a selected RBC for which an enlarged view is given below, where it is clearly seen the 
satisfactory matching of the optical and hyperspectral images. Coloured areas indicate regions whose reflectance spectra 
match with the spectral end-members of the library. 
 
 
It is known that the cell membrane curvature is determined by the orientation of the blood cells 
relative to the propagation vector of the illuminating electro-magnetic field. When a biconcave-
shaped RBC interacts with a linearly polarised light beam, it tends to orient its long axis in the 
direction of the electric field of the incident beam, due to RBC’s intrinsic birefringence. In our 
conditions, the light source was an unpolarized halogen light source, thus no “forced” orientation of 
the cells was observed. The lamp normalization routine was used in order to eliminate the background 
light, improving method robustness compared to previously published data [42]. 
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Under these careful set-up conditions, we constantly obtained a good match by mapping of the eight 
end-members spectral library with the small spectral angle onto images taken from different blood 
samples. Therefore, we could conclude that the identified spectral signatures are not sensitively 
affected by the cell orientation, but probably result from a curvature of the membrane surface 
connected to the morphological status. Indeed, the cell orientation dependency could be observed 
when differently shaped RBCs are examined, such as stacked RBCs forming roleaux and echinocytes, 
giving rise to different spectral end-members [42], that are currently under investigation for the 
biological importance of these changes. 
After the library was created to give the optimal surface match, the relative spectral distribution of 
the eight endmembers could be obtained using Spectral Angle Mapper (SAM) software. The mean 
distribution values with standard errors for the two children cohorts are reported in Table 3.2. 
 
Table 3.2. Relative distribution of the HDFM spectral patterns of the RBC samples of healthy and ASD children. 
 
Spectrum 
Control children 
(n=20) 
ASD children 
(n=21) 
p values 
1 0.46 ± 0.25 0.67 ± 0.67 0.5030 
2 2.15 ± 1.17 1.72 ± 1.043 0.5375 
3 7.42 ± 2.89 6.75 ± 1.71 0.6520 
4 13.10 ± 2.39 19.66 ± 3.80 0.0021** 
5 53.43 ± 9.02 53.53 ± 5.75 0.9835 
6 10.71 ± 3.00 7.91 ± 2.05 0.0883 
7 7.53 ± 4.01 6.24 ± 3.34 0.5775 
8 5.20 ± 3.00 3.53 ± 1.30 0.2494 
 
 
By analysis of variance (ANOVA) the spectrum 4 distribution resulted significantly different between 
healthy and ASD children (p value = 0.0021). 
Statistical analysis for the diagnostic performance of spectrum 4 distribution values was carried out 
using the receiver operating characteristic (ROC) curve analysis [62].  
ROC curve analysis is a statistical method that is becoming more and more widely applied in the 
biomedical field since it permits to evaluate the accuracy of a diagnostic procedure [63]. 
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The ROC graph plots on the y-axis sensitivity, that is the ability of a test to correctly identify patients 
with the disease, and on the x-axis (1-specificity), where specificity represents the ability of the test 
to correctly identify those without the disease.  
The parameter of interest is represented by the area under the curve. 
The diagonal line from the bottom left to the top right corners, represents points where sensitivity = 
1-specificity, meaning there is the same chance to have a negative result in the presence of the disease 
(false negative) and a positive one in case of no disease (false positive). The test in this case is 
unreliable, since positive or negative results cannot be related to the true disease status. 
The top left corner of the ROC box is the point where sensitivity = 100% (no false negatives) and (1-
specificity) = 0%, or better specificity = 100% (no false positives): this point represents the ideal test. 
The closer the ROC curve get to the top left corner, the better the test is overall. 100% sensitivity) 
and 100% specificity). 
When we performed the ROC analysis for spectrum 4 (Figure 3.5), very high statistical significance 
(p value = 0.0008) and a cut-off value at 16.225 were determined.  
 
AUC Cut off Sensitivity Specificity J 
0.8071 16.225 85.71% 80.00% 0.6571 
Figure 3.5. ROC curves and J values for HDFM spectrum 4. 
 
Additionally, the odds ratio (OR), that expresses the level of association between two factors, was 
calculated. In the case of spectrum 4 and ASD pathology, OR was found to be significant and 
corresponding to 24 (p value < 0.0001; IC 95%: [4.6488–123.9035]),  
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Therefore, statistic analyses evidenced that individuals with distribution values of spectrum 4 higher 
than 16.225 (cut-off value) have a probability of being autistic 24 times higher than those having 
values of spectrum 4 lower than 16.225. 
Looking closely at spectrum 4, and comparing its spectral profile with the spectra obtained from the 
analysis of membrane components [48], similarities were found with the maximum HDFM peaks 
(564, 587, 595, 620 nm) of phospholipid and protoporphyrin IX, which are important component of 
the RBC membranes (Figure 3.6). 
 
Figure 3.6. Superimposition of spectrum 4 with two reference compounds, phospholipids as liposome suspension (green) 
and protoporphyrin IX (brown). Principal bands of spectrum 4 are indicated. 
 
It is worth underlining that the phospholipid sample was prepared as aqueous liposome suspension18, 
an aggregation that mimics the membrane lipid organization. Some of the spectral bands in common 
between spectrum 4 and the two membrane components can be seen. However, further work is needed 
to make an unequivocal assignment of the spectral bands in RBCs.  
Spearman’s non-parametric correlations were calculated for spectrum 4 vs. a number of subject’s 
demographic and clinical features. The correlations found to be statistically significant are shown in 
Table 3.3.  
Again, the spectrum 4 was found to be positively and significantly correlated with CARS total scores 
(P = 0.0248), hyperactivity (P = 0.0279), stereotypies (P = 0.0225).  
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Table 3.3. Statistically significant Spearman’s non parametric correlations calculated for spectrum 4. 
Correlation of HDFM spectrum 4 and CARS 
 
 
 
 
Variable: CARS 
Spearman’s rho: 0.4881 
P value: 0.0248 
Correlation of HDFM spectrum 4 and hyperactivity 
 
 
 
 
Variable: CARS 
Spearman’s rho: 0.4794 
P value: 0.0279 
 
Correlation of HDFM spectrum 4 and stereotypies 
 
 
 
 
Variable: Stereotypies 
Spearman’s rho: 0.4950 
P value: 0.0225 
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3.7. Conclusions   
The lipidomic analysis of 41 children, 21 with ASD and 20 with typical development was performed. 
This study showed that the erythrocyte membranes of autistic children presented significantly reduced 
levels of DHA. 
Additionally, the characterization of human RBCs using hyperspectral optical imaging was provided. 
In particular, a reference spectral library made of 8 scattering spectra was built up from which it was 
possible to derive the relative spectral distribution for all samples.   
With this study we demonstrated that HDFM spectra can comprehensively describe the contribution 
of erythrocyte components with their organization and packing at the level of membrane and sub-
membrane regions. Indeed, some of the bands of the HDFM spectra matched the bands obtained by 
typical RBC molecular components, such as phospholipids and protoporphyrin IX, demonstrating the 
possibility of mapping single molecules (e.g. proteins) as well as obtaining information on the 
membrane phospholipid assembly.  
By setting up this innovative approach, the potentiality and effectiveness of hyperspectral imaging of 
RBC and its components for clinical applications can be envisaged. 
HDFM results, obtained through this fast, easy and reproducible protocol, can encourage further 
studies extended to larger cohorts, to explore the potentiality of RBC mapping in the presence 
different health conditions. This technique can be integrated with other diagnostic and intervention 
tools, such as personalized lipidomic profiles, to design personalized membrane-targeted therapies.  
To summarize, this study represents the proof of concept that hyperspectral imaging, being a fast and 
non-expensive screening methodology, can be used to gather comprehensive information on the 
erythrocyte cell membrane components and their organization, that are the premise of using HDFM 
methodology for clinical targets. This also opens the field to integrated approaches for the 
determination of cell impairment due to unbalances of its molecular components, such as those 
targeted to cell membranes using lipidomics. 
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Chapter 4 
Alzheimer’s Disease 
 
 4.1. Introduction 
Lipidomics is considered very important to investigate lipid signalling, metabolism, trafficking, and 
homeostasis that are associated with neurological disorders. The neuronal system is the second organ 
for concentration in lipids, exceeded only by adipose tissue.  
Disorders in the lipid metabolism in the central nervous system (CNS) have been associated with 
neurodegenerative diseases, such as Alzheimer’s Disease (AD). Indeed, it has already been mentioned 
that lipids are a large group of molecules which can act as cell membrane structure components, 
signalling molecules for normal cellular functions and energy storage. At a CNS level, changes in 
brain lipid balance due to impaired synthesis or metabolism may result in homeostatic dysregulation 
and ultimately in neurodegeneration [1]. 
In AD, a neurodegenerative, progressive and irreversible disease that affects the brain, ‘lipoidic 
granules’ in glial cells, suggesting aberrant lipid metabolism, have been reported [2]. Alterations in 
brain cholesterol metabolism were also observed in the cerebrospinal fluid and plasma of AD patients. 
In addition, the hypothesis of peroxisomal dysfunctions and/or of abnormal desaturase and elongase 
activities linked with some fatty acid alteration was formulated [3]. 
However, a connection between AD and abberant lipid metabolism was seriously considered only 
when the ε4 allele variant of the apolipoprotein E (APOE) gene was identified as the strongest genetic 
risk factor for late-onset AD. 
In the current state of knowledge, the mechanism of action of apoE4 has not been clarified yet. Since 
many studies support a possible link between lipid metabolism disorders and the pathogenesis of AD, 
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there has been a stronger focus on lipidomic studies to identify lipid biomarkers of AD. Taking into 
account the diagnostic significance of fatty acid-based membrane lipidomics for human health [4,5], 
we have planned a preliminary study to investigate whether fatty acid remodeling of cell membranes 
occurs in the presence of apoE proteins, since little is known about the effects of apoE on membrane 
fatty acid profile. In particular, the fatty acid remodeling of human neuroblastoma cell line (SK-N-
SH) exposed to apoE3 and apoE4 isoforms is reported.  
Results showed that the treatment with either apoE3 or apoE4 isoforms induced significantly different 
changes in the organization of the membrane fatty acids, which predominantly influence membrane 
properties and peroxidation susceptibility. 
This study was realized in collaboration with the group of Dr. Chroni, in Athens, which synthesized 
and purified ApoE isoforms and set up the biological assays.  
 
 4.2. Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is a chronic multifactorial neurodegenerative disease [6] that is considered 
the most common cause of age-related dementia. The clinical symptoms involve progressive decline 
in memory, starting with short-term memory loss, problems with language, mood swings, 
disorientation and loss of independence [7]. 
AD is characterized by the accumulation of abnormally folded amyloid β peptide (Aβ) in plaques and 
neurofibrillary tangles (NFTs), containing hyperphosphorylated tau protein, which can induce loss of 
neurons and synapses in the cerebral cortex and some subcortical regions, brain atrophy and 
inflammation [8]. 
Aβ peptide is generated by fragmentation induced by γ- and β-secretases of amyloid precursor protein 
(APP), a transmembrane protein that is critical for neuron growth, survival, and post-injury repair. 
This fragment gives rise to fibrils of amyloid β that form clumps, which can deposit outside neurons 
in dense formations known as senile plaques. 
Aβ can alterate the signalling pathways involved in the phosphorylation of the microtubule-associated 
protein tau, blocking its function of stabilizing the cytoskeleton and expelling potentially toxic 
proteins. Moreover, Aβ can inhibit the functionality of proteasome that is responsible for 
hyperphosphorilated tau degradation. Therefore, these two proteins and their associated signalling 
pathways represent important therapeutic targets for AD. 
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Although these have long been considered as the most important factors in the onset of AD, the first 
observations of patients with dementia also reported the presence of 'adipose inclusions' or 'lipoidic 
granules' in glial cells, suggesting aberrant lipid metabolism. 
Strong evidences now suggest the altered expression of the isoform APOE-ε4 in the apolipoprotein 
E (ApoE) gene being the most firmly established genetic risk factor in AD.  
 
 4.3. ApoE4 in the pathogenesis of AD 
ApoE is the predominant apolipoprotein in the brain and is crucial for cholesterol transport with a 
role in neuroplasticity-related phenomena, since it intervenes in lipid changes and cholesterol 
dependent function [9]. ApoE can regulate triglyceride metabolism throughout the body by enhancing 
triglyceride-rich lipoprotein particle uptake, triglyceride utilization and cholesteryl ester hydrolysis 
in macrophages [10]. In the peripheral nervous system, apoE influences neuronal growth and 
differentiation. ApoE is of critical importance for membrane repair and remodeling since it 
participates in the lipid removal from degenerated neurons, and for this reason its expression can be 
induced in response to stress or injury [11]. 
At a gene level, several single-nucleotide polymorphisms lead to three common isoforms of ApoE, 
that differ only for two amminoacids: apoE2 (cys112, cys158), apoE3 (cys112, arg158), and apoE4 
(arg112, arg158) [12]. These proteins are cooded by three different alleles, among which ɛ4 allele is 
considered the major risk factor for AD, while ɛ2 allele (the least common) and ε3 allele (the most 
frequently encountered worldwide) have protective properties [13-16].  
However, the mechanisms that elucidate the association of ApoE4 with AD have not been clarified 
yet. It has been proposed that apoE can bind Aβ and induce changes in Aβ conformation. In addition, 
apoE can modulate Aβ accumulation and deposition in the brain in an isoform- and lipidation status-
dependent manner [17-19].   
Several model studies pointed out the importance of the lipidation status of apoE since it can influence 
the protein conformation [20], the interaction of apoE with lipid transporters that are involved in the 
cellular lipid homeostasis [21] and the affinity of apoE for Aβ peptides [22]. The apoE lipidation 
status can also alter its ability to promote the degradation and clearance of Aβ from brain [23]. 
It is known that ApoE can exert protective effects against free radicals but that the response is isoform 
dependent, with ApoE4 being the less efficient free radical scavenger and the more sensitive to free 
radical attack [24,25]. Other studies have associated the differential effects of apoE isoforms on AD 
74 
 
pathogenesis with differences in their ability to affect neuronal repair and brain lipid transport or 
metabolism.  
In addition, massive disruption of the total membrane lipid bilayers caused by Aβ1–40 was reported 
in the presence of apoE4 but not of apoE3, individuating apoE4 as promotive element for Aβ 
fibrillation and membrane oxidative damage [26].  
It has been demonstrated that apoE4 is much more susceptible to proteolysis than apoE3 and apoE2 
and carboxyl-terminal truncated forms of apoE4 have been found in brains of AD patients and apoE4 
transgenic mice [27-29]. Specific apoE4 fragments have been linked with early events in the 
pathogenesis of AD including neuroinflammation, tau pathology, and accumulation of Aβ42 in 
neurons accompanied with the induction of oxidative stress [30,31].  
In the current state of knowledge, a few data are available on the molecular effects of apoE regarding 
lipid remodeling using in vitro experiments. Apolipoprotein E isoforms were found to enhance 
triglyceride-rich lipoprotein particle uptake, triglyceride utilization and cholesteryl ester hydrolysis 
in macrophages [32]. 
ApoE4-165 fragment was found to strongly reduce sphingomyelin levels in SKN-SH cells, thus 
inducing changes in the micro-fluidity [33]. Incorporation of sphingomyelin rather than 
phosphatidylcholines in lipid emulsion models of lipoproteins reduced the binding of apoE to the 
emulsions and the apoE-mediated uptake of the emulsions by human hepatoma HepG2 cells [34]. 
Very recently, the importance of cholesterol and phospholipid levels for the protein functioning in 
neuronal cells and their involvement in neurological diseases was assessed [35,36]. 
Thus, we hypothesized there could be a lipid coordination effect driven by the structure related to the 
unique properties of ApoE4, that might clarify the molecular bases of AD. 
Thanks to the recent and successful developments in revealing membrane unbalance and identifying 
specific biomarkers of pathological conditions, lipidomic analysis could be the means of achieving 
this aim. Cell membrane can be used as a mirror to identify specific fatty acid impairments induced 
by radical and oxidative processes, since it is the result of biophysical, biochemical and dietary 
processes. This work could provide molecular-level information of ApoE-membrane interactions and 
of its isoform-specific affinity, offering hints about the pathology of AD. 
To better understand the mechanism of interaction of ApoE4 with membrane lipids, we decided to 
study the possible effects of ApoE3 and ApoE4 isoforms on the membrane lipid remodelling. For 
these in vitro experiments SK-N-SH neuroblasma cell line was used since it exhibits a neuronal 
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phenotype with a variety of neurochemical markers that make it an ideal target to study 
neurodegenerative diseases like AD [37-38]. 
 
 4.4. Experimental part 
Human neuroblastoma SK-N-SH cells were purchased from American Type Culture Collection – 
ATCC (Manassas, VA, USA). Fetal bovine serum (FBS) was purchased from Biosera (France). 
Minimum Essential Medium (Eagle), L-glutamine, nonessential amino acids, sodium pyruvate and 
sodium bicarbonate were from Biochrom AG (Berlin, Germany). Antibiotics (penicillin and 
streptomycin) and Phosphate-buffered saline (PBS) were purchased by Sigma Aldrich (St. 
Louis, MO, USA); 0.05% trypsin solution and potassium hydroxide were purchased by Merck 
Millipore (Bedford, MA, USA). Chloroform, methanol and n-hexane (HPLC grade), were purchased 
by Merck (Darmstadt, Germany) and used without further purification.  
Silica gel thin-layer chromatography was performed on Merck silica gel 60 plates (0.25 mm 
thickness) and the spots were detected by spraying the plate with cerium ammonium sulfate reagent. 
Standard FAME references were commercially available from Supelco (USA) and all compounds 
were used without further purification. 
 
4.4.1. In vitro studies 
Human neuroblastoma SK-N-SH cells were cultured in Minimum Essential Medium Eagle medium 
supplemented with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 
1.5 g/l sodium bicarbonate, 10% (v/v) FBS and antibiotics. Care was taken to use the same FBS batch 
in all experiments. Cells were plated on 100-mm Petri dishes at a density of 106 cells/dish and cultured 
for 24 h at 37 °C in the presence of 5% CO2. The cells were then washed and incubated 
with fresh serum-free medium in the presence or absence of 1 μM of lipid-free apoE3 or apoE4 for 
24 h. The expression and purification of apoE4 and apoE3 was carried out according to protocols 
already described before [39,40]. At the end of the treatment, cells were thoroughly washed using 
PBS and pelleted by centrifugation at 2500 rpm × 10 min × 4 °C using a Heraeus, Labofuge 400R 
table centrifuge (Thermo Scientific, Rockford, IL, USA). 
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4.4.2. Membrane fatty acid analysis 
Cell membrane PL were isolated using the well-established Folch method (Chapter 2, Paragraph 
2.2). Briefly, the pellet was re-suspended in pure water and lipids were extracted with 
chloroform/methanol (2:1 v/v). Thin layer chromatography using chloroform/methanol/water 
(65:25:4 v/v) was performed to determine the purity of the PL fraction [41]. The PL residue was 
transesterified with a 0.5 M KOH/methanol solution for 10 minutes at 22 °C.  
The corresponding fatty acid methyl esters (FAMEs) were extracted with n-hexane and analyzed by 
Agilent 7890B GC system equipped with a flame ionization detector and a (50%-cyanopropyl)-
methylpolysiloxane (DB-23, Agilent, USA) capillary column (60 m, 0.25 mm i.d., 0.25 μm film 
thickness). The initial temperature was 165 °C, held for 3 minutes, followed by an increase of 1 
°C/min up to 195 °C, held for 40 minutes, followed by a second increase of 10 °C/min up to 240 °C, 
held for 10 minutes. The carrier gas was hydrogen, held at a constant pressure of 16.482 psi. All the 
FAMEs were identified by comparison with the retention times of standard references either 
commercially available orobtained by synthesis, as already described elsewhere [42]. 
 
4.4.3. Statistical analysis 
Results are given as means ± SD. Six samples were included in each group. Statistical significance 
(p values) of the results was calculated by unpaired two-tailed Student’s t-test using GraphPad 
Prism™ software version 6.01 for Windows (GraphPad Software Inc., La Jolla, CA, USA). 
The threshold for significance was set up at 0.05. 
 
 4.5. Results  
SK-N-SH cells were incubated in the presence or in the absence of lipid-free full-length apoE3 or 
apoE4 for 24 hours. Care has been taken in using FBS from the same batch to avoid external influence 
of lipid supply. The choice to use lipid free apoE was based on the knowledge that apoE secreted by 
brain cells (astrocytes, microglia, neurons) can scavenge lipids from cells and be lipidated in situ 
[43,44]. Therefore, the exogenously added apoE isoforms were expected to behave similarly to apoE 
secreted from brain cells. 
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After cell treatment, membrane fatty acid composition was determined using known methodologies 
for membrane pellet formation, phospholipid isolation and transesterification to FAME derivatives, 
that were analyzed by GC.   
Six samples for each group were analyzed. Controls were cells incubated in the same conditions but 
in the absence of apoE proteins. Fatty acid quantities are reported as percentages of the main peak 
areas obtained from GC analyses, calibrated and recognized with appropriate references, as already 
described [42,45]. 
The GC chromatograms obtained had very similar profiles (Figure 4.1). A cluster of twelve fatty 
acids (FAs) was choseen since it was representative of the total fatty acid contribution in SK-N-SH 
cell membranes. The most abundant FAs was the MUFA oleic acid (9c, 18:1), followed by two SFAs, 
palmitic (16:0) and stearic (18:0) acids. Among the MUFAs, palmitoleic (9c, 16:1) and vaccenic (11c, 
18:1) acids were found in similar percentages. Another significant contribution in the membrane fatty 
acid composition was given by the ω-6 PUFAs ARA (20:4 ω-6), that was found in concentrations 
comparable to DHA (22:6 ω-3), the main ω-3 PUFA.  The analytical conditions and the sensitivity of 
the instrument allowed to detect the presence of mono-trans derivatives of oleic acid and ARA.  
 
Figure 4.1. Representative GC chromatogram showing the FAME peaks of SK-N-SH cells. 
 
Tables 4.1 and 4.2 show the membrane fatty acid composition, the main membrane fatty acid families 
and the index of the SK-N-SH cells after 24 h incubation in the presence or absence of apoE3 or 
apoE4.  
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Table 4.1. Fatty acids obtained from SK-N-SH cell membrane phospholipids after incubation with 1 μM of apoE3 or 
apoE4 for 24 h. Controls are cells cultured for 24 h in the absence of these proteins. 
FAME 
Control  apoE3  apoE4  apoE3 vs. apoE4  
n=6 n=6 (p value)a n=6 (p value)b (p value)c 
16:0 25.70 ± 0.45  26.60 ± 0.82 (0.0396) 26.91 ± 0.18 (0.0001) 0.4020 
9c, 16:1 6.55 ± 0.72 6.91 ± 0.69 (0.4014) 8.20 ± 0.38 (0.0006) 0.0025 
18:0 9.72 ± 0.33 10.70 ± 0.58 (0.0049) 9.22 ± 0.14 (0.0043) 0.0002 
9t, 18:1 0.03 ± 0.01 0.04 ± 0.04 (0.4072) 0.06 ± 0.04 (0.1065) 0.5435 
9c, 18:1 36.76 ± 0.71 36.54 ± 0.59 (0.5668) 35.40 ± 0.36 (0.0018) 0.0024 
11c, 18:1 7.03 ± 0.20 7.47 ± 0.14 (0.0014) 7.23 ± 0.04 (0.0432) 0.0023 
LA 1.51 ± 0.04 1.47 ± 0.03 (0.0653) 1.53 ± 0.04 (0.4581) 0.0134 
DGLA  0.42 ± 0.00 0.47 ± 0.02 (<0.0001) 0.39 ± 0.02 (0.0200) <0.0001 
ARA 5.59 ± 0.12 4.95 ± 0.04 (<0.0001) 5.63 ± 0.12 (0.5377) <0.0001 
∑ARA mt 0.16 ± 0.06 0.12 ± 0.01 (0.1819) 0.14 ± 0.02 (0.5071) 0.0420 
EPA  0.87 ± 0.06 0.69 ± 0.04 (0.0001) 0.83 ± 0.04 (0.1741) <0.0001 
DHA 5.66 ± 0.26 4.05 ± 0.13 (<0.0001) 4.46 ± 0.14 (<0.0001) 0.0004 
The values obtained from GC analysis of FAMEs are reported as relative percentage (%rel) of the total fatty acid peak 
areas detected in the GC chromatograms, corresponding to >98% of the total peaks. mt= mono-trans 
a Significance between control and ApoE3. 
b Significance between control and ApoE4. 
c Significance between ApoE3 and ApoE4. 
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Table 4.2. Main FAME families and membrane homeostasis indexes obtained from the data of Table 4.1. 
FAME 
Control  apoE3  apoE4  apoE3 vs. apoE4  
n = 6 n = 6 (p value) a n = 6 (p value) b p value c 
Total SFA d 35.42 ± 0.36 37.30 ± 0.75 (0.0003) 36.12 ± 0.21 (0.0022) 0.0043 
Total MUFA e 50.34 ± 0.16 50.92 ± 0.59 (0.0449) 50.83 ± 0.08 (<0.0001) 0.7254 
ω-3 PUFA f 6.53 ± 0.24 4.73 ± 0.16 (<0.0001) 5.29 ± 0.17 (<0.0001) 0.0002 
ω-6 PUFA g 7.51 ± 0.14 6.89 ± 0.06 (<0.0001) 7.55 ± 0.15 (0.6701) <0.0001 
Total PUFA 14.05 ± 0.24 11.62 ± 0.21 (<0.0001) 12.84 ± 0.31 (<0.0001) <0.0001 
Total TFA h 0.19 ± 0.08 0.17 ± 0.04 (0.5007) 0.20 ± 0.04 (0.7824) 0.1631 
SFA/MUFA ratio 0.70 ± 0.01 0.73 ± 0.02 (0.0379) 0.71 ± 0.00 (0.2959) 0.0652 
SFA/PUFA ratio 2.52 ± 0.07 3.21 ± 0.12 (<0.0001) 2.81 ± 0.08 (<0.0001) <0.0001 
EPA/ARA ratio 0.16 ± 0.01 0.14 ± 0.01 (0.0191) 0.15 ± 0.00 (0.1284) 0.0478 
ω-6/ω-3 ratio 1.15 ± 0.05 1.46 ± 0.04 (<0.0001) 1.43 ± 0.03 (<0.0001) 0.1736 
PUFA Balance i 46.51 ± 1.10 40.72 ± 0.65 (<0.0001) 41.19 ± 0.43 (<0.0001) 0.1718 
Unsaturation Index (UI) j 115.29 ± 1.52 102.76 ± 1.66 (<0.0001) 108.50 ± 1.41 (<0.0001) <0.0001 
Peroxidation Index (PI) k 76.49 ± 1.93 59.95 ± 1.38 (<0.0001) 66.77 ± 1.75 (<0.0001) <0.0001 
The values are given as mean ± SD. 
a Significance between control and ApoE3. 
b Significance between control and ApoE4. 
c Significance between ApoE3 and ApoE4. 
d SFA = %16:0 + %18:0. 
e MUFA = %9c-16:1 + %9c-18:1 + %11c-18:1. 
f PUFA ω-3= %EPA + %DHA. 
g PUFA ω-6= %LA + %DGLA + %ARA. 
h TFA= %9t-18:1 + %∑mono-trans ARA. 
i PUFA balance = [(%EPA + %DHA) / total PUFA] × 100. 
j UI= (%MUFA × 1) + (%LA × 2) + (%DGLA × 3) + (%ARA × 4) + (%EPA × 5) + (%DHA × 6). 
k PI = (%MUFA × 0.025) + (%LA × 1) + (%DGLA × 2) + (%ARA × 4) + (%EPA × 6) + (%DHA × 8). 
 
In Figures 4.2 and 4.3 the main fatty acid and family values are graphically represented as relative 
percentage differences from controls, together with their statistical significance against controls and 
between the two apoE isoforms. 
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Figure 4.2. Percentage differences compared to controls for each type of fatty acid in the SK-N-SH cell membranes 
following incubation with 1 μM apoE3 (black) or apoE4 (grey) after 24 h. The values are given as mean ± SD (n=6). 
Each member of the fatty acid family is given in a row, the last column being the sum of the corresponding fatty acid 
family. Values significantly different from the control: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001. 
Black asterisks indicate the significance between control and apoE isoforms, blue asterisks indicate the significance 
between the two apoE isoforms. 
 
A more specific evaluation of single fatty acids present in the membrane phospholipids yieded 
interesting differences between the two treatments with different apoE isoforms. The SFA stearic acid 
(18:0) and the ω-6 DGLA (20:3 ω-6) were both decreased after incubation of cells with apoE4 (p < 
0.01 and p < 0.05, respectively) and increased after incubation with apoE3 (p < 0.01 and p < 0.0001, 
respectively). The ω-6 ARA (20:4 ω-6) was significantly diminished after incubation of cells with 
the apoE3 isoform (p < 0.0001) and negligibly increased after incubation with apoE4. These fatty 
acids were the only ones found with opposite trends for the two protein isoforms. Concerning the ω-
3 fatty acids, EPA (20:5 ω-3) and DHA (22:6 ω-3) levels were found to be lower after incubation of 
the cells with either of the two apoE isoforms, as compared to untreated cells, but the decrease was 
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of a greater extent after incubation with the apoE3 isoform as compared to apoE4 (p < 0.0001 and p 
< 0.001, respectively). 
 
Figure 4.3. Membrane homeostasis indexes in the SK-N-SH cells recorded after 24 h treatment with 1 μM apoE3 (black) 
or apoE4 (grey). Upper row: total PUFA, ω-6/ω-3 ratio and PUFA balance; Middle row: SFA/MUFA, SFA/PUFA and 
EPA/ARA ratios; Lower row: unsaturation and peroxidation indexes. The values are given as mean ± SD (n = 6). Values 
significantly different from the control: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001. Black asterisks 
indicate the significance between control and apoE isoforms, blue asterisks indicate the significance between the two 
apoE isoforms. 
 
 
Expanding the vision to the whole membrane, these single fatty acid variations affect the 
corresponding indicators of the membrane status (Table 4.2 and Figure 4.3). Among them, the 
SFA/PUFA ratio in membranes was significantly increased after incubation with both isoforms (p < 
0.0001), with apoE3 resulting in a higher increase compared to apoE4 (p < 0.0001). Also the ω-6/ω-
3 ratio (Fig. 2) was increased after incubation of cells with either apoE isoforms (p < 0.0001), whereas 
both peroxidation and unsaturation index (PI and UI) were lower than controls (p < 0.0001), with 
apoE3 inducing a greater decrease than apoE4 (p < 0.0001). The decrease of ω-3 affected also the 
PUFA balance indicator [46] with respect to control (p < 0.0001). In general, the effects of the 
addition of the apoE isoforms resulted in decreasing membrane fluidity, due to SFA increase and 
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PUFA loss. Other indicators of this significant decreasing trend, expressed as peroxidation index (PI) 
and unsaturation index (UI) [47] are shown in Table 4.2; for both indices, the difference from controls 
was higher with apoE3 than with apoE4 (p < 0.0001). 
Changes in the fatty acid composition of membrane phospholipids due to the addition in the medium 
of apolipoproteins is a novel finding, and may be valuable for the understanding of the membrane 
properties and of the cell predisposition to metabolic responses originated from membrane 
constituents. 
The effects of different fatty acids on the biophysical properties of cell membranes have been 
discussed by many Authors [48,49]. The increase in SFAs and the decrease in PUFAs, observed in 
the presence of both apoE isoforms, can influence membrane fluidity and permeability as measured 
by the PI and UI indexes, consequently bringing to a more rigid packing of the bilayer. It is interesting 
to note that apoE3 resulted in a more consistent reduction of the PI and UI indexes, thus suggesting 
a different influence of the two apoE isoforms on the properties of plasma membrane 
microenvironment. Indeed, biophysical and biological modifications induced by individual fatty acids 
deserve more attention in the apolipoprotein studies, as suggested by former observations on the 
palmitic acid-induced increase of de novo synthesis of ceramide in astroglia, known for being 
involved in Aβ production and in tau-protein hyperphosphorylation [50]. Notably, in the early stages 
of AD, sphingolipid balance is shifted towards ceramide accumulation and ceramide levels have been 
found to be increased in the brain, the CSF and the plasma of AD patients, as compared to the age 
matched neurologically normal control subjects [51-53]. Moreover, the observed changes can have 
important consequences on the cellular signalling. In fact, change in the membrane phospholipid fatty 
acids following apoE supplementation have direct connections with the signalling cascades mediated 
by eicosanoids, since ω-6 and ω-3 fatty acids are the precursor of signalling lipids after they are 
detached from membranes by the action of PLA2 [54]. ω-6 fatty acids are precursors of different 
molecules with respect to ω-3 fatty acids; in fact, the former regulate cell functions with 
inflammatory, atherogenic and prothrombotic signals, whereas the latter directly inhibit the pro-
inflammatory NF-kB activity, by binding peroxisome proliferator activated receptors and thus 
controlling several genes involved in lipid metabolism and cytokine production (Chapter 1, 
Paragraph 1.6). More specifically, the ω-6 DGLA is a precursor of series-1 prostaglandins and other 
oxidation metabolites with anti-inflammatory and anti-proliferative effects [55]. DGLA is the 
metabolic precursor of ARA and is converted to ARA by the activity of Δ5 desaturase. Therefore, its 
biological roles are determined by the partition into these two different pathways that must be 
evaluated in each specific condition. In this study, incubation of SK-NSH cells with apoE3 increased 
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the levels of DGLA and decreased the levels of ARA as compared to control cells. In contrast, 
incubation of cells with apoE4 had moderated diminution effect on DGLA levels and no significant 
effect on ARA levels.  
The effect of apoE3, but not of apoE4, on ARA could be attributed either to: i) a metabolic negative 
influence on DGLA transformation (desaturase and elongase enzymes), which correspondently 
increases in the glycerophospholipids of SK-N-SH cells, or ii) a different affinity of the two apoE 
isoforms for the two ω-6 containing lipids, influencing their distribution to cells and availability for 
membrane phospholipid biosynthesis.  
On the other hand, multiple mechanisms can be synergically operative. It was described that apoE4, 
but not apoE3, triggers a significant elevation of cytokines (IL6 and IL8, both implicated in AD) in 
SHSY5Y human neuroblastoma cells [56], through its connection with the formation of apoERelA 
transcriptional complex (RelA: v-rel avian reticuloendotheliosis viral oncogene homolog A/nuclear 
factor NF-kB p65 subunit – subunit of the NF-kB complex). As matter of facts, in our cell model 
apoE3 facilitates the increase of DGLA content inmembrane phospholipids thus increasing the 
probability for protective molecular pathways. The role of DGLA and its transformations in AD have 
not been considered so far, and our results suggest a more comprehensive understanding of 
neurological functions including an evaluation of the balance among membrane fatty acid content 
and production of lipid mediators in neuronal cells [57]. ω-6 fatty acid involvement in AD is already 
well documented. Altered neuroinflammatory markers and upregulation of the ARA cascades have 
already been widely described, supporting the association of ARA metabolism and cytokine 
production with neuronal damage in AD brains [58]. 
Moreover, the low ability of apoE4 to act as a radical scavenger is supported by our results, showing 
differences in the amount of trans ARA isomers in neuronal membranes (see Table 4.1). Indeed, 
trans fatty acids are generated endogenously, resulting from the radical stress of sulfur-centered 
radicals that convert the cis double bonds of fatty acids (Chapter 1, Paragraph 1.3.2). It appears that 
the apoE3 isoform is able to maintain a lower amount of trans-ARA in cell membranes than the apoE4 
isoform. Excess of trans-ARA could affect membrane integrity and contribute to alter lipid 
organization and cell responses. Moreover, the addition of the apoE3 isoform caused a higher 
reduction in the PI than apoE4, imparting to the cells greater stability against lipid oxidation. In a 
previous study, we found that an apoE4 fragment, the apoE4-165, promotes amyloidpeptide β 42 
(Aβ42) accumulation in SK-N-SH cells and increases intracellular reactive oxygen species formation 
[33]. ApoE4 fragments are produced at the onset of AD and co-exist with the full-length protein in 
the brain during the progression of the disease. The limited capacity of apoE4 to decrease the PI may 
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facilitate the formation of apoE4 fragments, which are related to oxidative damage in neurons. In fact, 
increased lipid peroxidation was found in post-mortem brains expressing the apoE4 isoform [59,60]. 
While the functions of lipoproteins in the brain and the recruitment of lipids by the ApoE isoforms 
have been thoroughly investigated [61], our work expands the scenario to the observation of the 
membrane lipid composition, whichis certainly influenced by the different availability of fatty acids. 
The results provided by these in vitro experiments are the first to connect molecular observations on 
membrane lipids to the systemic effects observed in the brain cells and tissues and to the clinical 
findings. Further targeted studies can be thus envisaged on the effects of supplementation with ω-3 
or other lipids, also in consideration of the fact that a-higher-than-normal ω-6/ω-3 ratio has been 
described in cell membranes of people carrying the apoE4 isoform [6]. 
Thus, membrane lipidomics may help to reach a better understanding of the observed differences 
between apoE3 and apoE4 allele carriers and of the nexus between apoE isoforms and AD onset. 
 
 4.6. Conclusions  
This work is a preliminary in vitro study aimed at investigating the membrane fatty acid remodeling 
in the presence of either apoE3 or apoE4. For this model, SK-N-SH neuroblastoma cell line was used.  
Although it is established that carrying the lipid binding proteins apoE3 or apoE4 is associated with 
opposite effects as for AD onset, with apoE4 being the major risk factor for AD, the effect of these 
protein isoforms on brain cells membrane fatty acid composition was largely unexplored. We found 
that cell incubation in the presence of either apoE3 or apoE4 induced fatty acid remodeling.  
The main results can be summarized as follows: 
 SFAs were significantly increased after incubation of cells with apoE3 or apoE4 (p < 0.001, 
p < 0.01, respectively), but the increase was higher in the presence of apoE3 than apoE4 (p < 
0.01); 
 MUFAs were significantly increased after incubation with both apoE3 and apoE4 (p < 0.05, 
p < 0.0001, respectively), with apoE4 mainly increasing palmitoleic acid concentration (p < 
0.001).  
 ω-6 PUFAs were significantly diminished in the cell membranes after incubation with apoE3 
(p < 0.0001) but their concentration was unchanged after incubation with apoE4. 
 ω-3 PUFAs were significantly diminished in the membrane of cells treated with both apoE 
forms if compared with untreated samples (p < 0.0001), but the decrease was of greater 
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magnitude in the presence of apoE3 (p < 0.001). The decrease of ω-3 affected also the PUFA 
balance indicator with respect to control (p < 0.0001). 
 TFAs tended to decrease after incubation of the cells with apoE3. On the contrary, the TFA 
content in cell membranes appeared to increase in the presence of apoE4. 
More specifically, ApoE3 increased the membrane level of stearic acid and of DGLA, whereas apoE4 
had opposite effects. The addition of both apoE3 and apoE4 increased membrane SFAs and MUFAs, 
ω-6/ ω-3 ratio and decreased total PUFAs, but with various intensities. Moreover, both apoE isoforms 
decreased membrane homeostasis indexes such as PUFA balance, UI and PI. 
The present results highlight membrane property changes connected to the apoE isoforms, suggesting 
that membrane lipidomics could be inserted in future model studies of apolipoproteins in health and 
disease. The membrane remodeling induced by the addition of apolipoproteins encourages further in 
vitro studies to better understand synergies between fatty acid-based membrane lipidomics and 
apolipoprotein lipid distribution, including the effects of different dietary conditions and lipid 
supplementation.  
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Chapter 5 
Trans liposomes 
 
 5.1. Introduction  
Liposomes, which are constituted by phospholipids, served as membrane models in the field of 
biomimetic chemical biology; at the same time, they have been extensively studied in medicinal 
chemistry for their potential in drug delivery.  
The biophysical characteristics of liposomes strongly depend on the fatty acid moieties. The influence 
of lipid double bond configuration has not been considered so far when evaluating the competence of 
liposomes in drug delivery; however, one should remember that natural unsaturated lipids are always 
in the cis configuration. 
The study we carried out focused on possible changes in the molecular properties of liposomes 
induced by the conversion of the double bonds from cis to trans geometry. In particular, we report on 
the effects of the addition of trans-phospholipids to other lipid constituents on size, ζ-potential and 
stability of liposomal formulations and on liposome ability to encapsulate two dyes, rhodamine B and 
fluorescein.  
From a biotechnological point of view, trans-containing liposomes proved to have different 
characteristics from those containing the cis analogues, and to influence the incorporation and release 
of the dyes. These results open new perspectives in the use of the unnatural lipid geometry, with the 
purpose of changing liposome behavior and/or of obtaining molecular interferences, also in view of 
synergic effects on cell toxicity, especially in antitumoral strategies. 
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 5.2. Liposome properties  
Liposomes are small artificial vesicular structures characterized by the presence of one or more 
phospholipid bilayers, that delimit a hydrophilic core. 
As previously mentioned for cell membrane (Chapter 1, Paragraph 1.1), phospholipids are 
amphiphilic molecules that expose their polar heads towards the surrounding acqueous environment 
or towards the internal acqueous cavity, while the apolar tails (the hydrophobic portion of the 
molecules) are buried in the inner core, where they interact each with the other; the lipidic bilayers 
sorround an internal acqueous cavity. Therefore, liposomes can remain immersed in an aqueous 
environment while simultaneously hosting an aqueous content in which active principles or other 
water-soluble molecules are dispersed. The release of polar molecules located in the inner acqueous 
volume is generally prevented, effectively isolating the liposome content. 
Liposomes can be classified according to different criteria, such as size, structure and preparation 
method. Depending on the structure and the number of double phospholipid layers, it is possible to 
distinguish liposomes as: 
 Unilamellar liposomes, that consist of a single phospholipid bilayer that encloses a 
hydrophilic core. Depending on their size, unilamellar liposomes can be further classified 
into:  
o Small unilamellar vesicles (SUVs) whose diameter may vary from 20 nm to 100 nm; 
o Large unilamellar vesicles (LUVs) whose diameter may vary from 100 nm to 1 μm; 
o Giant unilamellar vesicles (GUVs) whose diameter is greater than 1 μm. 
 Multilamellar vesicles (MLVs), that are characterized by the presence of concentric lipid 
layers (usually more than five), separated by aqueous phases (onion organization). 
Multilamellar liposomes can reach diameters between 500 and 10.000 nm. Oligolamellar 
vesicles (OLVs), consisting of few concentric phospholipid bilayers (less than five), are also 
included in this group. 
 Multivesicular vesicles (MVVs), that are characterized by the presence of a double 
phospholipid layer enclosing other not concentric liposomes (Figure 5.1). 
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Figure 5.1. Liposome classification based on size and structural characteristics. 
 
Not all phospholipids have the propensity to form liposomes. The aggregation structure is influenced 
by the phoshopholipid shape, which depends on the relative dimensions of their polar and apolar tails. 
The molecular self-assembly structure can be predicted by a factor known as packing parameter, P. 
This parameter, is defined as the ratio between the effective hydrophobic chain volume (V), and the 
product of the effective headgroup area (A0) by the alkyl chain length, (lc) (Figure 5.2).  
P parameter underlines the importance of the area ratio occupied by the cross section of the 
hydrophobic portion with respect to the hydrophilic portion [1]. 
When the head group and the lipid scaffold have similar cross section areas (P >1/2), the molecules 
have a cylindrical shape and form spherical vesicles, that are thermodynamically favoured over planar 
bilayers. This is the case of phosphatidylcholine and phosphatidylserine, the most aboundant 
phospholipids found in cell membranes.  
Lipids with a head occupying a relatively large surface area when compared with the cross-sectional 
area occupied by the hydrophobic chains (P <1/2), as for example in the case of lysophospholipids, 
usually prefere micellar (non-inverted) structures.  
In contrast, lipids with a relatively small polar head and acyl chains occupying an extended area 
(P >1), such as phosphatidylethanolamine, tend to adopt an inverse hexagonal phase HII.  
This lipid polymorphism has been considered of crucial importance in physiological processes such 
as the generation of curvatures that occurs in the formation of lipid vesicles or during membrane 
fusion. 
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Figure 5.2. Schematic representation of the liposome structure as a function of the lipid packing parameter (P). 
 
 5.3. Liposome preparation  
Liposomes can be prepared at a lab-scale level using reproducible and robust protocols that can be 
modified to suit specific needs [2,3]. 
The choice of the proper liposome preparation method depends on the physico-chemical 
characteristics of the material to be entrapped and consequentely of the medium in which they are 
dispersed. Additionally, it is important to consider the effective concentration of the entrapped 
substance, its potential toxicity but also the size distribution and the shelf-life of the vesicles for the 
intended applications [4,5]. 
The first step of liposome preparation consists in dissolving the phospholipids (or a mixture of lipid 
components) in an organic solvent, such as chloroform or chloroform/methanol mixtures, to assure 
the formation of a homogeneous mixture of lipids.  
Lipid solutions are usually prepared at a 10-20 mg lipid/mL concentration, however higher 
concentrations may be used, based on the lipid solubility and mixing capacity. Once the lipids are 
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thoroughly mixed in the organic solvent, the solvent is removed to yield a homogeneously distributed 
lipid film. Depending on the solvent volume, inhert gas stream (i.g. nitrogen or argon) or rotary 
evaporation can be used to evaporate the solvent. The residual traces of organic solvent can be 
removed by placing the vial or bottom round flask on a vacuum pump at least one hour prior to 
proceed with the rehydration step.  
Hydration of the dry lipid film can be achieved by adding an aqueous medium, followed by agition. 
Attention should be payed to the temperature of use, which should be above the gel-to-liquid crystal 
transition temperature (Tm) of the lipid with the highest Tm, and should be maintained constant until 
the end of the process. In the presence of a phospholipid mixture, the temperature to be used should 
be considered with caution since high temperatures can facilitate oxidative processes or induce lipid 
degradation. Hydration time may differ depending on the lipid species and structures, however 
hydrating and vigorous shaking usually lead to high homogeneity of the suspension and reduction in 
size of the vesicles. 
The hydration mediums are usually water or buffers, depending on the applications, to respect 
physiological pH and osmolarity, the desidered surface charge for the electrostatic interactions with 
the encapsulated molecules, but also the preparation method. For example, if the liposome procedure 
requires lyophilization, a cryoprotectant in the hydration medium is required.  
The product of hydration is a stable suspension composed by MLVs, analogous in structure to an 
onion, which can be downsized by a variety of techniques, including sonication or extrusion (Figure 
5.3). 
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Figure 5.3. Liposome preparation (image from http://www.intechopen.com/source/html/44386/media/image7.png). 
 
5.3.1. Sonication 
Sonication method is usually accomplished by placing a vial containing the MLV suspension to be 
downsized in a bath sonicator and sonicating for 5-10 minutes above the Tm of the lipid mixture. 
Sonication of MLVs typically produces SUVs with diameters in the range of 15-50 nm. Approaching 
homogeneity and nanometric sizes, the suspension becomes transparent, however different factors, 
such as concentration, temperature, sonication time and power, can influence the nanoparticle size 
distribution. Despite being a quick and inexpensive technique, sonication hardly gives reproducible 
results and chances of scale-up.  
 
5.3.2. Extrusion 
An alternative to sonication is represented by the extrusion technique [6].  
Extrusion consists in the forced passage of a MLV suspension through small, regular pores of a 
resistant membrane by applying an external pressure. The passage through the pores destroys the 
large aggregates and produces liposomes similar in size to the membrane pore diameter. For this 
purpose, the extrusion apparatus is composed of two syrings that should fit tight into a central support 
containing the membranes with suitable pore diameters (Figure 5.4). Membrane supports and o-rings 
are also included in the system to guarantee the hermetic sealing of the downsizing chamber and to 
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avoid suspension leakage. The temperature can be controlled by placing the extruder heating block 
on a hot plate. After equilibrating the temperature and pre-wetting of the instrument with clean buffer, 
the suspension can be inserted in one of the two syrings and gently pushed from the plunger to the 
second syringe and again back to the original syringe. This step can be repeated several times since 
the more passages through the membrane are accomplished, the more homogenous the suspension 
becomes. The final extrusion should fill the alternate syringe, in order to reduce contamination from 
larger particles or undesired material (i.g. dust) that did not pass through the membrane. 
The method is simple and reproducible, but it is usually time-waisting and difficult to scale-up 
because it is limited to processing small volumes.  
 
 
Figure 5.4. Extruder system (image from www.avantilipids.com). 
 
 5.4. Liposome characterization  
The quality of the liposomes obtained by the methods previously described can be assessed by 
monitoring various parameters. From the analytical point of view, the most important features include 
the average mean diameter, the polydispersity and the morphology. Other commonly monitored 
parameters for the therapeutic use of liposomes are the encapsulation efficiency and the surface 
charge.  
 
98 
 
5.4.1. Dynamic Light Scattering (DLS)  
Dynamic light scattering (DLS) is the most commonly used technique for liposome size and surface 
charge measurements [7]. 
The sample is illuminated by a laser beam, and the variations in light intensity diffused by the sample 
are measured as a function of time. The intensity variations measured by the detector are generated 
by the Brownian movement of the particles at the origin of the scattering. 
The phenomenon at the basis of DLS is that, in the same conditions of temperature and viscosity, 
'small' particles move quickly, creating rapid variations in the scattering intensity. On the contrary, 
'big' particles move more slowly, creating slow intensity variations.  
Thanks to an auto correlator, the speed of the intensity variations can be measured, and the particle 
diffusion coefficient calculated by the correlation function. Stokes–Einstein equation (Figure 5.5), 
where D is the diffusion constant, kB is Boltzmann's constant, T is the absolute temperature, η is the 
dynamic viscosity and r is the radius of the spherical particle, allows then to convert the diffusion 
coefficient into the hydrodynamic diameter.  
 
 
Figure 5.5. Stokes-Einstein equation. 
 
Additionally, through this technique it is possible to obtain information regarding the surface charge 
of the nanoparticles, also known as zeta (ζ-) potential. ζ-potential is useful to predict the stability of 
the dispersions or the electrostatic interactions. Most of the nanoparticles dispersed in water have a 
surface charge, induced by ionization or absorption of charged species. The charged particles in 
solution are surrounded by different ionic layers, whose composition is different from that of the bulk. 
When moving in solution, the particles move together with a double ionic layer.  
The ζ-potential appears to be the main force of interactions between the particles, and for this reason 
allows to predict the stability of a suspension. In fact, a high ζ-potential value (i.e. <-30mV and> + 
30mV) indicate particles that reject each other keeping the formulation stable. On the other hands, ζ-
potential values close to neutrality are associated with the high tendency of particles to interact, thus 
giving rise to aggregation and flocculation phenomena.  
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5.4.2. Atomic Force Microscopy (AFM) 
Atomic force microscopy (AFM), also known as scanning force microscopy (SFM), is one of the 
most common techniques for morphological characterization of liposomes [8,9]. AFM is largely 
exploited in the field of nanoparticles since it provides high nanoscale spatial resolution combined 
with minimal sample preparation that preserves unaltered the sample characteristics. Indeed, 
compared to scanning electron microscopy (SEM) and transmission electron microscopy (TEM), 
which require complex sample preparation such as chemical fixing or metal coating, AFM leaves 
unaltered the surface to be scanned [10,11]. 
In AFM technique (Figure 5.6), the sample is mounted on a stage and a sharp tip, which is fixed to a 
cantilever, is placed in proximity to the sample surface. Weak interaction forces between the tip and 
the sample are established and transduced into changes of the cantilever motion. Several different 
aspects of the cantilever motion can be used to quantify the interaction between the tip and sample, 
most commonly the value of the deflection, the amplitude of an imposed oscillation of the cantilever, 
or the shift in resonance frequency of the cantilever. The deflection and motion of the cantilever are 
recorded by a detector. 
 
 
Figure 5.6. Schematic representation of the operation of the AFM technique. 
 
There are several ways to scan the sample surface, depending on the application and the nature of the 
tip motion. Imaging modes can be in general be classified as static, also called contact, or dynamic, 
or tapping, modes [12]. 
In contact mode, the tip is gently dragged over the sample surface and the details of the surface can 
be measured either by directly measuring the deflection of the cantilever or by using the feedback 
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signal required to keep the cantilever at a constant position. In the contact mode, the forces involved 
are mainly repulsive. The main drawback in contact mode is that side forces could possibly distort 
the image and capillary forces due to a fluid layer can cause significant hindrance to the probe-sample 
interaction.  
In tapping mode, the cantilever is driven by a small piezo element to vibrate or oscillate up and down 
near its resonance frequency. The frequency and amplitude of the driving signal are kept constant to 
have a constant amplitude of the cantilever oscillation in the absence of drift or interaction with the 
surface. The interaction of forces acting on the cantilever when the tip and the surface enter in contact, 
such as Van der Waals, dipole-dipole or electrostatic interactions, cause the amplitude of the 
cantilever's oscillation to change (usually decrease) as the tip gets closer to the sample. This amplitude 
is monitored by an electronic servo that adjusts the height of the cantilever to maintain constant the 
oscillation amplitude along the sample scanning. By imaging the force of the intermittent contacts of 
the tip with the sample surface, a tapping AFM image is produced. Tapping mode imaging is usually 
favourable for the visualization of lipid vesicles, since it is gentler than contact mode and does not 
modify the sample characteristics, thus is suitable for elastic materials. Additional information can be 
collected observing the height of the sample. As a result, the height/diameter ratio can be calculated 
[13]. 
 
 5.5. Liposome applications  
Thanks to their characteristics, liposomes can find multifold applications, from the medical to the 
pharmaceutical and to the cosmetic field, due to their high affinity with the epidermal stratum 
corneum. Regarding the medical and pharmaceutical applications, however, liposomes can be 
employed both for therapeutic and diagnostic purposes. The ability of liposomes to isolate their 
contents from the outer environment is particularly useful in the delivery of perishable substances 
(such as, for example, proteins and nucleic acids). At the same time, liposomes can be exploited to 
reduce the toxicity of certain drugs. This is the case, for example, of doxorubicin - an anticancer drug 
largely used for ovarian and prostate cancer - that, if encapsulated in long-range liposomes, shows 
altered pharmacokinetics, as well as reduced toxicity and improved effectiveness. 
Liposomes were initially proposed as simplified models of cell membranes since they faithfully 
reproduce the arrangement of phospholipids in membrane bilayers [14]. 
Over the years, liposomes have gained attention for their ability of carrying therapeutics, thanks to 
their high versatility combined with their high biological compatibility. Indeed, due to their 
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amphiphilic properties, drugs with different partition coefficients can be incorporated into liposomes 
allowing control of the degradation rate and the harmful side effects. Moreover, the similarity of 
liposomes to biological membranes makes them non-immunogenic, physiologically inert and highly 
tolerated by the organism [15]. 
Liposome surface and composition can be finely modulated to achieve the desired distribution and 
pharmacokinetics, promoting controlled and sustained drug release together with drug accumulation 
in the targeted site of action [16,17]. 
To face the complexity and multifactoriality of many disease states and healing processes, several 
strategies can be combined in the so-called stimuli responsive liposomes, going from internal 
(biologically occurring) stimuli such as pH, temperature, redox microenvironment, to external 
stimuli, such as magnetic field, ultrasound, light and heat. 
As far as the fatty acid residues of the membrane phospholipids are concerned, changes of the 
unsaturation index and of the double bond geometry of natural fatty acids affect physical properties 
of the membrane bilayer, such as fluidity and permeability, with consequences on the surface 
interactions, protein functioning and lipid signalling. 
In particular, we were interested in the geometry of the double bonds, given the evidence that in 
bacteria the conversion from cis to trans geometry is enzymatically induced to create a membrane 
barrier, as a protective mechanism against high temperatures or high toxic substance concentrations 
of the surrounding environment (Chapter 1, Paragraph 1.2). In humans, such enzymatic 
transformation does not occur.  
In the last two decades the occurrence of trans lipids has been reported in foods that have undergone 
industrial procedures such as partial hydrogenation and deodorization (Chapter 1, Paragraph 1.4) 
but also as the results of endogenous reactions induced by sulfur centered radicals, that cause the cis-
trans double bond isomerization of biological lipids (Chapter 1, Paragraph 1.3.2).  
The idea that TFA incorporation in the fluid mosaic of cell membranes affects their assembly 
properties and in vivo functions is sustained by the effect of high dietary consumption of these 
unnatural lipids. In fact, cell membrane incorporation of TFAs is associated with the rise in several 
endothelial dysfunction markers - including ICAM-1 intercellular cell adhesion molecules, VCAM-
1 vascular cell adhesion molecules and E-selectin - and with the loss of vasodilatatory endothelium-
mediated response (Chapter 1, Paragraph 1.5).  
So far, the trans geometry of the cell membrane fatty acid pool has been poorly addressed. Some 
preliminary differences between cis- and trans-containing monounsaturated liposomes, regarding 
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diameter and fluidity properties, were found, which could be related to the molecular shapes [18,19]. 
Whether such variations induced by trans-phospholipids might be used for imparting differences in 
drug encapsulation efficiency or release profile, influencing liposome stability and drug leakage, it is 
not known so far.  
In this study we report the effects induced by the presence of trans-phospholipids on size, ζ- potential 
and stability of liposomal formulations. In liposome formulations containing known components 
(such as cholesterol, neutral phospholipids and cationic surfactants) and differing for their cis- or 
trans-phospholipid geometry, the encapsulation efficiency and the in vitro release of two different 
dyes, rhodamine B and fluorescein (commonly used to study the properties of different nanocarriers 
[20,21], were compared. In perspective, the results suggest that trans-phospholipids may be 
interesting players in antitumoral formulations, because of their ability to influence the liposome 
behavior; the synergy of the drug effect with the trans geometry of phospholipids can be envisioned 
as an innovative antitumoral strategy. It is worth mentioning that the formation of cis double bonds 
(stearic to oleic acid transformation) is a crucial enzymatic pathway involved in tumorigenesis 
[22,23]. 
 
 5.6. Experimental part  
1,2-dipalmitoyl, phosphatidylcholine (DPPC), 1-palmitoyl,2-oleoyl, phosphatidylcholine (POPC), 
and 1-palmitoyl,2-oleoyl, phosphatidylethanolamine (POPE) were purchased from NOF American 
Corporation (Irvine, CA, USA). Sodium sulfate anhydrous, phosphate-buffered saline (PBS) tablets, 
cholesterol and myristoyl trimethylammonium bromide (MTMAB) were purchased from Sigma 
Aldrich (St. Louis, MO, USA). Rhodamine B was purchased from Janssen Chimica (Beerse, 
Belgium) and fluorescein was purchased from Merck (Darmstadt, Germany). 2-mercaptoethanol 
(98% purity) was purchased by Alfa Aesar (Karlsruhe, Germany). 30% ammonium hydroxide 
(NH4OH) aqueous solution was purchased from Panreac Quimica SA (Barcelona, Spain). Potassium 
hydroxide (KOH) was purchased from Riedel De Haen AG (Seelze, Hannover, Germany). 
isopropanol (Analytical grade) and chloroform (HPLC grade) were purchased from Fisher Scientific 
(Atlanta, GA, USA). Methanol and n-hexane, were purchased from Macron Fine Chemicals (Center 
Valley, PA, USA). Silica gel thin-layer chromatography was performed on Merck silica gel 60 plates 
(0.25 mm thickness) and the spots were detected by spraying the plate with cerium ammonium 
sulphate reagent. Standard methyl ester references (FAME mix C14-C22 and 37 component FAME 
mix) were commercially available from Supelco (Bellefonte, PA, USA) and were used without further 
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purification. Trans FAME references were synthesized according to previously reported protocols 
[18, 24].  
 
5.6.1. Synthesis and purification of PEPC  
A solution of 1-palmitoyl,2-oleoyl, phosphatidylcholine, POPC (60 mg, ca. 0.079 mmol) in 
isopropanol (4 mL) was placed in a vial and degassed with argon for 20 minutes. Then, 2-
mercaptoethanol (2.73 mg; 0.035 mmol) was added, and the solution was irradiated for 1h (dose rate 
= 2.84 Gy/min). The crude reaction product was purified to pure phospholipids (59 mg; 0.077 mmol; 
98% yield) using the chromatographic procedure described in literature [18]. Briefly, the solvent 
was evaporated and the crude reaction product was dissolved in chloroform and charged on a silica 
column conditioned with chloroform/methanol (8:2 v/v). The sample was collected in one fraction 
procedure using chloroform/methanol/water/30% NH4OH aq (20:10:0.4:0.2 v/v) mixture as mobile 
phase.  The purity of phosphatidylcholine was verified by TLC using the above specified eluent (Rf= 
0.5). A small aliquot underwent GC analysis to determine the trans isomer content. In the product, 
60% of oleic acid was converted in the corresponding trans isomer, elaidic acid. To this 
phosphatidylcholine mixture was given the name of 60-PEPC.  
 
5.6.2. Liposome preparation  
LUVETs were prepared using the hydration-extrusion technique. Briefly, POPC (76 mg; 0.1 mmol) 
or a mixture of phospholipids with the same molarity were dissolved in chloroform/methanol (2:1 
v/v) until a clear lipid solution was obtained. The organic solvent was removed using a rotary 
evaporator to yield a homogeneous lipid film on the sides of a round bottom flask. The lipid film was 
thoroughly dried to remove residual organic solvent by placing the vial or flask on a vacuum pump 
for 1 h. The dried lipid film was left to hydrate for 30 minutes in PBS and then vortexed for 10 minutes 
until a milky mono-phasic solution containing MLVs was obtained. For high transition lipids, PBS 
1X was warmed up above the phase transition temperature (Tm) of the lipid with the highest Tm 
before adding to the dry lipid, and all the steps that follow were done under the same conditions. Once 
a stable suspension was formed, MLVs were downsized to LUVETs using a LiposoFast hand 
extrusion device (Avestin Inc., Ottawa, ON, Canada) equipped with 100 nm pore size polycarbonate 
filters through which the lipid suspension was passed 19 times, controlling the temperature with a 
heat block when required. The resulting suspension was used in the encapsulation and release 
experiments with the same molarity (i.e., 10 mM). 
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5.6.3. Dye encapsulation  
Rhodamine B (MW 479.02 g/mol) and fluorescein (MW 332.31 g/mol), were chosen as inexpensive 
and common luminophore drug models.  
Starting from a 5 mM total lipid concentration, 1:1, 1:10, 1:50 and 1:100 dye/lipid ratio were tested 
in order to determine the optimal encapsulation conditions. Lipids were first dissolved in chloroform 
then dryed to form a thin lipid film using the rotary evaporator and left under vacuum for 30 minutes. 
10 mM stock solutions of rhodamine B (in PBS) and fluorescein (in methanol) were used to prepare 
the dye-containing diluted solutions used to rehydrate the thin lipid film. In the case of rhodamine B, 
the diluted solution could be immediately used to rehydrate the lipid film, while fluorescein solution 
in methanol was added to the lipid film prior to the vacuum step in order to remove any trace of 
organic solvent. The lipid suspension was left 30 minutes to hydrate and then vortexed for 10 minutes. 
When freeze-annealing-thaw cycles were required, the samples were frozen at -196 °C using liquid 
nitrogen (3 minutes), left to anneal at 0 °C in an ice bath (30 minutes) and then thawed at 40 °C in a 
liquid bath (30 minutes). Four different procedures were tested. Method A: samples underwent 10 
minutes vortexing performed at 22 °C; Method B: the vortexing step of 10 minutes duration was 
carried out at 40 °C, followed by two sonication cycles, each one of 5 minutes; Method C: after 10 
minutes vortexing at 22 °C, samples underwent two freeze-annealing-thaw cycles; Method D: 
samples were vortexed for 10 minutes at 22 °C and then subjected to five freeze-annealing-thaw 
cycles. The non-encapsulated dye was removed by sequential centrifugations (18000 g × 4 °C × 30 
min) and washed with fresh PBS until a transparent supernatant was obtained. Rhodamine B 
concentration was determined by measuring its absorbance at 553 nm using a V-560 Jasco UV/Vis 
Spectrophotometer. The dose-response curve was linear (r= 0.999) in the concentration range of 0.1-
10 µM. Fluorescein concentration was determined by measuring its absorbance at 491 nm and its 
fluorescence at 512 nm, using a Fluorostar OPTIMA Spectrophotometer. The dose-response curve 
was linear in the concentration range of 0.5-100 µM in absorbance (r= 0.9994) and 0.01-5 µM in 
fluorescence (r= 1). The measurements were recorded both in PBS 1X and in 30% ethanol.  
 
5.6.4. Encapsulation Efficiency (EE%)  
After removal of the non-encapsulated dye, the pellet of dye-containing liposomes was dissolved in 
30% ethanolic aqueous solution and thoroughly sonicated in order to fully disrupt the liposome pellet 
and release the encapsulated dye (Direct method). This method was preferred over the commonly 
used detergent treatment with 10% Triton X-100 because this latter one induced a significant 
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quenching in the fluorescence. The encapsulated amount of dyes was confirmed by measuring the 
not encapsulated dye (Indirect method) using the following equation: 
 
 
5.6.5. In vitro release study  
Cellulose dialysis membranes with a MWCO of 12-14000 Daltons and 28.6 mm diameter (Visking 
Medicell International, London, UK) were hydrated using PBS 1X. 0.5 mL of the dye-loaded 
liposome suspension (10 mM lipids, pH 7.4) was placed into the dialysis bag, which was then 
transferred into a becker containing 10 mL of PBS 1X. The becker was put on a magnetic stirrer and 
kept continuously under stirring. The dye release was monitored at 22 and 37 °C to simulate storage 
and physiological conditions, respectively. For comparison, a solution of free dye dissolved in PBS 
was analysed under the same conditions. Samples of 1 mL volume were withdrawn at fixed time 
intervals (30 minutes, 1, 2, 4, 8 and 24 hours) and analyzed by UV/Vis or fluorescence spectroscopy. 
  
5.6.6. Lipid extraction and GC analysis  
Liposome phospholipids were isolated using the well-established Folch Method (Chapter 2, 
Paragraph 2.2). Briefly, the liposomal suspension in PBS 1x was treated with 2:1 
chloroform/methanol (2:1 v/v) mixture. The organic phase was collected and dried using anhydrous 
sodium sulphate, evaporated and left under vacuum for 30 minutes. A small fraction was analyzed by 
thin layer chromatography using chloroform/methanol/water (65:25:4 v/v) as eluent to check the 
purity of the phospholipid fraction, according to published procedures [25]. The residue was treated 
with a 0.5 M KOH/methanol solution and left under stirring for 10 minutes at 22 °C to convert the 
fatty acid residues of the phospholipids into their corresponding fatty acid methyl esters (FAMEs). 
The reaction was quenched with water and FAMEs were extracted using n-hexane (3 x 2 mL); the 
organic phase was collected and dried with anhydrous sodium sulphate. The solvent was eliminated 
by evaporation using a rotary evaporator, and the thin white film of the FAME was subsequently 
dissolved in a small volume of n-hexane and injected into the GC.  
An Agilent 7890B gas chromatograph, with a flame ionization detector and a (50%-cyanopropyl)-
methylpolysiloxane (DB-23, Agilent, USA) capillary column (60 m, 0.25 mm i.d., 0.25 µm film 
thickness) was used for the analysis. The initial temperature was 165°C, held for 3 minutes, followed 
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by an increase of 1 °C/min up to 195 °C, held for 40 minutes, followed by a second increase of 
10 °C/min up to 240 °C, held for 10 minutes. The carrier gas was hydrogen, held at a constant pressure 
of 16.482 psi. All the methyl esters were identified by comparison with the retention times of standard 
references either commercially available or obtained by synthesis, as described elsewhere [18,24]. 
 
5.6.7. Dynamic Light Scattering (DLS)  
Hydrodynamic diameter and ζ-potential of LUVETs were measured using DLS technique (Malvern 
Instruments Series, NanoZS) with a detection angle of 173°. The optimal concentration for size 
distribution was 1 mM, while 0.1 mM concentration was used to measure ζ-potential. All 
measurements were recorded at 25 °C. In the present study, the data reported are the mean values 
obtained from 3 measurements, each one including 10 runs of 10 seconds. The polydispersity of the 
sample, a reverse parameter to describe the homogeneity of the system, is reported as polydispersity 
index (PDI). 
 
5.6.8. Atomic Force Microscopy (AFM)  
Morphological characteristics were monitored using AFM. Tapping mode was choosen for 
recording image parameters. The probes used were Bruker RTESPA-300 model, unmounted Si (n-
type doped Sb) with nominal constant 40-80 N/m and resonance 300-400 kHz. 20 µL of a 10 mM 
liposome solution were deposited on a mica support. After 2 minutes of incubation at 22 °C, the 
excess of liquid was removed from a corner using a kimtech tissue. Samples were analyzed in 
triplicates. Results are expressed as mean ± SD. 
 
5.6.9. Statistical analysis  
All data reported are presented as mean or percentage ± SD (n=3). Statistical significance (p values) 
of the results was calculated by unpaired two-tailed Student's t-test using GraphPad Prism version 
6.01 for Windows. Differences were considered statistically significant when p < 0.05. 
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 5.7. Results  
Trans-phospholipids were prepared by a synthetic procedure using γ-radiation (Cobalt-60 source) on 
the natural 1-palmitoyl,2-oleoyl, phosphatidylcholine (POPC), having the natural oleic acid (9c, 18:1) 
as monounsaturated chain, in the presence of 2-mercaptoethanol [24,26]. Thiyl radical, generated 
from thiol, catalyzed the conversion of oleic moiety to the corresponding geometrical isomer (9t, 
18:1). More specifically, the product of the reaction was a trans fatty acid-containing 
phosphatidylcholine mixture, composed by 60% by 1-palmitoyl,2-elaidoyl, phosphatidylcholine 
(PEPC) and 40% POPC. The trans content was established after purification and conversion of a 
small sample fraction to the corresponding FAMEs followed by GC analysis. This phospholipid 
mixture was named 60-PEPC. Another phospholipid mixture containing an intermediate percentage 
of elaidic acid, i.e., consisting of 30% PEPC and 70% POPC, was prepared and named 30-PEPC. 
Multilamellar vesicles (MLVs) were obtained from a 0.01M phosphate buffered saline (PBS) 
suspension of 5 mM cis and trans-containing phospholipids. The MLV suspensions were then 
downsized by extrusion technique using 100 nm polycarbonate membrane filters to form large 
unilamellar vesicles (LUVETs), which are more suitable for drug delivery purposes. Liposomes were 
analyzed by DLS, that gives information about the size distribution, the homogeneity and the surface 
charge of the liposomal suspensions, as well as on aggregation or disruptive phenomena. 
 
5.7.1. Effect of TFAs on size and ζ-potential  
The results of the particle sizing and ζ-potential measurements of the various liposomal formulations 
are summarized in Table 5.1 and Figure 5.7.  
The simplest formulation to investigate the differences due to the percentages of cis and trans bonds 
consisted of the natural POPC in comparison with formulations having 30-PEPC and 60-PEPC. A 
decrease in size was observed as the trans phospholipid percentage increased (Table 5.1 - 
Formulation A0, A30, A60). A significant drop in size, from 149.1±0.18 nm to 117.4±0.55 nm 
(p≤0.0001), was observed by replacing POPC with 60-PEPC. As for the Polydispersity Index (PDI), 
that provides information about the size distribution of the suspensions, and for the average surface 
charge of the particles, indicated as ζ-potential, no large differences were noticed among the three 
formulations.  
The inclusion of cholesterol in the formulation, used in a phospholipid/cholesterol molar ratio of 
70:30 [27], induced an increase in size compared to natural phosphatidylcholine liposomes (Table 
5.1 - Formulations B0, B30, B60). This is one of the expected changes due to the cholesterol 
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interactions within the lipid bilayer, which are known to influence lipid order, bilayer width and 
properties, such as permeability and fluidity [28-30]. The presence of 60-PEPC (B60), but not 30-
PEPC (B30), led to a decrease in size and PDI and an increase in ζ-potential compared to POPC (B0). 
The decrease caused by the trans geometry to the size and PDI in the presence of cholesterol is worth 
of note, since at the 60% PEPC concentration in the bilayer the cholesterol effect seems to be 
annihilated. This aspect could suggest an interesting connection with the role of cholesterol in the cis-
trans isomerization process in bacteria, as protection against environmental changes (Chapter 1, 
Paragraph 1.2). In all cases the presence of cholesterol decreased the ζ-potential value that is a known 
effect such as in case of Na+ ion binding with the lipid head group [31], although in the presence of 
60-PEPC the decrease is much less.   
Due to the expanding field of gene therapy, that requires positively charged liposomes to carry 
negatively charged oligonucleotides, a cationic formulation containing the cationic surfactant, 
myristoyl trimethyl ammonium bromide (MTMAB), was also tested. In particular, formulations 
containing a mixture of POPC/DPPC/CHOL/POPE/MTMAB 25:25:20:15:15 or the analogous 30-
PEPC or 60-PEPC in replacement of POPC, were prepared (Table 5.1 - Formulations C0, C30, C60). 
Components able to synergize in the enhancement of the membrane stability were chosen in such 
formulations. In fact, a) 1,2-dipalmitoyl, phosphatidylcholine (DPPC) is important to preserve the 
thermostability of liposomes in physiological conditions, due to its high transition temperature 
[32,33]; b) 1-palmitoyl,2-oleoyl, phosphatidylethanolamine (POPE) is a phosphatidylethanolamine 
(PE) that can form stable bilayers at physiological pH when intercalated with other amphiphilic 
molecules, although protonation of its carboxylic group in an acidic environment causes the shift to 
the inverted hexagonal phase that destabilizes the liposome structure. For this reason, PE is widely 
used in cancer gene therapy since it can lead to lysosome destabilization and selective drug release in 
the acidic extracellular tumour environment [34,35]; c) MTMAB is a quaternary surfactant able to 
enhance the cellular internalization and the DNA transfection in gene therapy [36,37]. Indeed, 
cationic liposomes appear to be the safest and cheapest alternative to viral vectors for protecting DNA 
from enzymatic degradation and efficiently delivering high molecular weight molecules without 
provoking dangerous immunological responses [38-40]. The diameter range of the three cationic 
formulations was smaller compared to the above-mentioned ones and their ζ-potentials were close to 
+20 mV.  The presence of surface positive charges, as observed in this case, induces electrostatic 
repulsions that prevent formation of aggregates or flocculation of liposomes. Moreover, positive net 
charges could promote the interaction of liposomes with cells, due to the asymmetric membrane lipid 
distribution of phosphatidylserine that confers a negative charge to cell membranes [41]. Very small 
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values of PDI (< 0.15) were recorded for POPC and 60-PEPC formulations, which indicates narrow 
monodisperse systems.  
 
Table 5.1. Average size diameter, polydispersity index and ζ-potential of various liposomal 
formulations The values are given as mean ± SD. Each experiment was performed in triplicate (n=3). 
Formulation Composition  Size (nm) PDI ζ -potential (mV) 
A0 POPC 149.1±0.18 0.18±0.01 -6.03±1.05 
A30 30-PEPC 144.45±0.78 0.11±0.06 -4.35±0.95 
A60 60-PEPC 117.40±0.55 0.16±0.01 -2.98±0.86 
B0 POPC/CHOL 7:3 170.70±2.19 0.31±0.01 -7.52±1.23 
B30 30-PEPC/CHOL 7:3 167.80±2.51 0.32±0.01 -7.22±0.56 
B60 60-PEPC/CHOL 7:3 156.60±1.03 0.17±0.01 -3.45±0.97 
C0 POPC/DPPC/CHOL/POPE/MTMAB 25:25:20:15:15 138.2±0.95 0.09±0.03 +20.5±1.45 
C30 30-PEPC/DPPC/CHOL/POPE/MTMAB 25:25:20:15:15 134.7±1.85 0.31±0.12 +20.9±0.98 
C60 60-PEPC/DPPC/CHOL/POPE/MTMAB 25:25:20:15:15 134.5±0.28 0.13±0.19 +19.2±1.11 
 
 
Figure 5.7. Size distribution and ζ-potential of various liposomal formulations (taken from Table 
5.1). Significant differences (p value) are reported as follow: (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 
0.001, (****) p ≤ 0.0001. 
 
In general, it was observed that, as the trans content in the membrane increases, the mean particle 
size decreased. Only small differences with the cis formulations were observed when 30-PEPC is 
used. Particle diameters greater than 100 nm, the size of the filter pores, can be explained by the 
interaction of the phospholipid heads with buffer ions in the surrounding environment; on the other 
hand, the fact that the liposome size is still <200 nm is important for the escape from complement 
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recognition and uptake by the mononuclear phagocytic system [42]. Smaller sizes are desired to 
exploit the passive targeting due to the so-called enhanced permeability and retention effect (EPR) 
where extravasation of liposomes into solid tumours is essential [43]. The accumulation of liposomes 
in tumours is size-dependent, as tumour capillaries have larger pores (100 to 700 nm in diameter) 
than normal blood vessels (typically<50 nm). Thus liposomes between 90 and 200 nm in diameter 
are able to selectively penetrate tumour capillaries [44,45].  
 
5.7.2. Effect of TFAs on stability  
Since formulations with 60-PEPC gave better results in terms of size and PDI compared to the 30-
PEPC formulations, further studies were performed to understand the effect of trans-inclusion in 
liposomal membrane in comparison with cis-analogues. Stability studies were conducted by storing 
the formulations at the temperatures 22, 37 and 45°C for 72 hours and by analyzing them by DLS, 
GC and TLC.  
Figure 5.8 shows the DLS results for the formulations A0, B0 and C0 using commercially available 
POPC (left side) and for the analogous formulations using 60-PEPC (right side). The formulation 
A0 showed aggregation phenomena when stored at 37 and 45 °C. The formulation A60 reduced this 
tendency but the aggregation, driven by the neutral charge of the phospholipid employed for this 
preparation, could not be avoided [46].  
Addition of cholesterol improved the stability of the formulations at all the temperatures, both in the 
presence of POPC (B0) and 60-PEPC (B60).  
Good stability was also observed when the cationic formulation was tested, regardless of the 
inclusion of trans lipids (C0 and C60). Reasonably, the presence of surface charges reduced the 
tendency of liposomes to flocculate and form bigger particle aggregates.  
TLC and GC analyses, useful to detect formation of by-products or oxidative consumption of 
unsaturated lipids, did not evidence any alteration in lipid composition (data not shown). 
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Figure 5.8. DLS measurements of liposomes at 22 °C (solid line), 37 °C (spotted line) and 45 °C (dashed line) versus 
time. Left side: POPC formulation A0, B0 and C0; Right side: 60-PEPC formulation A60, B60 and C60. The red line 
shows the size threshold of 200 nm.  
 
5.7.3. Effect of TFAs on morphology and rigidity  
POPC and 60-PEPC liposomes were analyzed by AFM, which is one of the most common techniques 
for liposome description. AFM provides high nanoscale spatial resolution combined with minimal 
sample preparation that preserves unaltered the sample characteristics. Indeed, compared to other 
scanning techniques, such as SEM and TEM, which require complex sample preparation such as 
chemical fixing or metal coating, AFM leaves unaltered the surface to be scanned. High sensitivity is 
reached using the tapping mode that, through small oscillations of the cantilever, permits to collect 
information about nanocarrier morphology and thickness. As a result, differences in rigidity can be 
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observed and numerically expressed by the height/diameter ratio. Measurements of approximately 10 
liposome diameters were performed for each sample. The results are provided (as mean of triplicate 
measurements) in the Table 5.2 and in the Figure 5.9 a representative AFM image is shown for 
POPC and 60-PEPC liposomes.  
Table 5.2. AFM analysis of POPC and 60-PEPC. 
 POPC 60-PEPC 
Diameter (nm) 145.00 ± 37.98 122.78 ± 13.15 
Height (nm) 6.04 ± 1.22 9.28 ± 1.80 
Height/diameter ratio 0.04 0.08 
 
Figure 5.9. Representative AFM images (on the left) and cross-section probles (on the right) of POPC (A) and 60-
PEPC (B) liposome acquired with tapping mode. 
 
Both formulations showed spherical shape with homogeneous distribution. POPC liposomes resulted 
to be larger if compared with 60-PEPC. Considering the liposome height, POPC liposomes resulted 
to be collapsed on the support. This property can be expressed by the height/diameter ratio that gives 
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general information about the liposome rigidity. Indeed, the higher the height/diameter ratio, the more 
rigid the system is. 
These scanning probe microscopy measurements confirm the different properties of trans-containing 
liposomes compared to cis-containing ones, as previously shown by other techniques, detailing the 
features of dimensions and rigidity. 
 
5.7.4. Effect of TFAs on encapsulation  
Four different conditions were tested to ensure the maximal drug encapsulation yield, as summarized 
in Table 5.3. The conditions were optimized on the POPC formulations (A0, A30, and A60) using 
rhodamine B as drug model. Since rhodamine B is an aminoxanthene with amphiphilic 
characteristics, it was dissolved in the aqueous solution and used to rehydrate the phospholipid film. 
Briefly, the effect of vortexing at 22 °C and 40 °C, followed by sonication or freeze-annealing-thaw 
cycles was studied. The molar ratio between the dye and the lipids (D/L) played a crucial role in the 
successful encapsulation of the fluorescent molecule. Four different D/L of 1:1, 1:10, 1:50, and 1:100 
were tested. 
 
Table 5.3. Methods used to optimize the liposomal encapsulation of rhodamine B. 
Method Procedure 
A Vortexing (10 minutes, 22 °C) 
B Vortexing (10 minutes, 40 °C) + 2 sonication cycles (5 minutes each)  
C Vortexing (10 minutes, 22 °C) + 2 freeze-annealing-thaw cycles 
D Vortexing (10 minutes, 22 °C) + 5 freeze-annealing-thaw cycles 
 
Results are reported in Figure 5.10. With the lowest D/L ratio, when the suspensions were vortexed 
at 22 °C for 10 minutes at maximum speed (Method A), only 20 to 40% of dye encapsulation 
efficiency (EE) was observed. 
Warming up of the buffer to 40 °C prior to the hydration step, followed by two brief sonication cycles 
of 5 minutes (Method B), resulted in a significant improvement of rhodamine B loading in the 
liposomal vesicles. Among the three formulations, POPC liposomes (A0) were the most efficient in 
including the dye in the inner aqueous volume. Probably, the presence of cholesterol decreased the 
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encapsulation efficiency of the fluorescent molecule since it induced membrane condensation and 
directly competes with rhodamine B in the bilayer assembly [47]. 
 
 
Figure 5.10. Effect of the encapsulation technique on the encapsulation efficiency (EE%) of rhodamine B in liposomes 
formulations A0 (white), B0 (grey) and C0 (black). The procedures are described in Table 5.3. 
 
Another important technique often used to enhance drug encapsulation into nanocontainers is the 
freeze-thaw procedure [48,49], but high variability in the number of cycles has been reported in 
literature [50,51].  
In this work, the sample underwent two (Method C) or five (Method D) freeze-anneal-thaw cycles 
(freezing to −196 °C with liquid nitrogen, annealing at 0 °C for 30 minutes in ice bath, thawing at 40 
°C in a water bath), since drug diffusion occurring in the frozen state and fusion/destabilization of 
liposomes led to higher EE compared to the traditional method [52]. 
Apparently, an increase in the number of freeze-anneal-thaw cycles gave higher percentages of 
encapsulated dye but not as much as sonication. Probably, the steric hindrance of the molecule to be 
encapsulated does not favour its entrapment and interaction with the lipid fraction.  
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It is worth to underline that the molar ratio between dye and lipid was very important, since by varying 
the D/L it is possible to optimize the drug loading and release from liposomal formulation [53].  
In this set of experiments, 1/100 was chosen as the best D/L not only because it allowed to reach 60 
to 90% of EE using Method B, but also because using higher D/L ratio could induce drug precipitation 
and membrane bilayer destabilization [54]. In these formulations the total lipid concentration was 10 
mM. 
In the light of these results, Method B, that combines temperature and sonication effects, and a 1:100 
dye/lipid ratio, for the best encapsulation efficiency, was chosen as the most favorable encapsulation 
conditions to be applied with the 60-PEPC containing formulations, i.e., A60, B60 and C60 (Figure 
5.11).  
 
 
Figure 5.11. Encapsulation efficiency (EE) of rhodamine B (left side) and fluorescein (right side): in liposomes 
formulations A0, B0 and C0, and the corresponding formulations containing 60-PEPC (A60, B60 and C60 respectively). 
The encapsulation procedure was carried out at 40 °C using two sonication cycles of 5 minutes each (Method B) and 
1:100 dye/lipid ratio. Experiments were run in triplicate. Results are shown as mean EE% ± SD. Significant differences 
(p value) are reported as follow: (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001, (****) p ≤ 0.0001. Differences between cis 
and trans containing liposomes having the same formulation (black), but also between cis containing formulations (blue) 
and trans containing formulations (red), are reported.  
 
Comparing the effects of the three different formulations in the EE of rhodamine B, only the charged 
liposomes were less prone to incorporate the dye (Figure 5.11, left side). Comparing the effects of 
the trans geometry of the phospholipid (60-PEPC), the reduction of the EE was significant in case of 
the simplest formulation (cf., A0 vs. C0, A60 and B60 vs. C60), indicating the direct effect of the 
packing of these liposomes compared to simple phospholipids and cholesterol assemblies.  
The same procedure was used to encapsulate a different dye, fluorescein (Figure 5.11, right side), an 
oxyxanthene insoluble in water. Here, the effect due to the hydrophobic nature of this dye is clear, 
leading in all formulations to a diminished incorporation compared to rhodamine B. However, both 
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the addition of cholesterol and of the charged lipids significantly increased EE (cf., A0 vs. B0 and 
C0). The effects of the trans geometry (60-PEPC) on these liposomes is again evident in the simplest 
composition (A0 vs. A60), whereas cholesterol brought a significant increase of EE for the trans 
lipid, confirming the spacing effect created by the sterol presence in the bilayer (B0 vs. B60). The 
charged surface of liposomes in the case of C0 and C60 resulted into an intermediate effect on EE. 
The presence of cationic lipids in the “C” formulation can also have a stabilizing effect on the 
incorporation of fluorescein, which is negatively charged at pH 7.4 (pKa1 = 4.45; pKa2 = 6.8). 
 
5.7.5. Effect of TFAs on release  
The in vitro release of rhodamine from the liposomal formulations at 22 °C and 37 °C was tested. 
Dialysis bags containing 0.5 mL of dye-containing liposomes were dialyzed against 10 mL of PBS 1 
X under continuous stirring. A solution of pure rhodamine B dissolved in PBS, was used as a control 
to show the ability of liposome to give a controlled and sustained release over time.  
In all cases the dialysis of the free dye is evidently different from the encapsulated dye formulations. 
They reach the same dye release in the end of the process, and no differences are seen at 22 °C (data 
not shown). Instead, at 37 °C the B formulation gave the best effect of retardation when 60-PEPC is 
present (Figure 5.12). In the formulations A and B, the release detected at the first hours are always 
reduced in the 60-PEPCliposomes, whereas in cationic liposomes these effects are lost. This could be 
due to the different partition coefficient of the dyes used for the experiments. It is possible that 
fluorescein, having hydrophobic characteristics, is localized in the proximity or in the depth of the 
double lipid layer and this causes it to be less retained by the liposomal structure. On the contrary, 
rhodamine B, which has amphiphilic characteristics, can be localized both in the internal cavity 
created by the liposomal bilayer and in the depth of the liposome membrane itself and for this reason 
it is released slower than fluorescein. 
The data presented here using dyes can be extrapolated to drug encapsulation and release behaviors, 
highlighting the role of trans-containing liposomes as potential carriers with additional properties 
compared to the known phospholipid formulations. Resistance and release experiments, either using 
human plasma and cell cultures, will be required and our results suggest the utility of further work 
where advantages of the liposomal lipid diversity could be explored, also considering the double bond 
geometrical features. 
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Figure 5.12. In vitro release of rhodamine B (left side) and fluorescein performed at 37 °C (right side). The POPC 
containing formulations (in black) were compared with the corresponding 60-PEPC containing ones (in red). The release 
profiles of free rhodamine B and free fluorescein (dashed lines) are also reported.  
 
 5.8. Conclusions  
In this study, the effects of TFAs on the membrane properties of liposomal models have been 
investigated. In particular, different formulations containing increasing percentages of trans-
phospholipids have been characterized in their size, surface charge (ζ-potential) and morphology. 
Additionally, the stability in size over time at different temperature has been monitored. Finally, since 
trans lipids are known to induce changes in the membrane permeability, the efficiency of 
encapsulation of two different fluorescent compounds, rhodamine B and fluorescein, and their release 
profiles have been described.  
It emerged that trans-phospholipids included in membrane composition are able to affect the bilayer 
properties. Trans-containing liposomes showed reduced diameter compared to their cis-analogues. 
Moreover, AFM analyses showed that trans-phospholipids enhanced the rigidity of the nanoparticles, 
as expressed by the height/diameter ratio.  
Concerning the encapsulation efficiency of the two dyes, the main differences were due to the 
encapsulation procedure, to the lipid formulation of liposomes and to the dye characteristics, and not 
to the double bond geometry.  
Finally, a slightly slower release profile of rhodamine B encapsulated into trans-containing liposomes 
compared to their cis-analogues was observed, thus encouraging further experiments about the use of 
trans-phospholipids in drug delivery applications for the optimization of pharmacokinetics and 
pharmacodynamics.  
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The results suggest further experiments where such effects would be explored in biological 
membranes, where trans lipids can be formed by endogenous or exogenous sources. Because of the 
distinct features imparted to the membrane by the presence of trans lipids, the use of TFA-containing 
liposomes could be exploited for synergic effects in antitumoral strategies. 
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Chapter 6 
DHA  
 
6.1. Introduction 
The ω-3 fatty acid DHA belongs to the family of ω-3 PUFAs, essential components of cell 
membranes, which play many important biological functions. In vivo, DHA is produced through a 
nine-step biosynthetic pathway, requiring elongation and desaturation reactions, which starts from α-
linolenic acid, its essential precursor introduced by the diet. 
The efficiency of the biosynthetic pathway has different degrees of efficiency in humans, therefore 
the semi-essential nature of DHA is emerging. DHA has gained increased interest over the years, as 
multiple roles in various molecular pathways and signalling networks have been described in the last 
decades. Noteworthy, all biological activities are dependent on the naturally occurring 
polyunsaturated cis geometry [1].  
As a sign of its recognized importance in biological fuctions, the main international food safety and 
health agencies established that 100-200 mg are an adequate daily intake from dietary sources, such 
as algae or fish, especially for children and pregnant women [2]. This led to an increased marketing 
of DHA-rich formulas, both as functional foods and as nutraceuticals.  
In the industrial process, the unpleasant fishy smell of fish oils is eliminated by deodorization, using 
high temperature and low-pressure procedures, however such conditions have been found to affect 
the natural cis structure of the PUFAs, converting them to the geometrical unnatural trans isomers 
(Chapter 1, Paragraph 1.4.1). The dire consequences of trans PUFA uptake for health have been 
discovered two decades ago and nowadays the presence of trans fats in foods is banned in the USA 
and is matter of careful evaluation in Europe [3].  
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In the frame of our research on free radical modification of biomolecules, we studied TFAs obtained 
by sulfur-centered radical-induced isomerization process occurring with an addition-elimination 
mechanism, where no double bond shift was taking place, so that only trans geometrical isomers were 
produced (Chapter 1, Paragraph 1.3.2).  
The number of geometrical isomers for the unsaturated fatty acids is equal to 2n, where n is the number 
of double bonds. In case of PUFAs, the process yields a complex mixture of isomers; by a biomimetic 
approach, which makes use of unilamellar liposomes as membrane models, we established that the 
first isomers to be formed by a step-by-step mechanism of the isomerization reaction, at a low radical 
concentration, are mono-trans fatty acids. Indeed, when ARA is exposed to thiyl radicals produced 
during oxidative metabolism, its mono-trans isomers are the most relevant products thus created, 
which are distinguishable from those TFAs deriving from dietary intake of chemically manipulated 
foods [4-6]. 
We undertook such studies in order to support functional investigations on the biological effects of 
single TFAs. In fact, the literature on the subject is scanty [7-10], owing to the limits of commercially 
available molecular libraries of TFAs.  
Being able to obtain mono-trans isomers of PUFAs by synthetic and efficient routes will allow us to 
build up a trans lipid library, aimed at addressing analytical and biological applications.  
Studies from our group reported the formation and the analysis of four mono-trans isomers of ARA 
[11] and of five mono-trans isomers of EPA [12] using a combination of GC and of carbon-13 nuclear 
magnetic resonance (13C NMR) for the assignment of each isomer structure. In the case of EPA, the 
efficiency of a dual synthetic approach to obtain the five mono-trans isomers was tested.  
The strategy consisted in the comparison of mono-trans isomers obtained by free radical-catalysed 
isomerization with mono-trans isomers isolated and characterized as mono-epoxide precursors 
(Figure 6.1). The separation and assignment of the mono-epoxide structures successfully provided 
the first unambiguous determination of the trans alkene position, thus integrating data already present 
in the literature [13-15].  
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Figure 6.1. Dual synthetic approach from cis-alkene to obtain the geometrical trans isomer. 
 
We applied the same analytical approach for the synthesis and characterization of the mono-trans 
DHA isomers. For the production of the six mono-epoxides of DHA methyl ester, published methods 
rely on the classical epoxidation reaction, being the yield for each individual regioisomers higher as 
the distance between the targeted double bond and the carbomethoxy group increased [16]. 
Therefore, for the chemically unstable 4,5-epoxy, docosapentaenoic (EDP) derivative, protocols have 
been developed for the selective synthesis of this mono-epoxide of DHA modifying a previously 
published three-step procedure [17,18]. In both cases the identification of mono-epoxides is reported 
by HPLC-MS and GC-MS analyses.  
As far as trans-DHA isomers are concerned, only the 4-trans regioisomer of DHA is commercially 
available and can be used in GC analysis as reference, whereas all mono-trans DHA isomers were 
described under GC conditions and used to examine the deodorization/isomerization reaction, but the 
assignment of the trans-double bond position was still lacking.   
The isomeric mono-trans DHA mixture was then characterized by GC analysis and this protocol was 
useful to follow up the isomerization reaction of a fish oil sample by free radical catalysed process, 
as well as to analyse commercially available fish oil-containing capsules.  
  
6.2. Importance of DHA  
DHA (4c,7c,10c,13c,16c,19c, docosahexaenoic acid) is a long chain polyunsaturated fatty acid (LC-
PUFA) belonging to the ω-3 series [19]. Concerning its chemical structure, DHA is a carboxylic acid 
characterized by 22 carbon atom chain having 6 double bonds in cis position (Figure 6.2). The last 
double bond is located three carbons from the methyl end, thus it is a so-called ω-3 fatty acid. 
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Figure 6.2. Chemical structure of DHA. 
 
Among the PUFAs present in the human body, DHA has the longest acyl chain and the higher number 
of double bonds. DHA can be endogenouly synthesized through enzymatic pathways, or come from 
dietary exogenous sources.  
There are some controversies about the mechanism of DHA biosynthesis in mammals. From a 
synthetic point of view, DHA can be synthesized de-novo from its precursor, α-linolenic acid, that is 
an essential fatty acid, through a series of elongation and desaturation steps that alternatively occur 
in the endoplasmatic reticulum (Figure 6.3).  
Initially, it was hypothesized that DHA could be directly formed from its immediate precursor 22:5ω3 
by the action of a Δ4 desaturase that introduced a double bond in position Δ4. In lower eukaryotes, 
like Thraustochytrium sp, the existence of a Δ4-desaturase has been demonstrated [20], but the 
presence of this enzyme in mammals has never been ascertained [21]. 
An alternate route, that involves peroxisomes, known as the “Sprecher pathway”, has been generally 
accepted [22]. This pathway requires an elongation step to convert 22:5 ω3 to 24:5 ω3, followed by 
a second Δ6-desaturation step to 24:6 ω3; the product would finally be β-oxidated in the peroxisome 
to produce DHA. 
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Figure 6.3. Enzymatic pathways for the synthesis of DHA in Thraustochytrium and mammals.  
 
De-novo synthesis of DHA is influenced by several factors that modify the catalytic activity of some 
of the enzymes involved in the process; moreover, some of these enzymes compete for different 
PUFAs, such as the the ω-6 chain ones.  
The desaturation step, carried out by Δ6 desaturase is the first and rate-limiting step of the PUFA 
synthesis [23,24]. This enzyme, in a similar way as Δ5-desaturase, is inhibited by cholesterol, SFAs 
and TFAs [Mahfouz 1981]. Additionally, the activity of both desaturases was found to be reduced by 
alcohol, glucocorticoids, and adrenaline [26] and in hyperlipidemia and hypertension conditions [27]. 
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Finally, competition between α-linolenic acid and 24:5 ω3 for the enzyme could explain the reduction 
in DHA levels observed following α-linolenic acid intake beyond certain values [28]. 
These costraints made it necessary to increase DHA assumption through the diet. In this regard, DHA 
can be found in discrete quantities in fish, particularly in salmon, mackerel, sardines, herring, tuna 
and anchovies [29]. Fish meat is enriched with DHA because a preferential fish food is microalgae, 
such as Crypthecodinium Cohnii, Schizochytrium and Ulkenia, which constitute the main source of 
DHA in nature [30]. Apart from these foods, DHA's dietary sources are particularly limited. Only 
small amounts of DHA are found in meat and in eggs, especially if the animal has been fed algae-
based fodder [31].  
DHA plays a crucial role in the human body. It is found in high levels in the neuronal system and in 
the retina because it is essential for nervous neurotransmission and visual development [32,33]. For 
this reason, appropiate ammounts of this fatty acid must be introduced during pregnancy and breast 
feeding to guarantee the proper childhood development. Considerably high levels of DHA are needed 
in the pregnancy period that immediately precedes birth, that is when celebral growth occurs and 
DHA is required for rapidly expanding neuronal cell biosynthesis [34]. Studies report that children 
which are nor breastfed nor supplemented with DHA enriched formulas show mental retardation in 
comparison with children which received appropriate supplies of DHA. Nutraceutical 
supplementations in ω-3 fatty acids are a new trend in the prevention approach, to ensure the proper 
development of brain tissue, visual function and cognitive ability of fetuses and newborns. Moreover, 
in children affected by attention deficit and hyperactivity disorder, DHA supplementation was 
reported to reduce aggressivity and improve learning and social relationship ability [35,36]. 
Although the molecular mechanism is still unknown, DHA is hypothesized to modulate 
neurotransmission by improving signal transduction processes and ensuring optimum communication 
between nerve cells: in fact, a study on patients admitted for severe depression and other behavioral 
disorders (bipolarism and schizophrenia), shows that a balanced ω-3 regime reduces the frequency 
and intensity of depressive events and stabilized the mood [37].  
As mentioned in Chapter 5, recent studies from our group on the cellular membrane of autistic 
children, DHA deficiency was observed and associated with the loss of function of Na+ / K+ ATPase 
of the erythrocyte membrane [38]. Several studies highlighted the possible role of DHA in inhibiting 
the progressive neurodegeneration, such as Alzheimer's disease, that may occur in the elders [34]. 
Concerning visual diseases, DHA can prevent senile degeneration of the macula in adults [39].  
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DHA is also present in considerable quantities in sperm cells, where it participates in the regulation 
of spermatogenesis and membrane fluidity to guarantee spermatozoa migration from seminiferous 
tubules to epididymis [40].  
Additionally, DHA can be found in the cardiac tissue, where it is considered to reduce triglycerides 
in the blood. DHA enriched diets were reported to be beneficial for cardiopathic and hypertensive 
patients, decreasing cardiovascular risk factors, such as atherosclerosis and hypertension that are 
responsible for heart attacks and stroke [41,42]. Clinical benefits of dietary supplementation with 
DHA are reported for people suffering from rheumatoid arthritis [43] and ulcerative colitis [44]. 
Regulation of cell growth by DHA can have a significant impact on the development of certain types 
of tumors, such as colorectal, prostate and breast cancer [45-47].  
Therefore, studies concerning DHA, its chemical transformations and nutraceutical use are of great 
interest not only for scientific research, but also for industrial and therapeutic applications. 
 
6.3. Experimental part  
Chloroform, methanol, n-hexane, isopropanol and acetonitrile (HPLC purity) were purchased from 
Merck, USA. Absolute ethanol was purchased from VWR BDH Prolabo, Poole, UK (Normapur 
grade) and 2-mercaptoethanol was purchased from Sigma-Aldrich, USA. Silver nitrate (AgNO3), 
30% aq ammonium hydroxide (NH4OH), sodium bicarbonate (NaHCO3) and anhydrous sodium 
sulfate (Na2SO4) were purchased from Carlo Erba, Italy. All FAMEs used as reference standard for 
GC analyses were purchased from Sigma Aldrich or Fluka, USA, and used without further 
purification. 
Silica gel thin-layer chromatography (analytical and preparative) was performed on Merck silica gel 
60 plates (0.25 and 2 mm thickness, respectively).  
Photolysis was carried out in a quartz photochemical reactor (Sigma Aldrich, USA) equipped with a 
5.5 W low-pressure mercury lamp. The temperature was maintained at (22 ± 2) °C by means of a 
thermostat bath. 
The gas chromatograph used for the analyses (Agilent 6850, Milan) was equipped with a (50%-
cyanopropyl)-methylpolysiloxane (DB-23, Agilent, USA) capillary column (60 m × 0.25 mm i.d. × 
0.25μm film thickness). The instrument had a flame ionization detector (FID) that requires air (450 
mL/min) and hydrogen (40 mL/min) and was maintained at a temperature of 250 °C.  
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Two identical equipments were used for the analyses, applying the same injection temperature (230 
°C) but different oven conditions and carrier gas.  
Method A: the initial temperature was set up at 165 °C and held for 3 minutes, followed by an increase 
of 1 °C/min up to 195 °C, held for 40 minutes. A final ramp, with a temperature increase of 10 °C/min 
up to a maximum temperature of 240 °C, was mantained for 10 minutes for column purge. A constant 
pressure mode (29 psi) was chosen with helium as carrier gas.  
Method B: temperature started from 195 °C, held for 26 minutes, followed by an increase of 10 °C/min 
up to 205 °C, held for 13 minutes, followed by a second increase of 30 °C/min up to 240 °C, held for 
10 minutes. A constant pressure mode (29 psi) was chosen with hydrogen as carrier gas. 
FAMEs were identified by comparison with the retention times of commercially available standards 
or trans fatty acid references, obtained as described elsewhere [4,12,48,49].  
GC/MS spectra were recorded on a Clarus 500 GC apparatus equipped with a Clarus 560S mass 
spectrometer (GC/MS transfer line temperature 230 °C) and a (50%-cyanopropylphenyl)-
dimethylpolysiloxane (DB-225ms, Agilent, USA) column (60 m x 0.25 mm i.d. x 0.25 µm film 
thickness). Injection temperature was set up at 230 °C, a split ratio of 50:1 was applied and helium as 
carrier gas was kept at a constant flow of 1.2 mL/min. The oven conditions were the following ones: 
temperature started from 195 °C, held for 52 minutes, followed by an increase of 3 °C/min up to 205 
°C, held for 10 minutes, followed by a second increase of 3 °C/min up to 225 °C, held for 15 minutes 
and a final increase of 5 °C/min up to 230 °C, held for 10 minutes.  
All NMR spectra were collected with a fully automated Agilent NMR system, consisting of a 54-mm 
bore, 500 MHz (11.7 T) Premium Shielded superconducting magnet, a DD2 Performa IV NMR 
console and the Agilent OneNMR probe. All samples were dissolved in C6D6 and transferred in 3 
mm thin wall NMR tubes (Wilmad 335-PP-8). After having calibrated the 90º pulse-width (pw90) 
for each sample, sevenNMR experiments were perfomed on each sample. 2D spectra were collected 
with 50% nonuniform sampling (NUS) and F2 spectral width (sw) (1H): 10 ppm, from-0.5 to 9.5 ppm.   
 1H NMR spectra: pw 90 was calibrated for each sample, sw: -0.5 to 9.5 ppm 
 one gHSQC: F1 sw (13C) 135 ppm, from 5.0 to 140 ppm; number of transients (nt) =32; 
number of increments (ni) =512; resolution (res): 33 Hz (0.26 ppm). F2 sw (1H): 10 ppm, from 
-0,5 to 9,5 ppm, NUS: 50%. 
 two bsgHSQCAD:  
o First F1 sw (13C): 60 ppm, from 5.0 to 65 ppm; nt=32; ni=512; res: 15 Hz (0.12 ppm); 
F2 sw (1H): 10 ppm, from -0.5 to 9.5 ppm, NUS: 50%.  
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o Second: F1 sw (13C): 20 ppm, from 120.0 to 140 ppm; nt=32; ni=512; res: 5 Hz 
(0.04 ppm); F2 sw (1H): 10 ppm, from -0.5 to 9.5 ppm, NUS: 50% 
 one gHMBCAD: F1 sw (13C): 175 ppm, from 5.0 to 180 ppm; nt=64; ni=512; res: 43 Hz (0.34 
ppm); F2 sw (1H): 10 ppm, from -0.5 to 9.5 ppm, NUS: 50% 
 two bsgHMBC:  
o First F1 sw (13C): 60 ppm, from 5.0 to 65 ppm; nt=64; ni=512; res: 15 Hz (0.12 ppm); 
F2 sw (1H): 10 ppm, from -0.5 to 9.5 ppm, NUS: 50%.  
o Second F1 sw (13C): 60 ppm, from 120.0 to 180 ppm; nt=64; ni=512; res: 15 Hz 
(0.12 ppm); F2 sw (1H): 10 ppm, from -0.5 to 9.5 ppm, NUS: 50% 
 
6.3.1. Synthesis of mono-trans DHA-Me isomers  
6.3.1.1. Synthesis by Photolysis  
A 15 mM solution of all-cis DHA methyl ester, (20 mg, 0.058 mmol) in isopropanol (3.87 mL) was 
transferred into a quartz photochemical reactor (Sigma Aldrich, USA) equipped with a 5.5 W low-
pressure mercury lamp. The reaction mixture was degassed with argon for 20 minutes to remove 
oxygen, then an aliquot of a previously degassed stock solution of 2-mercaptoethanol was added (0.03 
mmol) and the UV lamp was turned on for 5 minutes at the temperature of 22 ± 2 °C, kept by means 
of a thermostat bath. The reaction was monitored by Ag-TLC, spraying the plate with CAM, to 
evidence the formation of the mono-trans fraction and other poly-trans products, and stop the reaction 
when mono-trans isomers were prevalently formed, in the presence of remaining cis-DHA.  
The solvent was removed under vacuum, by addition of chloroform to help the removal of 2-
mercaptoethanol. The crude reaction product was subsequently dissolved in 1 mL of n-hexane and 
loaded onto a preparative Ag-TLC plate. A rapid and efficient separation was obtained using diethyl 
ether/methanol/n-hexane/acetic acid (95:10:5:3 v/v) as mobile phase. After elution, the area 
corresponding to the mono-trans isomer fraction (Rf = 0.58), detected by spraying a small portion of 
the plate with CAM, was scraped off.  
Silica was washed with chloroform (3 x 5 mL).  The solvent was evaporated to give a solid material, 
which is the Ag-fatty acid complex insoluble in n-hexane. This material was dissolved in a 5% 
aqueous solution of NH4OH, vigorously stirred (600 rpm) for 10 minutes and extracted with aliquots 
of n-hexane. Finally, the organic phase was dried over Na2SO4, filtered and evaporated. The unreacted 
all-cis DHA-Me was recovered and subjected to a second isomerization cycle. This procedure led to 
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the collection of a colorless oil that corresponded to the mono-trans DHA methyl ester isomer mixture 
(5.2 mg, 0.0152 mmol, overall yield from two isomerization cycles 26%), that was characterized by 
GC and NMR analyses.  
 
6.3.1.2. Synthesis by Epoxidation – Elimination  
A 5.84 mM solution of meta-chloroperoxybenzoic acid in dichloromethane (2.5 mL corresponding 
to 0.1 eq; 0.0146 mmol; 2.51 mg) was added dropwise to a solution of DHA methyl ester (50 mg; 
0.146 mmol) in dichloromethane (2.5 mL). After the addition was completed, the mixture was stirred 
for 10 minutes at 22 °C under argon atmosphere, following the formation of monoepoxides with 
traces of di-epoxides by TLC using n-hexane/diethyl ether (7:3 v/v) as mobile phase. Work-up was 
carried out by addition of 5 mL of ice-cold NaHCO3 (25% w/v) stirred for 2 minutes. Then, the 
reaction mixture was transferred in a separating funnel, the aqueous layer was discarded and the 
organic layer was washed two times with NaHCO3, deionized water and dried over Na2SO4.  
The crude reaction product was purified with flash chromatography using n-hexane/diethyl ether (9:1 
v/v) as eluent, to give a first fraction with the pure methyl(cis)-4,5-epoxy-all-(cis)-7,10,13,16,19-
docosapentaenoic acid methyl ester (4,5-EDP-Me) (structure 2 in Figure 6.8) colorless oil (5 mg; 
0.0134 mmol; 9.2% yield), followed by an inseparable mixture of 16,17-EDP-Me and 13,14-EDP-
Me (colorless oil; 8 mg; 0.0223 mmol; 15.3% yield; structures 6 and 5 in Figure 6.8, respectively, in 
a 71:29 ratio, as calculated by the integration of protons of C-22 on 1H NMR spectrum) with traces 
of 10,11-EDP-Me (structure 4 in Figure 6.8). The structural assignment of each regioisomer in the 
fractions was performed by dissolving the fractions in C6D6 as NMR solvent in which they are stable, 
and carrying out mono- and bi-dimensional experiments as described in the Method section. EDP-
Me regioisomers 5 and 6 were further purified by preparative TLC using toluene/isopropanol (100:0.5 
v/v) to give 6 (Rf = 0.5, 3 mg; 0.0084 mmol; 37.5% yield) with only traces of 5 (Rf = 0.4).  
A third fraction was then isolated containing an inseparable mixture of 19,20-EDP-Me and 7,8-EDP-
Me (colorless oil; 7mg; 0.0195 mmol; 13.4% yield; structures 7 and 3 in Figure 6.8, respectively, in 
a 57:43 ratio, as calculated by the integration of protons of C-22 on 1H NMR spectrum).  
The starting all-cis DHA-Me (1) was also recovered (30 mg; 0.0877 mmol; 60% yield).  
 
132 
 
6.3.2. Isomerization of fish oil by Photolysis  
A sample of commercially available fish oil, from a company that provides material for ω-3 
containing food and nutraceutical preparation, was isomerized following the procedure described for 
the DHA-Me isomerization by photolysis. The 1H NMR and 13C NMR spectra of the isomerized oil 
were recorded. The oil underwent a transesterification reaction as described below for nutraceutical 
formulas, in order to analyse the cis and trans fatty acid content by the corresponding fatty acid 
methyl esters.  
 
6.3.3. Nutraceutical analysis  
Nutraceutical products commercially available in Italy and Spain were examined. Lipids were 
extracted from the products according to the Folck method (Chapter 2, Paragraph 2.2). Briefly, 
approx. 3 mg of each sample were treated with chloroform/methanol (2:1 v/v) and brine; organic 
phases, containing lipids, were joined and dried over anhydrous Na2SO4. After filtration, the solvent 
was eliminated using a rotor evaporator and the oily residue was left under vacuum for 10 minutes to 
remove any possible trace of water. The lipid fraction was controlled by TLC using n-hexane/ethyl 
ether (7:3 v/v) as eluentand then treated with freshly prepared 0.5 M KOH/methanol solution for 30 
minutes at 22 °C under stirring. The reaction was quenched using brine and FAMEs were extracted 
using n-hexane; the organic phases were collected and dried over anhydrous Na2SO4. After filtration 
and solvent evaporation, the FAME mixture was dissolved in the appropriate volume of n-hexane and 
analysed by GC.  
 
6.4. Results  
6.4.1. Synthesis by Photolysis 
According to the scheme represented in Figure 6.1, we approached the dual synthetic strategy first 
by carrying out the direct radical-catalysed isomerization of DHA methyl ester, as previously 
described by our group for EPA [12], thus obtaining a mixture of the six mono-trans DHA isomers. 
Ag-TLC (Chapter 2.3.1) was used to purify the mono-trans DHA isomers from the starting material 
(Figure 6.4).  
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Figure 6.4. Ag-TLC after 5 minutes of isomerization under photolysis in the presence of 2-mercaptoethanol. Commercial 
standard all-cis DHA-Me (A). Mono-trans isomers of DHA-Me (B). Reaction mixture (C) containing all-cis (I), mono-
trans (II) and traces of di-trans (III) and tri-trans (IV) isomers of DHA-Me. 
 
The separation of each mono-trans isomer is not realizable at this stage, however satisfactory 
separation of the isomers could be obtained by gas chromatography, the GC trace showing five out 
of six separable peaks, meaning that only two isomers are superimposed (Figure 6.5). It is also worth 
noting that one mono-trans DHA isomer elutes close to cis-DHA.  
This separation was previously described under similar conditions [50], but again the assignment of 
each mono-trans isomer was not performed. Only by elution of the commercially available 4-trans-
DHA-Me, the third eluting peak could be assigned to this isomer. 
The mono-trans DHA-Me mixture was also analysed by gas chromatography coupled to mass 
spectrometry (GC/MS). The fragmentation pattern of the mono-trans isomers showed the typical 
mass-to-charge ratios characteristic of ω-3 PUFAs, or rather m/z=41, m/z=55, m/z=67, m/z=79, 
m/z=91, m/z=105 and m/z=119 (Appendix 1). No other data worthy of note could be gathered at this 
point of the study.  
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Figure 6.5. GC chromatograms showing the mixture of mono-trans DHA methyl ester isomers obtained after free radical 
isomerization by photolysis, all-cis DHA methyl ester and commercially available 4-trans DHA methyl ester.  
 
 
6.4.2. Synthesis by Epoxidation – Elimination  
By the second synthetic strategy, DHA-Me was transformed in two-steps to the mono-trans alkenes 
(Figure 6.1), via mono-epoxide formation, ring-opening of the epoxide, using the stereoselective 
formation of the dibromide derivatives followed by elimination reaction, that provides the trans 
geometry of each starting double bond. In this strategy, the key step is the separation and 
characterization of the mono-epoxide products, to assign the double bond position for the subsequent 
elimination step. Epoxidation of DHA methyl ester was performed using meta-chloroperoxybenzoic 
acid (m-CPBA), followed by purification using flash chromatography with n-hexane/diethyl ether 
(9:1 v/v) as eluent. Preparative TLC using n-hexane/diethyl ether (7:3 v/v) provided a separation of 
three fractions of monoepoxide regioisomers (Figure 6.6). 
The structures of the six regioisomers expected in the reaction are shown in Figure 6.7.  
Epoxydocosapentaenoic acids (EDPs) are naturally occurring compounds obtained from DHA by 
cytochrome P450 enzyme, exhibiting a variety of biological effects in inflammation, pain, 
angiogenesis and cancer [51]. Actually, cytochrome P450 is able to provide the stereoselective 
epoxidation of DHA, preferably at the last double bond obtaining 19,20-EDP [52]. However, also 
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16,17-EDP, 13,14-EDP, 10,11-EDP and 7,8-EDP have been detected and separated by HPLC 
analysis, whereas 4,5-EDP was reported to be unstable [53,54].  
 
 
Figure 6.6. TLC after DHA-Me epoxidation and column separation. (A) Reaction mixture, (B) all-cis DHA-Me; Epoxide 
fractions: 1-2-3 mono-epoxide fractions and assignment, (right TLC), separated using n-hexane/diethyl ether (7:3 v/v) as 
mobile phase. 
 
 
Figure 6.7. (a) m-CPBA, DCM, RT, 10 min; quantitative conversion based on the recovery of starting material; (b) dry 
DCM, pyridine, Ph3PBr2, 5°C, overnight; (c) DMF, activated Zn, AcOH, 0°C, 10 h. 
 
To the best of our knowledge, EDP analysis by NMR spectroscopy has not been reported so far, 
whereas we were interested to carry out mono- and bi-dimensional NMR experiments in order to 
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assign the epoxide position in each compounds of the reaction mixture. For stability reasons, NMR 
measurements were recorded in deuterated benzene (C6D6), since deuterated chloroform (CDCl3) 
creates a slightly acidic environment that induces decomposition of DHA derivatives.  
Under our experimental conditions, the 4,5-EDP (product 2 in Figure 6.8) was isolated in pure form 
as first fraction of the chromatography. The fraction was characterized by NMR spectroscopy (13C 
and 1H) in CDCl3 and in C6D6. The spectral data were identical with those previously reported in 
CDCl3 [17]. 
The other regioisomers were obtained in the subsequent two chromatographic fractions, each as 
mixture of two compounds. In Table 6.1, the 13C NMR data of the EDP isomers are collected, 
showing that the 10,11-EDP regioisomer is present only in traces. The reasons to justify the absence 
of this strereoisomer were not investigated.  
The C resonances were attributed by comparison with the DHA assignment individuating five EDP 
regioisomers for the resonances for the carbon atoms of the epoxy functionality. The 13C NMR in 
CDCl3 of two epoxy-isomers, 4,5-EDP and 19,20-EDP, were described in the literature [17,55] and 
for comparison they were also reported in the table together with the data obtained in this study.  
The structures of the five EDP isomers with their proton and carbon atom resonances as assigned in 
this study are summarized in Appendix 2.  
The subsequent transformations by ring opening as dibromides and elimination to the corresponding 
alkenes were performed in one-step for each fraction. The latter reaction sequence was adapted for 
DHA-Me from a procedure described for arachidonic acid methyl ester [56] and also eicosapentanoic 
acid methyl ester (EPA) [12].  
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Table 6.1. 13C NMR Resonances of EDP isomers of DHA-Me. 
 
 
 
 
                                               
Figure 6.8. Structures of the six EDP regioisomers and the corresponding mono-trans DHA methyl ester isomers. 
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It was observed that, during the in situ transformation of epoxides to dibromide derivatives and the 
subsequent elimination to trans alkenes, the concerted elimination is not the only occurring 
mechanism, indeed cis-DHA-Me can be formed. Therefore, after elimination, the resulting mono-
trans DHA products can be further purified by Ag-TLC using diethyl ether/n-hexane/methanol 
(9:1:0.4 v/v) prior to GC injection, as shown in Figure 6.9, in order to have a pure isomeric fraction 
from the elimination step.  
 
Figure 6.9. Ag-TLC showing all-cis DHA-Me (left), 19trans and 7trans DHA-Me isolated after after bromination and 
elimination reaction (center) and the mixture of mono-trans DHA-Me obtained by photolysis (right). 
 
Using GC analysis after the elimination step of each mono-epoxide fraction, the panel of the mono-
trans DHA-Me was clarified as shown in Figure 6.10. The 16-trans isomer was almost overlapping 
with DHA-Me, and other two mono-trans isomers, namely 7-trans and 10-trans, were superimposed 
(compare lanes (III) and (IV) corresponding to the transformation of two different mono-epoxide 
fractions). The 10-trans isomer was indeed obtained from the traces of the 9,10-EDP that was found 
to be the product with the lowest yield among all EDP isomers, as ascertained by the study of the 
NMR spectra reported in the following section.  
Therefore, taking also into account previously reported retention times for some of the mono-trans 
geometrical isomers of DHA-Me, the following GC order of elution could be assigned: 19-trans < 
16-trans = all-cis < 4-trans < 13-trans < 7-trans = 10-trans.  
This is the first time that assignment of mono-trans geometrical isomers of the ω-3 fatty acid DHA 
is made, by a combination of Ag-TLC, NMR spectroscopy, gas chromatography, and this result 
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completes the overall picture of the non-commercially available trans lipid library referred to the 
most important polyunsaturated fatty acids. 
 
 
Figure 6.10. GC chromatograms of (I) all cis-DHA methyl ester; (II) mixture of mono-trans DHA-Me isomers obtained 
by photolysis; (III) 16-trans isomer superimposed with all cis-DHA-Me, 13-trans and traces of 10-trans isomers; (IV) 
19-trans, all-cis and 7-trans DHA-Me; and (V) 4-trans DHA-Me. 
 
6.4.3. NMR Analysis  
 As previously mentioned, the examination of the 1H and 13C NMR resonances were carried out in 
C6D6 to avoid decomposition of these compounds. A careful examination of the spectra obtained from 
the EDP isomer formed during the epoxidation allowed the structures of these regioisomers to be 
assigned, using mono- and bi-dimensional experiments.  
A first observation came from the 1H NMR spectra of the EDP regioisomers (see Appendix 3,4,5), 
where the terminal methyl group (C-22) appears as triplet in the 0.80-0.91 ppm region and is 
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influenced by the relative position of the epoxide functional group. As shown in Figure 6.11, in Me-
DHA the triplet is centered at 0.885 ppm (trace I), whereas the pure 4,5-EDP isomer shows the triplet 
centered at 0.888 ppm (trace IV). Two fractions obtained from the EDP separation contained the other 
four isomers: i) a mixture with the 16,17-EDP isomer with the triplet centered at 0.853 ppm and the 
13,14-EDP isomer with the triplet centered at 0.880 ppm, with traces of the 10,11-EDP isomer (trace 
II); ii) a mixture with the 19,20-EDP isomer with the triplet at 0.838 ppm (major isomer) and the 7,8-
EDP isomer with the triplet centered at 0.892 ppm. The assignment of the triplet was made by 
correlation experiments, crossing the 1H and 13C resonances of the methyl group and epoxide carbon 
atoms, respectively. 
 
 
Figure 6.11. Enlargement of the 1H NMR region related to the terminal methyl group (C-22) of EDP regioisomers. The 
triplet is centered at different ppm depending on the position of the epoxide along the fatty acid chain; (trace I) all-cis 
DHA-Me; (trace II) mixture of 13,14-EDP (5), 16,17-EDP (6) with traces of 10,11-EDP (4); (trace III) mixture of 7,8-
EDP (3) and 19,20-EDP  (7); (IV) 4,5-EDP (2). 
 
 
In the 13C NMR spectrum, the carbon atom resonance of the methyl ester group appears at 50.65 ppm 
in all EDP isomers. Using the assigned resonances of DHA methyl ester, it is also possible to assign 
the structures of the five mono-epoxides.  
In fact, for the 16,17-EDP two peaks at 55.79 and 55.65 ppm are assigned to the carbon atoms of the 
epoxide function, since at the same time in the spectrum are absent the chemical shifts of the ethylenic 
carbon atoms assigned at this C16-C17 double bond in DHA-Me (128.50 and 127.91 ppm, 
respectively).  
The 13,14-EDP has two peaks at 55.66 and 55.65 ppm assigned to the epoxide function, whereas the 
C13-C14 double bond resonances of DHA-Me at 128.22 and 128.11 ppm, are not present.  
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The 19,20-EDP has the epoxide carbon atoms at 57.38 and 55.75 ppm, and correspondently the 
chemical shifts at 131.78 and 127.11 ppm (C19-C20 of DHA-Me) are absent. In the 19,20-EDP 
regiosiomer it is also worth mentioning the chemical shift of the C-22 shifted at 10.45 ppm (instead 
of the range 14.08 – 14.00 ppm for all the other EDP regioisomers), indicating an upfield shift due to 
a different electronic distribution influencing the end of the carbon atom chain.  
7,8-EDP showed the chemical shifts of the epoxy carbon atom at 55.65 and 55.63 ppm, corresponding 
to the absence of the resonances at 128.15 and 128.11 ppm (corresponding to the C7-C8 in the DHA-
Me).  
Finally, 4,5-EDP was individuated by the chemical shifts at 56.07 and 55.32 ppm corresponding to 
the absence of the peaks at 129.08 and 128.06 ppm (C4-C5 of DHA-Me).   
Since the synthetic pathway of mono-epoxides was of crucial importance for the identification of the 
regioisomers, it was very important to gather further confirmation of such assignments by running 
specific bidimensional NMR (2D NMR) experiments. Indeed, 2D NMR spectra provide information 
about a molecule that cannot be obtained by mono-dimensional NMR, and are important to determine 
the structure of complex molecules.  
In this study, heteronuclear single-quantum coherence (HSQC) and heteronuclear multiple bond 
correlation (HMBC) were applied. HSQC experiment is used to determine proton-carbon single bond 
correlations, where the protons lie along the observed F2 (X) axis and the carbons are along the F1 
(Y) axis. The results obtained by HSQC can be combined with HMBC experiments, that gives 
correlations between carbons and protons that are separated by two, three, and, sometimes in 
conjugated systems, four bonds, while direct one-bond correlations are suppressed.  
The relevant correlations studied in the 2D NMR experiments for the assignment of the 19,20-EDP 
are shown in Appendix 6.  
 
6.4.4. Isomerization of fish oil  
Omega-3 containing oil are important sources of cis isomers, therefore the trans-isomers of EPA and 
DHA have been considered by several authors as contaminants after the deodorization or distillation 
procedures that are used to eliminate the fishy odour (Chapter 1, Paragraph 1.4.2).  
Since the DHA isomerization in oil has been described to occur by heating procedure and was not yet 
reported by thiyl radical catalysed process, we performed the isomerization of a DHA-rich fish oil, 
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commercially available as raw material for nutraceutical formulas. The reaction was carried out as 
described in the Experimental part.  
 
Figure 6.12 (part a) shows the superimposition of the GC traces of the fish oil isomerization (after 
transesterification of the triglycerides into the corresponding fatty acid methyl esters) and the 
appropriate references relative to the cis and mono-trans DHA isomers as obtained from the 
previously described dual approach. 
In the same Figure 6.12 (part b) the region of the 13C NMR spectra enlarged at the region 
corresponding to the C-20 (ethylenic carbon atom) resonance is shown for the DHA-Me (trace I) in 
comparison with the cis-trans DHA-Me mixture (trace II). In the same Figure also the C-20 of the 
DHA-containing triglycerides of fish oil (trace III) is shown, and it is gratifying to see that the 
chemical shift are not influenced by the different derivatives (FAME or triglyceride) that contains the 
DHA residues. Moreover, after fish oil isomerization, also the mixture of trans-DHA-containing 
triglycerides shows similar C-20 resonances for the resulting isomer mixture. In Appendix 7 and 8 
the full 13C NMR spectra of DHA-containing triglycerides before and after isomerization are shown.  
 
Figura 6.12. a) Partial GC traces of the isomerized fish oil (III) in comparison with all-cis DHA-Me (I) and mono-trans 
isomer mixture obtained by photolysis (II). b) Enlargement of the 13C NMR region corresponding to the C-20 ethylenic 
carbon atom of the cis and trans triglyceride isomers obtained from fish oil isomerization (IV) in comparison with all-cis 
DHA-Me (I), mono-trans DHA-Me isomers in the presence of all-cis DHA-Me (II) and fish oil triglycerides prior to 
isomerization (III). 
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Therefore, either the GC analysis and the resonance of the C-20 can be of diagnostic value for 
individuating mono-trans DHA isomers as triglycerides and FAMEs. It is also worth noting that the 
region between 131.5 and 132.5 ppm is also a region free of other resonances from biologically 
important compounds, therefore the DHA isomer assignment presented in our work can be relevant 
for further development in metabolomics research. 
 
6.4.5. Nutraceutical analysis  
Making use of these data, we performed the analysis of the triglyceride fractions contained in 
nutraceutical and food formulas available on the market in Italy and Spain.  
As matter of facts, analytical protocols as quality control of nutraceuticals are important for the 
interest of producers and consumers, and recently several papers have raised attention on the presence 
of oxidized and trans fatty acids in commercial products of different countries [12,57-60].  
Nutraceutical manufacturers are generally concerned with ensuring the absence of heavy metals and 
other carcinogenic pollutants, such as dioxins and polychlorinated biphenyls, present in the marine 
habitat [61,62]. However, the current legislation does not yet take into account other pollutants such 
as those deriving from industrial processes that induce significant transformations of natural oils. 
A total of 16 commercially available ω-3 supplements were analysed. Among them, products 1-6 
were ω-3 supplements present in the Italian market, of which samples 1-5 made of fish oil and sample 
6 by microalgae. Product 7 was a refined and deodorized fish oil based-raw material used for 
functional foods and product 8 was a milk powder for infants enriched in LC-PUFAs. Products 9-16 
were nutraceuticals present in the Spanish market. 
A representative chromatogram obtained from nutraceutical products is shown in Figure 6.13, while 
the fatty acid content of the ω-3 supplements analysed for this study is reported in Table 6.2 and 
Table 6.3.  
144 
 
 
Figure 6.13. GC chromatogram of a representative nutraceutical sample obtained with GC Method A. 
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Table 6.2. Fatty acids present in nutraceutical products that are commercially available in Italy. 
FAME 1 2 3 4 5 6 7 8 
14:0 5.75±0.04 0.56±0.01 0.68±0.01 6.11±0.08 6.01±0.05 0.81±0.03 7.58±0.12 3.33±0.06 
16:0 12.86±0.01 1.45±0.05 12.94±0.05 22.54±0.15 13.14±0.08 23.48±0.08 19.21±0.14 24.39±0.07 
9t, 16:1 0.34±0.02 0.07±0.01 0.21±0.01 0.64±0.06 0.46±0.00 nd 0.52±0.02 nd 
6c, 16:1 0.16±0.01 0.03±0.00 0.11±0.01 0.26±0.05 0.15±0.01 nd 0.31±0.01 0.04±0.00 
9c, 16:1 6.75±0.05 2.31±0.07 3.96±0.02 9.05±0.03 5.02±0.04 0.44±0.00 9.46±0.06 0.18±0.01 
18:0 3.00±0.05 1.44±0.06 16.35±0.13 3.17±0.05 3.86±0.01 1.48±0.12 4.07±0.13 3.59±0.11 
9t, 18:1 0.11±0.03 0.04±0.00 0.31±0.00 0.11±0.00 0.09±0.00 nd 0.13±0.00 0.02±0.00 
11t, 18:1 0.06±0.02 0.01±0.00 0.29±0.14 0.62±0.01 0.02±0.00 nd 0.08±0.00 0.03±0.00 
9c, 18:1 8.41±0.04 10.09±0.10 28.31±0.57 26.70±0.10 6.39±0.13 0.02±0.00 10.43±0.05 44.04±0.19 
11c, 18:1 2.73±0.09 3.59±0.07 10.21±0.15 5.48±0.03 2.41±0.05 0.56±0.04 3.61±0.11 1.25±0.08 
LA 1.36±0.05 2.18±0.09 1.26±0.17 1.83±0.04 1.08±0.01 0.14±0.00 1.45±0.01 18.98±0.07 
∑ LA mt nd 0.18±0.02 0.48±0.01 0.09±0.00 0.03±0.00 0.12±0.00 0.04±0.00 0.11±0.00 
18:3 ω-6 0.32±0.08 0.29±0.03 0.44±0.03 0.03±0.00 0.43±0.00 nd 0.30±0.02 0.07±0.00 
ALA 0.58±0.06 0.98±0.08 0.11±0.01 0.69±0.03 0.49±0.01 nd 0.93±0.11 2.72±0.12 
20:0 0.22±0.02 0.13±0.00 2.22±0.06 0.14±0.00 0.37±0.00 0.31±0.01 0.50±0.05 0.31±0.04 
20:1 0.98±0.08 1.06±0.04 11.70±0.34 7.75±0.05 1.44±0.12 nd 1.52±0.00 0.28±0.07 
20:3 ω-6 0.25±0.09 0.41±0.04 0.43±0.09 0.07±0.00 0.27±0.00 0.21±0.01 0.23±0.04 nd 
ARA 1.95±0.07 2.35±0.07 0.14±0.01 0.19±0.01 1.82±0.10 0.13±0.00 1.31±0.11 0.17±0.04 
∑ ARA mt 0.08±0.00 0.07±0.00 nd nd 0.08±0.00 nd 0.07±0.05 nd 
20:3 ω-3 0.12±0.00 0.17±0.00 nd 0.12±0.01 0.10±0.01 nd 0.10±0.02 nd 
20:4 ω-3 1.08±0.04 2.05±0.06 nd 0.64±0.07 1.14±0.01 0.91±0.01 0.95±0.01 nd 
EPA 28.05±0.28 44.34±0.12 0.31±0.01 3.47±0.05 27.40±0.15 0.66±0.01 20.53±0.26 0.07±0.01 
∑ EPA mt 0.75±0.02 0.16±0.01 nd 0.03±0.00 0.68±0.02 nd 0.09±0.00 nd 
22:0 0.09±0.02 0.08±0.00 1.08±0.03 0.04±0.00 0.13±0.01 0.20±0.01 0.14±0.00 0.21±0.04 
22:1 0.12±0.01 0.08±0.00 2.16±0.59 2.06±0.05 0.28±0.06 nd 0.28±0.03 nd 
22:5 ω-6 0.70±0.03 0.69±0.00 nd nd 0.55±0.00 11.91±0.13 nd nd 
DPA 3.67±0.07 4.31±0.02 0.08±0.00 0.77±0.05 3.91±0.18 0.15±0.02 2.44±0.14 nd 
24:1 0.34±0.03 0.10±0.00 5.45±0.14 1.30±0.00 0.66±0.01 nd 0.57±0.10 nd 
∑ DHA mt 0.65±0.07 0.12±0.01 nd 2.40±0.08 0.62±0.12 1.13±0.03 0.18±0.08 nd 
All-cis DHA 18.51±0.10 20.64±0.37 0.75±0.02 3.69±0.04 20.98±0.07 57.35±0.15 12.98±0.15 0.25±0.01 
Total SFA 21.92±0.05 3.66±0.10 33.27±0.24 32.00±0.17 23.52±0.14 26.28±0.21 31.49±0.13 31.81±0.16 
Total MUFA 19.49±0.20 17.27±0.23 61.91±0.17 52.60±0.14 16.34±0.06 1.03±0.04 26.18±0.03 45.78±0.08 
Total PUFA 56.59±0.22 78.41±0.37 3.53±0.11 11.51±0.22 58.16±0.05 71.44±0.27 41.22±0.11 22.25±0.10 
ω-6 PUFA 4.58±0.20 5.93±0.16 2.27±0.13 2.12±0.05 4.15±0.09 12.39±0.14 3.29±0.10 19.21±0.09 
ω-3 PUFA 52.01±0.31 72.48±0.51 1.26±0.03 9.38±0.18 54.01±0.06 59.06±0.18 37.93±0.15 3.04±0.12 
SFA/PUFA 0.39±0.00 0.05±0.00 9.44±0.36 2.78±0.07 0.40±0.00 0.37±0.00 0.76±0.00 1.43±0.01 
ω-6/ω-3 ratio 0.09±0.00 0.08±0.00 1.81±0.13 0.23±0.00 0.08±0.00 0.21±0.00 0.09±0.00 6.33±0.25 
Total TFA 2.00±0.07 0.66±0.04 1.30±0.16 3.89±0.10 1.98±0.15 1.25±0.02 1.12±0.13 0.15±0.00 
ω-3 TFA 1.40±0.10 0.27±0.01 nd 2.43±0.09 1.30±0.14 1.13±0.03 0.27±0.08 nd 
% trans / Total 
DHA 3.40±0.35 0.57±0.04 nd 39.46±0.67 2.87±0.55 1.94±0.05 1.36±0.65 nd 
FAMEs are expressed as relative percentages of the peak areas detected in the chromatograms (>98% of the total peak 
areas of the chromatogram). Results are expressed as relative percentages (% rel) ± SD (n=3). nd= not detectable, 
mt=mono-trans. 
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Table 6.3. Fatty acids present in nutraceutical products that are commercially available in Spain. 
FAME 9 10 11 12 13 14 15 16 
14:0 0.67±0.01 8.73±0.04 7.28±0.05 0.03±0.00 0.01±0.00 0.01±0.00 10.24±0.19 0.29±0.00 
16:0 13.78±0.06 17.72±0.07 17.68±0.13 0.10±0.00 0.06±0.00 0.06±0.00 42.32±0.69 1.02±0.18 
9t, 16:1 0.38±0.03 0.45±0.03 0.52±0.02 nd nd nd 0.63±0.03 nd 
6c, 16:1 0.19±0.02 0.21±0.01 0.24±0.02 nd nd nd 0.07±0.01 nd 
9c, 16:1 7.21±0.03 11.59±0.05 8.88±0.01 0.09±0.00 0.03±0.00 0.01±0.00 3.73±0.32 0.77±0.03 
18:0 3.40±0.09 3.25±0.01 3.91±0.01 0.06±0.00 0.04±0.00 0.03±0.00 1.97±0.17 2.25±0.14 
9t, 18:1 0.25±0.09 0.15±0.03 0.14±0.04 nd 0.01±0.00 nd 0.08±0.02 nd 
11t, 18:1 0.22±0.05 0.03±0.01 0.13±0.02 nd nd nd 0.01±0.00 nd 
9c, 18:1 17.78±0.06 8.58±0.01 9.08±0.06 0.24±0.00 0.12±0.00 0.04±0.00 9.04±0.03 nd 
11c, 18:1 6.27±0.04 3.44±0.04 3.15±0.06 0.03±0.00 0.16±0.00 0.01±0.00 5.53±0.02 nd 
LA 3.40±0.05 1.53±0.02 4.94±0.02 0.05±0.01 0.13±0.00 0.05±0.01 2.07±0.08 5.61±0.21 
∑ LA mt 0.81±0.07 0.19±0.02 0.24±0.03 nd 0.01±0.00 nd 0.04±0.00 nd 
18:3 ω-6 0.56±0.06 0.35±0.04 2.14±0.07 0.03±0.00 nd nd 0.14±0.02 nd 
ALA 1.53±0.02 0.81±0.02 0.81±0.02 0.02±0.00 nd nd 0.85±0.14 nd 
20:0 0.24±0.03 0.31±0.01 0.48±0.03 0.04±0.00 nd nd 0.08±0.01 0.30±0.01 
20:1 0.91±0.03 0.64±0.04 1.81±0.04 0.08±0.00 0.02±0.00 nd 0.56±0.05 0.35±0.11 
20:3 ω-6 0.21±0.01 0.23±0.03 0.19±0.04 0.03±0.00 0.01±0.00 nd 0.07±0.02 0.23±0.00 
ARA 1.49±0.03 1.73±0.01 1.22±0.01 0.12±0.00 0.72±0.00 0.02±0.01 0.28±0.01 0.48±0.01 
∑ ARA mt 0.010±0.09 0.05±0.01 0.03±0.00 nd 0.04±0.00 nd 0.03±0.00 nd 
20:3 ω-3 0.13±0.01 0.07±0.02 0.11±0.01 0.02±0.00 nd nd 0.09±0.00 nd 
20:4 ω-3 0.86±0.03 0.80±0.02 0.92±0.02 0.09±0.00 0.06±0.00 0.09±0.01 0.33±0.01 nd 
EPA 21.87±0.19 21.41±0.11 19.60±0.19 2.29±0.00 3.24±0.01 5.59±0.01 13.48±0.34 2.35±0.03 
∑ EPA mt 0. 25±0.03 0.16±0.02 0.14±0.01 0.07±0.00 0.08±0.01 0.15±0.01 0.06±0.00 nd 
22:0 0.08±0.01 0.11±0.01 0.15±0.01 0.06±0.00 0.02±0.01 nd 0.07±0.01 0.55±0.08 
22:1 0.16±0.02 0.09±0.01 0.44±0.02 0.15±0.00 nd nd 0.45±0.01 nd 
22:5 ω-6 nd nd nd 1.97±0.00 6.24±0.01 0.52±0.03 nd 3.92±0.80 
DPA 2.10±0.03 2.18±0.01 1.98±0.00 9.94±0.32 1.17±0.02 13.32±0.04 0.38±0.02 2.09±0.33 
24:1 0.24±0.01 0.31±0.02 0.54±0.03 0.14±0.03 nd nd 0.04±0.00 0.34±0.14 
∑ DHA mt 0.32±0.02 0.18±0.05 0.16±0.04 0.66±0.10 1.64±0.08 1.32±0.09 0.08±0.01 2.71±0.39 
All-cis DHA 
 
14.60±0.15 14.71±0.05 13.11±0.06 83.68±0.17 86.19±0.11 78.78±0.11 7.16±0.31 76.75±0.41 
Total SFA 18.17±0.12 30.12±0.09 29.50±0.17 0.30±0.00 0.13±0.01 0.10±0.01 54.74±0.82 4.40±0.22 
Total MUFA 32.75±0.04 24.86±0.05 24.12±0.15 0.73±0.03 0.33±0.01 0.06±0.01 19.45±0.25 1.47±0.19 
Total PUFA 46.75±0.31 43.83±0.06 45.02±0.11 98.24±0.14 97.76±0.10 98.37±0.09 24.87±0.62 91.43±0.56 
ω-6 PUFA 5.66±0.07 3.84±0.08 8.49±0.14 2.19±0.01 7.10±0.01 0.59±0.04 2.57±0.13 10.25±0.90 
ω-3 PUFA 41.09±0.36 39.99±0.13 36.53±0.23 96.05±0.14 90.66±0.10 97.78±0.11 22.30±0.74 81.18±0.61 
SFA/PUFA 0.39±0.00 0.69±0.00 0.66±00 0.00±0.00 0.00±0.00 0.00±0.00 2.20±0.09 0.05±0.00 
ω-6/ω-3 ratio 0.14±0.00 0.10±0.00 0.23±0.01 0.02±0.00 0.08±0.00 0.01±0.00 0.12±0.01 0.13±0.01 
Total TFA 2.33±0.26 1.19±0.08 1.36±0.14 0.72±0.10 1.78±0.08 1.47±0.09 0.93±0.04 2.71±0.39 
ω-3 TFA 0.57±0.04 0.34±0.06 0.30±0.05 0.72±0.10 1.72±0.08 1.47±0.09 0.14±0.01 2.71±0.39 
% trans / Total 
DHA 2.13±0.12 1.21±0.30 1.20±0.31 0.78±0.11 1.87±0.09 1.65±0.11 1.05±0.08 3.40±0.48 
Fatty acid methyl esters (FAMEs) are expressed as relative percentages of the peak areas detected in the chromatograms 
(>98% of the total peak areas of the chromatogram).  Results are expressed as relative percentages (% rel) ± SD (n=3). 
nd= not detectable; mt=mono-trans. 
 
The GC analyses showed that these products markedly differed one from the other. This was 
somehow expected since some products declared their lipid content in the labels.  
Although all products claimed to contain fish or algal oil, in some of them PUFAs were not the most 
abundant lipid family. It is known that PUFA content is strongly conditioned by the fish species used, 
the type of food and the environmental conditions of breeding [63,64]. For example, fish living in 
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cold waters generally have a high ω-3 PUFA content, which guarantees the fish survival in very cold 
water by maintaining membrane fluidity.  
For example, Product 15 was found to contain more than 50% of SFAs (54.74±0.82) and less than 
25% (22.30±0.74) of ω-3 PUFAs, corresponding to a SFA/PUFA ratio of 2.20±0.09. 
Only two samples, i.e. Product 12 and 14, were constituted almost exclusively (>95%) by ω-3 PUFAs 
(96.05±0.14 and 97.78±0.11, respectively). Products of this quality are usually obtained by subjecting 
the raw materials to the winterization process.  
Winterization is a technique of fractional crystallization that requires slow cooling, which allows the 
separation of based on their melting temperature. In this way, waxes and saturated fats, that are 
characterized by high melting temperatures, can be solidified and separated by the liquid oily bulk by 
slowly decreasing the preparation temperature.  
Unfortunately, also in these samples, TFA derivatives were detected, corresponding to 0.72±0.10 and 
1.47±0.09 of the total fatty acids, of which 0.66±0.10 and 1.32±0.09 corresponded to trans-DHA, 
respectively. Considering the high quantity of DHA in the capsules (83.68±0.17 in Product 12 and 
78.78±0.11 in Product 14), the percentage of trans-DHA referred to the total DHA was lower that 
1% in Product 12 (0.78±0.11), while in Product 14 1.65% of DHA in the capsule was in the form of 
its trans geometrical isomer.   
These data provide important information regarding the quality of the starting raw materials used for 
supplement preparation. However, considering the amount of PUFAs over the total fatty acids, it is 
not sufficient to establish the quality of the product under investigation. Indeed, focusing on DHA, 
all the samples analyzed, with the exception of Product 3 and Product 8, contained mono-trans 
isomers of DHA, in percentages ranging from 0.12±0.01 up to 2.71±0.39 of the total fatty acid 
content.  
An excess of mono-trans isomers of DHA, corresponding to a relative percentage of 2.40±0.08, was 
detected in Product 4. It was astonishing to notice that the percentage of trans-DHA over the total 
DHA present in the sample was almost 40% (39.46±0.67). Considering the total TFAs, and not only 
trans-isomers of DHA, the total trans content of Product 4 was 3.89±0.10, i.e. almost 4% of fatty 
acids in the capsule were trans geometrical isomers of natural lipids.  
On the other hand, Product 3 and Product 8, that do not contain trans-isomers of DHA, contained 
only traces of all-cis DHA, the lipid which originates trans-isomers (0.75±0.02 in Product 3 and 
0.25±0.01 in Product 8 respectively). More specifically, in Product 3 the most abundant lipid family 
is represented by MUFAs (61.91±0.17 percent of total lipids), followed by SFAs (33.27±0.24 
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percent). MUFAs were the major source of TFAs, whose percentage (1.30±0.16) was higher than that 
of total ω-3 PUFAs in the supplement (1.26±0.03). In Product 8, a powdered milk for infants claimed 
to be enriched in long-chain PUFAs (> 18 carbons), EPA and DHA are contained only in traces 
(0.07±0.01 of EPA and 0.25±0.01 of DHA), whereas oleic (9c, 18:1) and linoleic (LA, 9c,12c, 18:2) 
acids are more abundant (44.04±0.19 and 18.98±0.07 respectively). Despite these fatty acids are 
normally present in milk lipid composition, such percentages are reached by vegetable oil addition, 
and this makes it difficult to understand whether the trans-isomers detected in this product (0.15% of 
the total lipids) is due to the industrial manipulation (oil addition) or to the natural biohydrogenation 
process occurring in ruminants (Chapter 1, Paragraph 1.4.4). In any case, although the percentage 
of TFAs in this product may be negligible, its nutritional value is questionable, owing to the extremely 
low content in ω-3 FAs.  
Apart from DHA mono-trans FAs, other trans-fatty acid derivatives were identified using trans 
reference libraries synthesized by our group. In particular, mono-trans isomers of palmitoleic 
(9c,16:1), oleic (9c, 18:1), vaccenic (11c, 18:1) and arachidonic (20:4 ω-6) acids were individuated. 
A significant percentage on mono-trans isomers of EPA (20:5 ω-3) was detected, especially in some 
of those samples that contain more than 20% of EPA, such as product 1 (EPA content of 28.05±0.28) 
and product 5 (EPA content of 27.40±0.02) that were found to have 0.75±0.02 and 0.68±0.02% of 
mono-trans isomers of EPA, respectively.  
In the GC area corresponding to the elution of all-cis and mono-trans DHA-Me, using helium as 
carrier gas, the presence of other three fatty acid methyl esters, namely all-cis 7,10,13,16,19 
docosapentaenoic acid (DPA, 22:5 ω-3), 24:0 and 15c, 24:1, was detected. Among them, the elution 
time of 24:0 corresponded to the elution time of all-cis DHA-Me.  Although the overlap did not affect 
the mono-trans isomers of DHA-Me, which are the main focus of this study, a second GC method, 
described in details in the Experimental part and named Method B, was applied. Hydrogen as carrier 
gas, and variations in the oven program, led to shifts in the time and the elution order of some long-
chain fatty acids. With GC Method B, 24:0 and 24:1 fatty acids were strongly retained by the 
stationary phase, avoiding misleading FAME assignments (data not shown).  
However, it was important to reconsider at this step the characterization of mono-trans isomers of 
DHA-Me carried out by GC-MS. By comparing the elution profile and the fragmentation pattern of 
trans-containing nutraceutical samples with the data collected from mono-trans isomers produced by 
photolysis, the identity of the peaks was confirmed. Indeed, the match with the mass-to-charge ratio 
(m/z) of ω-3 PUFAs allowed to exclude false positives such as saturated or mono-unsaturated FAMEs 
eluting in the same region, as well as excessive background noise. These analyses demonstrate that 
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the synthetic library of mono-trans isomers of DHA used as standard reference in gas 
chromatography constitutes a reliable analytical tool for the identification of these byproducts in 
commercially available ω-3 supplements. Additionally, since almost all the analyzed samples 
contained detectable amounts of trans lipids, this research underline the importance of the full trans-
isomers characterization of the most common polyunsaturated fatty acids.  
 
6.5. Conclusions  
In this study we report the first separation and identification of mono-trans isomers of DHA, obtained 
by a dual synthetic approach consisting of: i) the direct radical-catalysed isomerization of cis-DHA, 
and ii) mono-epoxide formation from DHA, separated and identified by bidimensional nuclear 
magnetic resonance experiments, followed by elimination to obtain the corresponding mono-trans 
alkenes.  
The full characterization of mono-trans derivative of DHA was used as reference library to set up a 
gas chromatography protocol in order to identify trans isomers from a representative fish oil 
isomerization reaction and from commercially available ω-3-containing supplements.  
The GC analyses run on ω-3 enriched supplements showed the presence of mono-trans isomers of 
DHA and other mono-trans isomers (including trans-palmitoleic, trans-oleic, trans-vaccenic, trans-
ARA and trans-EPA derivatives), that were identified using previously established synthetic 
procedures. Some nutraceuticals were found to contain more than 95% of ω-3 PUFAs with 
SFA/PUFA ratio approximated to zero and only one of them was found to have less that 1% of trans-
DHA over the total DHA in the preparation, thus suggesting winterization as a valid refining 
technique for the oils that have nutritional applications, to be used in alternative to deodorization. 
Our results underlined that the quality of the final commercially available ω-3 supplements is 
conditioned by the quality of the raw materials and the type of industrial processes employed. The 
synthetic library of mono-trans isomers of DHA could be a useful tool for the detection and 
quantification of these geometrical artifacts in ω-3 supplements that can find application in food and 
nutraceutical studies.    
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Chapter 7 
Conclusions 
 
The results presented in this PhD thesis concern the role of cell membrane lipid composition, in 
physiological and pathological conditions.  
In the first part (Chapter 3), the focus was directed at establishing a membrane-based comprehensive 
approach to be applied to the study of Autism Spectrum Disorder (ASD). The protocol consisted of 
erythrocyte membrane lipidomic analysis and erythrocyte characterization using hyperspectral dark-
field microscopy (HDFM). The study was performed on 41 children, 21 with ASD and 20 with typical 
development. We found that children affected by ASD had significantly reduced levels of erythrocyte 
membrane DHA, pointing the attention to the crucial role of this ω-3 fatty acid in neuronal 
development and brain functioning. The HDFM analyses led to the creation of a hyperspectral library 
made of 8 scattering spectra, reflecting the contribution of still unidentified erythrocyte components. 
The relative contribution of each spectrum was examined for each sample. It was found that spectrum 
4 (whose characteristic peaks could be attributed to phospholipids and protoporphyrin IX) was 
significantly increased in erythrocytes from ASD children. The statistical elaboration of data 
demonstrated an inverse correlation between DHA content of erythrocyte membranes and relative 
values of spectrum 4. Further statistical analysis showed that individuals with a spectrum 4 percentage 
higher than 16.225 (cut-off value) have a 24-times higher probability of having ASD. These 
preliminary results encourage further studies on a larger scale, aimed at integrating this innovative 
protocol with other diagnostic and intervention tools for the optimization of personalized membrane-
targeted therapies.  
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In the second part (Chapter 4), we investigated the possible membrane fatty acid remodeling induced 
by two apolipoproteins, apoE3 or apoE4, involved in lipid transport in the brain, on cultured SK-N-
SH neuroblastoma cells. Apo E3 and apoE4 are two allelic isoforms of the same lipid transporter 
protein, where carriers of the apoE4 isoform are notably at risk for Alzheimer’s disease (AD). SK-N-
SH neuroblastoma cells were incubated in the presence or the absence of either apoE3 or apoE4, then 
the GC analysis of the extracted cell membrane fatty acids was performed. It emerged that the addition 
of both apoE isoforms induced fatty acid remodeling, but with different outcomes. SFAs and MUFAs 
were significantly increased after cell incubation with both apoE3 or apoE4, while ω-6 PUFAs were 
significantly decreased after incubation with apoE3 but were unchanged after incubation with apoE4. 
ω-3 PUFAs were significantly decreased in the membrane of cells treated with both apoE forms if 
compared with untreated samples (p < 0.0001), but the decrease was of greater magnitude in the 
presence of apoE3 (p < 0.001). As a consequence of the ω-3 reduction, PUFA balance indicator was 
also decreased compared to controls (p < 0.0001). For what TFAs was concerned, the total mono-
trans isomers tended to decrease after incubation of the cells with apoE3 but TFA content appeared 
to increase in the presence of apoE4. Opposite trends were observed with regard to stearic acid and 
DGLA, apoE3 increasing while apoE4 reducing their levels in neuroblastoma cell membranes. Both 
apoE isoforms decreased membrane homeostasis indexes such as PUFA balance, unsaturation index 
and peroxidation index. These results suggest further in vitro experiments to better clarify the 
mechanism of action of apolipoproteins on membrane lipid distribution; it may be envisioned a future 
use of nutritional strategies in the prevention and treatment of AD in the presence of AD predisposing 
factors, taking into consideration the possibility of monitoring, by membrane lipidomics, the effects 
of dietary changes.   
In Chapter 5, the effects of the trans geometry of the double bonds on the properties of liposomal 
models of cell membrane were studied. In particular, different formulations containing increasing 
percentages of TFAs were prepared and characterized for their size, ζ-potential and morphology. 
Additionally, since trans-lipids are known to influence membrane permeability reducing its fluidity, 
the stability over time and possibly the efficiency of encapsulation, the encapsulation of two different 
dyes and their release profile at 37 °C were studied. The data demonstrated that TFAs affect both 
liposome size and stability, reducing the mean particle diameter and the aggregation phenomena. The 
encapsulation efficiency was mainly affected by the liposomal formulation and the encapsulation 
conditions rather than the lipid geometry. However, the presence of trans-containing phospholipids, 
by reducing liposome permeability, gave slightly slower release compared to their cis-analogues. 
These results suggest further experiments where such effects would be explored in biological 
membranes, where trans lipids can be endogenously formed or introduced by exogenous sources. 
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Given the possibility to functionalize liposome surface in order to favor their concentration in cancer 
areas due to specific micro-environmental characteristics, it would be interesting to evaluate the 
possibility to disturb cell signaling and replication of tumor cells and to produce local cytoxicity by 
enhancing the concentration of trans lipids in the area.  
Finally, in Chapter 6, we reported the separation and identification of mono-trans isomers of DHA, 
obtained by a dual synthetic approach consisting of direct photolysis of cis-DHA in the presence of 
thiol and formation of mono-epoxide derivatives that can be separated by TLC and GC and 
characterized by 2D-NMR. The synthesized molecules were used as reference library to set up a GC 
protocol for the identification of trans isomers of DHA in isomerized fish oil and commercially 
available ω-3 containing supplements. The GC analyses showed the presence of mono-trans isomers 
of DHA and other mono-trans isomers (including trans-palmitoleic, trans-oleic, trans-vaccenic, 
trans-ARA and trans-EPA derivatives) in the majority of samples, that were identified using 
previously established synthetic procedures. The presence of these byproducts could be attributed to 
industrial processes, like deodorization, that induce the cis-trans conversion of double bonds in 
unsaturated lipids. Other differences in the lipid profile of the analysed products, such as excess of 
SFAs and MUFAs underlined that the quality of the final commercially available ω-3 supplements is 
conditioned not only by the type of industrial processes but also by the quality of the raw starting 
materials employed. These results confirmed that the synthetic library of mono-trans isomers of DHA 
could be a useful tool for the detection and quantification of trans geometrical artefacts of DHA in 
ω-3 supplements that can find application in food and nutraceutical studies. This study brings the 
attention to the need of globally standardizing the legislation and imposing limitation regarding the 
TFA content in commercially available products, that have harmful effects for health.  
Taken together, these results can better clarify the role of fatty acids in the composition of cellular 
membranes, which is affected by environmental, nutritional and metabolic conditions, providing also 
a palette of methodologies for the examination of membrane behaviors, impairments and changes 
linked with the fatty acid geometry and types.  
This PhD thesis encompasses many fields, ranging from the roles of free radicals in medicine, 
characteristics of membrane composition in different culture conditions, biotechnology of liposomes, 
lipid analysis and evaluation of nutraceuticals.  
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Appendices 
 
Appendix 1. GC-MS chacterization of mono-trans isomers of DHA-Me. 
GC-MS separation. Mixture of mono-trans isomers of DHA-Me obtained by photolysis, in 
comparison with all-cis DHA-Me. 
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GC-MS separation. Mass fragmentation at 68.31 min (19t, DHA-Me). 
 
GC-MS separation. Mass fragmentation at 70.39 min (16t, DHA-Me). 
 
  
160 
 
GC-MS separation. Mass fragmentation at 70.82 min (4t, DHA-Me). 
 
GC-MS separation. Mass fragmentation at 71.78 min (13t, DHA-Me). 
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GC-MS separation. Mass fragmentation at 72.45 min (7t + 10t, DHA-Me) 
 
GC-MS separation. Mass fragmentation at 70.45 min (all-cis DHA-Me). 
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Appendix 2. Summary of the 1H and 13C resonances assignments for all-cis DHA-Me and EDP 
regioisomers.  
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Appendix 3. 1H NMR spectrum of the first fraction (in C6D6) corresponding to 16,17-EDP and 13,14-
EDP (6 and 5 in a ratio 71:29) with traces of all-cis DHA-Me and an unknown compound (probably 
10,11-EDP) that were not characterized.  
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Appendix 4. 1H NMR spectrum of the second fraction (in C6D6) corresponding to 19,20-EDP and 
7,8-EDP (structures 7 and 3 in a 57:43 ratio). 
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Appendix 5. 1H NMR spectrum of the third fraction (in C6D6), corresponding to pure 4,5-EDP (2).  
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Appendix 6. Relevant correlations in the 2D-NMR (in C6D6) for the assignment of 19,20-EDP. 
Connections follow the left lane a-f, then the right lane g-o.  
a. The bsgHSQCAD 5-70 showed that H1’ 
(3.31 ppm) corresponds to C1’ (50.65 ppm). 
 
b. The gHMCBAD attributed C1 (172.32 
ppm) to individual signals (2.11 e 2.29 ppm), 
corresponding to H2 and H3. 
 
c. The gHMCBAD showed the attribution of 
H2 (2.11 ppm), H3 (2.29 ppm) to C4 (128.08 
ppm) and C5 (129.06 ppm) since H2 interacts 
only with C1 (170.32 ppm) and C4, while H3 
interacts C1, C4 and C5. 
 
d.The bsgHSQCAD 5-70 showed C2 (33.64 
ppm) and C3 (22.76 ppm). 
g. The bsgHSQCAD 5-70 showed that H22 (0.84 ppm) 
corresponds to C22 (10.45 ppm). 
 
h. In gHMCBAD C21 (21.10 ppm) and C20 (57.38 ppm) 
are shown. 
 
i. The bsgHSQCAD 5-70 confirmed the two 
diastereotopics protons H21 (1.40-1.28 ppm, I1) and H20 
(2.60 ppm; Fig I2) 
 
 
l. The gHMCBAD showed C19 (55.75 ppm, L1) and the 
bsgHSQCAD 5-70 confirmed H19 (2.75 ppm, L2). 
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e. In bsgHSQCAD 110-140 the protons H4 
(5.29 ppm) and H5 (5.38 ppm) are shown. 
 
f. GHMCBAD confirmed the interaction of 
H6 (2.79 ppm) with C4 (129.06 ppm, F1) and 
from bsgHSQCAD 5-70 C6 (25.58ppm, F2) 
is shown. 
 
 
From here, the overlapping of the signals 
made the attributions difficult, and for this 
reason we proceeded with the attribution 
starting from the C22. 
 
 
 
m. From gHMCBAD the two diastereotopic protons H18 
are confirmed (2.29-2.10 ppm, M1) and bsgHSQCAD 5-
70 showed C18 (26.31 ppm, M2). 
 
 
n. From gHMCBAD, C17 and C16 were identified 
(130.03 and 124.96 ppm, N1), while bsgHSQCAD 110-
140 attributed the corresponding protons (130.03/5.46 
ppm; 124.96/5.44 ppm, N2). Finally, gHMCBAD 
showed H17 (5.44 ppm) attached to C19 (N3). 
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o. Proton H15 was identified (2.78 ppm, O1) by 
gHMCBAD and bsgHSQCAD 5-70 provided strong 
evidence that H15 (130.03 ppm) is attached to C15 (5.46 
ppm, O2). 
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Appendix 7. Full 13C NMR spectrum of DHA-containing triglycerides.  
 
Appendix 8. Full 13C NMR spectrum of DHA-containing triglycerides after isomerization.  
 
